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Abstract 
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of 
disability globally. There are no disease modifying treatments, and for end stage disease, total 
joint replacement is the only therapeutic option. There is a major unmet clinical need for OA 
patients. Compared to peripheral blood and inflammatory arthritis (IA), there has been less 
research into the cellular mechanisms and inflammatory processes involved in the synovial 
tissue of OA. A barrier to this research has been difficulty in isolating cells from tissues at the 
site of disease activity. I aimed to identify and compare the cellular phenotype, functional 
capacity and gene expression of synovial tissue mononuclear cell subsets in OA and IA. 
 
After assessing an array of published tissue digestion protocols, I developed a standardised 
synovial tissue digestion protocol allowing the isolation of multiple cell subsets with high 
yields, preserved cellular antigens and high cell viability. A multi-colour flow cytometry panel 
was established to allow the accurate identification and fluorescence-activated cell sorting of 
cDC2 dendritic cells, CD14+ monocytes, HLA-DR+CD14+ macrophages and CD4+ T cells.  
 
Computational analysis of flow cytometry data sets demonstrated greater cellular infiltrate in 
IA, but an increased proportion of macrophages in OA. However, this proportion was not seen 
in all OA patients. Owing to their increased but varied proportion, and previously described 
role in OA pathogenesis, I conducted an in-depth analyses of these cells.  OA macrophages had 
higher expression of surface proteins associated with activation such as CD206, FOLR2 and 
CD86. Functionality of isolated macrophages was retained, demonstrated by their high 
phagocytic activity. Next generation RNA-sequencing was performed to better understand their 
function and heterogeneity in OA synovial tissue. Two distinctive OA endotypes were proposed 
based on functional gene signatures. One gene signature comprised of cell cycle and 
proliferation mechanisms, whilst the other consisted of cartilage and tissue development. 
 
Despite its central role in arthritic processes, the role of the synovium has remained obscure. 
This optimised digestion protocol now allows the interrogation of individual cell subsets. 
Analysis of synovial macrophages using this protocol has demonstrated distinct endotypes 
within OA patients. Improved investigation into the pathogenesis of OA, especially in the 
context of OA subtypes, can now be conducted. This could ultimately lead to the modification 
of treatment strategies for OA patients. 
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Chapter 1. Introduction 
1.1 Overview 
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of 
disability with knee OA affecting ~18.2% of adults over the age of 45 in England (Arthritis 
Research UK, 2017). Progressive destruction of cartilage and bone is multifactorial, resulting 
in pain and loss of joint function. As OA risk factors include age, obesity and metabolic 
syndrome, OA is particularly becoming a major health burden for the western world. There is 
no treatment for OA. Clinically, pain is managed, and for patients at end stage disease, total 
joint replacement is the only therapeutic option. In 2015, >90,000 patients received a total knee 
replacement in the U.K; this figure is expected to double over the next decade (Guerra, Singh 
et al. 2015) (National Joint Registry, 2016). Disease modifying anti-rheumatic drugs 
(DMARDs) often used for treatment in IA, have been trialled in patients with OA with limited 
success (Hunter 2008, Philp, Davis et al. 2017).  
Synovial inflammation present in OA patients is usually low grade and does not lead to overt 
systemic inflammation (Sokolove and Lepus 2013). However, this local synovial inflammation 
is present in 50%-70% of OA patients throughout disease progression, and it is becoming 
recognised that inflammation within the joint of OA patients contributes to disease pathogenesis 
(Haywood, McWilliams et al. 2003, Baker, Grainger et al. 2010, Roemer, Crema et al. 2011).  
Macrophages are a diverse population of tissue resident cells. They are relatively large cells 
which specialise in phagocytosis, but have great multifunctional capacity and heterogeneity. 
These functional roles encompass phagocytosis, antigen presentation, inflammation, tissue 
homeostasis and tissue repair. Synovial macrophages have been previously described in the 
pathogenesis of OA. It has been found that the number of macrophages in synovium correlates 
with the degree of synovial angiogenesis (Haywood, McWilliams et al. 2003, Kraus, McDaniel 
et al. 2016). However, compared to the research of blood in OA and the study of the synovium 
in rheumatoid arthritis (RA), there has been relatively little research into macrophages and 
cellular mechanisms in the synovial tissue of OA.  
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1.2 The mononuclear phagocyte system 
Furth, Hirsch and Cohn described the mononuclear phagocyte system (MPS) in the late 1960s, 
comprising of dendritic cells (DCs), monocytes and macrophages. The MPS contributes to the 
immune system through the initiation of innate and adaptive immune responses, pathogen 
clearance, tissue maintenance and healing.  
Guilliams et al., (2014) proposed a unified nomenclature system in mice, consisting of a two 
tiered approach based on ontogeny, location, function and phenotype (Guilliams, Ginhoux et 
al. 2014). From this, and existing information, a model of mononuclear phagocyte 
differentiation can be compiled (Fig. 1.1). However, much knowledge of the MPS in humans 
has been derived from studying its components in blood. Research on tissue has been difficult 
due to limited sample availability, methods to derive single cell suspensions and identification 
of unique markers for cell subsets. It is these tissue environments that may heavily manipulate 
cells of the MPS in steady state as well as in disease. For example, macrophages can 
functionally differ between tissues; Kupffler cells of the liver specialise in the degradation of 
red blood cells whereas muscularis macrophages contribute to gut peristalsis. Additionally, 
during inflammation monocytes can infiltrate inflamed tissue and acquire macrophage-like 
properties, similar to that of in vitro monocyte-derived macrophage (moMac) differentiation. 
There is a need to advance knowledge of the MPS in human tissues and in the context of 
inflammation and disease. 
 
1.3 Macrophages 
In 1882 Elie Metchnikoff, regarded the father of natural immunity, described antimicrobial 
defence and the requirement of the immune system to kill and eat pathogens as part of this 
defence (Gordon 2008). Specialised cells termed phagocytes were observed to uptake and 
intracellularly digested foreign bodies and microorganisms. ‘big-eater’ is the English 
translation of the Greek word macro-phage, describing this cells large size and high ability to 
phagocytose pathogens and apoptotic cells. In addition to phagocytosis, macrophages can also, 
present antigen and produce large quantities of secretory molecules including chemokines, 
cytokines and proteinases. Macrophages are functionally variable throughout different tissues. 
In mice, macrophages from different tissue sites were shown to have great transcriptomic 
diversity (Gautier, Shay et al. 2012). In addition to tissue-specific environments, macrophages 
are additionally influenced by exposure to activation signals and their ontogeny, be that 
monocyte or embryonically derived.  
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Macrophages can be identified by the expression of CD11b, CD14, CD68 and colony 
stimulating factor 1 (CSF1R) in both mice and humans. F4/80 is an additional marker exclusive 
to mice. However, in humans none of these markers are exclusive to macrophages, and can be 
co-expressed on monocytes and dendritic cells. Macrophages additionally express a range of 
membrane proteins for specific cellular functions. These include macrophage receptor with 
collagenous structure (MARCO) for the clearance of microbes, T cell immunoglobulin mucin 
protein 4 (TIM-4) for the clearance of apoptotic cells, toll-like receptor 4 (TLR4) and CD14 for 
recognition of bacterial membrane components such as lipopolysaccharide (LPS) and 
chemokine receptor 2 (CCR2) for the recognition of chemokine monocyte chemoattractant 
protein-1 (MCP-1) (Gordon and Pluddemann 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The mononuclear phagocyte system differentiation 
Depiction of differentiation in the mononuclear phagocyte system based on Guilliams et al., (2014). 
Macrophages are derived from embryonic yolk sac precursors and are maintained by self renewal in addition 
to monocyte replacement. Hematopoietic stem cells give rise to the macrophage and dendritic cell progenitor 
(MDP), and subsequent monocytes can further differentiate into monocyte-derived macrophages. The 
common dendritic cell precursor (CDP) differentiates into pre-pDC and pre-cDC precursor cells, 
differentiating into pDCs and cDC1/cDC2 respectively. 
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1.3.1 Macrophage development 
Although macrophages were historically considered to be exclusively derived and replenished 
by circulating monocytes, it is now known that many types of macrophages are self-renewing 
and embryonically derived (van Furth and Cohn 1968). During development, macrophages are 
seeded throughout the tissues of the body by embryonic yolk sac and foetal liver precursors. 
These tissue resident populations are mostly self-replenishing. After development, bone 
marrow-derived blood monocytes contribute to the replenishment of these macrophages to 
various extents. However, this renewal process is variable by tissue site and in the presence of 
inflammation. For example, in the gut there is a large proportion of monocyte-derived 
macrophages during steady state. Additionally, during inflammation, infection or after tissue 
injury, there can be an increase in the proportion of these monocyte-derived macrophages. 
Control of macrophage regulation, differentiation, proliferation and survival is contributed to 
by macrophage-colony stimulating factor 1 (CSF1) (Yu, Chen et al. 2012, Zhang, Wang et al. 
2014). However, the transcriptional requirements of embryonically derived macrophages differ 
considerably from that of haematopoetic stem cell-derived macrophages. For example 
embryonic microglial macrophages require the transcription factors Pu.1 and interferon 
regulatory factor 8 (IRF8), and develop independently of myeloblastosis proto-oncogene 
protein (MYB), DNA-binding protein inhibitor ID-2 (ID2), basic leucine transcription factor, 
ATF–like (BATF) and kruppel-like factor 4 (KLF4) (Kierdorf, Erny et al. 2013). It is also 
thought that specialised tissue macrophages express independent transcription factors. For 
example, osteoclasts require the transcription factor nuclear factor of activated T-cells, 
cytoplasmic 1 (NFATc1) for development whereas splenic macrophages require Spi-C 
(Kohyama, Ise et al. 2009, Kim and Kim 2014). 
1.3.2 Macrophage activation 
Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs) are molecules that initiate and perpetuate infectious and non-infectious inflammatory 
responses, respectively. Macrophages express pattern recognition receptors (PRRs) such as 
TLRs, which allow them to recognise PAMPs and DAMPs. In addition to recognising 
pathogens and damage signals, macrophages can respond to cytokines. An in vitro model of 
macrophage activation has been studied for many years, the M1 and M2 paradigm. This has 
advanced our understanding of macrophage activation greatly. M1 macrophages are considered 
to be the classically activated subset and have enhanced antimicrobial, inflammatory and 
antigen-presenting properties. These cells have been observed in intracellular infections and 
tissue injury such as seen in tuberculosis (Mosser and Edwards 2008). M2 macrophages have 
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anti-inflammatory properties and have been observed in allergy, parasitic infection, repair and 
fibrosis (Murray and Wynn 2011, Wynn and Ramalingam 2012). Interferon gamma (IFN-γ) 
largely produced by T-helper (Th)1 cells can induce an M1 phenotype, whereas the Th2 
signature cytokines interleukin 4 (IL-4) and IL-13 promote an M2 phenotype (Mantovani, Sica 
et al. 2004, Wallet, Wallet et al. 2010). IRF3, IRF4 and NF-kappa B p50 are transcription factors 
shown to influence M2 polarisation whereas IRF5 is thought to influence M1 (Biswas, Gangi 
et al. 2006, Porta, Rimoldi et al. 2009, Satoh, Takeuchi et al. 2010, Krausgruber, Blazek et al. 
2011).  
However, the M1/M2 model of macrophage activation is becoming recognised as polar 
representations of activation states and may not be representative of in vivo macrophages 
(Barros, Hauck et al. 2013, Martinez and Gordon 2014, Xue, Schmidt et al. 2014). Additionally, 
Xue et al. showed stimulated macrophage transcriptome data demonstrating a range of 
additional macrophage activation states extending past the current M1/M2 models (Xue, 
Schmidt et al. 2014). The differences between macrophages at different polarisation states is 
clear, however these states are not easily identifiable in the tissue, and may not be completely 
representative of in vivo macrophage activation.  
1.3.3 Macrophage tissue residency 
It has been shown in mice that monocytes can differentiate into macrophages at interfaces with 
specific environments such as gut, lung and skin (Varol, Landsman et al. 2007, Bain, Bravo-
Blas et al. 2014, Cerovic, Bain et al. 2014). The mechanisms that induce macrophage 
differentiation and tissue specific functions are yet to be fully understood. For example, it is 
known that osteoclast differentiation mechanisms involve the receptor activator of NF kappa-
B (RANK) signalling cascade (Boyle, Simonet et al. 2003). In addition, Okabe et al. explored 
the tissue-specific controls of peritoneal macrophages in mice, finding that GATA6 and retinoic 
acid are responsible for their localisation (Okabe and Medzhitov 2014). This demonstrates the 
ability of macrophages to acquire tissue-specific functions dependent on their location.  
Influences of specific tissue environments can be exemplified by a number of macrophage 
populations (Fig. 1.2). Kupffer cells specialise in the degradation of red blood cells, muscularis 
macrophages in gut peristalsis, osteoclasts in bone resorbtion and microglia in neural network 
development and maintenance (Willekens, Werre et al. 2005, Kettenmann, Kirchhoff et al. 
2013, Muller, Koscso et al. 2014). This demonstrates how tissue-specific environments can 
influence these cells. 
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1.4 Dendritic Cells 
DCs are professional antigen-presenting cells and specialise in initiating adaptive immune 
responses. Although found in the blood and throughout the body, they are concentrated in 
tissues with environmental exposure. These tissues include the skin, lungs and gut. Paul 
Langerhans first described Langerhans cells, a skin-resident cell population resembling DCs in 
1868. However, characterisation of DCs as professional antigen presenting cells, did not occur 
until 1973 by Ralph Steinman (Steinman and Cohn 1973). Isolated from mouse spleen, 
Steinman reported that these cells were required for mixed lymphocyte reactions. These DCs 
were described as having dendrite-like branching projections, few lysosomes and limited 
phagocytic activity compared to other immune cells such as macrophages.  
1.4.1 DC activation 
Similarly to macrophages, DCs also recognise PAMPs and DAMPs through a similar range of 
PRRs. Key differences include the expression of Galectin 3 and TLR6 on macrophages, aiding 
Figure 1.2: Specialised tissue macrophages 
In addition to wide ranging macrophage functions, macrophages from different tissue environments can 
perform specialised functions. These include microglia of the brain and neural network development, lymph 
node macrophages and antigen capture, lung macrophages and particle clearance, heart macrophages and 
cardiomyocyte regulation, spleen macrophages and clearance of cells and debris, Kupffer cells of the liver and 
clearance of red blood cells (RBC), Osteoclasts of the bone and bone remodelling, Gut macrophages and 
peristalsis and skin macrophages and wound healing. 
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in phagocytosis and inflammation (Netea, Brown et al. 2008), and the expression of dendritic 
cell-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) on dendritic 
cells (Netea, Brown et al. 2008). DC-SIGN functions as an adhesion molecule and antigen 
receptor (Garcia-Vallejo and van Kooyk 2013).  However, DC-SIGN expression has been 
reported on tissue macrophages (Soilleux, Morris et al. 2002, Conde, Rodriguez et al. 2015). 
Additionally, DCs express high levels of major histo-compatibility complex II (MHCII), 
allowing the efficient presentation of antigens (Steinman 1991, Steinman and Idoyaga 2010). 
Once activated through these mechanisms, DCs can migrate to T cell areas of draining lymph 
nodes where they present antigen on MHC stimulating cell proliferation and differentiation 
(Ganguly, Haak et al. 2013). DCs are efficient at activating naïve T cells, hence they are referred 
to as ‘professional’ antigen-presenting cells. 
T cells are key effector cells in the adaptive immune response, contributing through the 
secretion of cytokines and activation of other immune cell types, including B cells and 
macrophages. They also play a crucial role in destroying tumour cells and infected cells in 
addition to preventing auto-reactive immune responses to self-antigens. To become fully 
activated, a T cell requires three types of activation signals (Corthay 2006). The first is binding 
of peptide:MHC to the T cell receptor complex. Secondly, co-stimulatory molecules on DCs, 
CD80 and CD86, bind to T cell CD28. This promotes expansion and survival of the T cell. The 
third signal involves a polarising signal such as cytokine production by the DC, and membrane 
molecules including OX40L and ICAM-1. This polarisation signal instructs the differentiation 
of T cells towards functionally distinct Th subsets.  
During maturation, DCs lower their rate of antigen uptake and reduce Fc receptor expression, 
but upregulate co-stimulatory molecules such as CD80, CD86 and peptide:MHC complexes. 
These changes in expression allows DCs to become proficient in T cell stimulation (Liu, Gao 
et al. 2006). Expression of chemokine receptors is also altered during DC maturation, including 
the upregulation of CCR7. Chemokine ligand 19 (CCL19) and CCL21 are the ligands of CCR7, 
and are expressed by stromal cells in the T cell areas of lymph nodes. Adhesion molecules such 
as intercellular adhesion molecule 1 (ICAM-1) and CD58 are upregulated allowing initial 
binding to T cell integrin lymphocyte function associated antigen 1 (LFA-1) (Staunton, Dustin 
et al. 1989, Long 2011). These signalling pathways facilitate migration of DCs to the draining 
lymph nodes (Hansson, Lundgren et al. 2006). DCs that migrate in steady state without 
activation may ‘patrol’ for pathogenic stimuli (Banchereau and Steinman 1998). 
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1.4.3 DC subsets 
Human DCs can be split into functionally distinct subsets, conventional DCs (cDC), including 
cDC1 and cDC2, and plasmacytoid DCs (pDCs). Identification of these subsets in blood is 
determined by their expression of surface markers BDCA1 (CD1c; cDC2), BDCA2 (CD303; 
pDC), BDCA3 (CD141; cDC1) and BDCA4 (CD304; pDC). DCs found in the blood are 
thought to be the likely immature precursor of DCs found in tissue and lymphoid organs (Collin, 
McGovern et al. 2013). The independence of these subsets from one another has been confirmed 
by their requirement for specific transcription factors. These include BATF3 (cDC1), IRF4 
(cDC2) and E2-2 (pDC) (Guilliams, Dutertre et al. 2016). 
Although the nomenclature proposed by Guilliams et al is now commonly recognised and used, 
a previous nomenclature system can still be found in use. This can cause confusion owing a 
relative similarity in naming of subsets. This alternative nomenclature classifies the 
conventional DC subsets (cDCs) as myeloid DCs (mDCs) and again splits them by their 
expression of BDCA1 (CD1c) and BDCA3 (CD141). Those CD1c+CD141- are referred to as 
mDC1 (cDC2 equivalent). Those CD1c-CD141+ are referred to as mDC2 (cDC1 equivalent) 
(Nizzoli, Krietsch et al. 2013, Chen, Denniston et al. 2015). Since this alternative nomenclature 
can still be found in use in recently published journals, as well as by commercial brands, it is 
important to highlight this difference. The remainder of this thesis discusses the nomenclature 
outline by Guilliams et al (cDC1, cDC2 and pDC). 
cDC1s are highly efficient at cross-presentation to CD8+ T cells once activated with poly I:C, 
promoting cytotoxic Th1 responses, in addition to producing large amounts of IFN-α after 
stimulation through TLR3 (Jongbloed, Kassianos et al. 2010, Meixlsperger, Leung et al. 2013). 
The murine equivalent of human cDC1 DCs has been identified as CD8+ DCs (Jongbloed, 
Kassianos et al. 2010). cDC2s are the dominant subset of DCs driving CD4+ Th2 and Th17 
responses and express TLR1-8, with TLR 2, 4 and 5 expressed at high levels (Schlitzer, 
McGovern et al. 2013, Segura, Touzot et al. 2013). Although cDC2s can cross-present to CD8+ 
T cells, they are less efficient than cDC1s (Haniffa, Shin et al. 2012). CD11b DCs are the murine 
equivalent of human cDC2s (Collin, McGovern et al. 2013).  As well as being inducers of Th2 
and Th17 responses, cDC2s are capable of inducing Th1 responses (Nizzoli, Krietsch et al. 
2013). pDCs largely respond to viral components through TLR7 and TLR9, and produce large 
quantities of type I IFNs, especially IFN-α (Reizis, Bunin et al. 2011). They are distinguished 
from cDCs by their expression of CD303 and CD304 (Dzionek, Fuchs et al. 2000). 
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Recently, a reclassification of DC subsets was proposed based on single cell RNA-sequencing 
and functional studies of human blood DCs and monocytes (Villani, Satija et al. 2017). In total, 
six DC populations were identified. In addition to the identification of cDC1 (DC1) and pDCs 
(DC6), an additional DC population was discovered within the traditional pDC gate, identified 
by its AXL+SIGLEC6+ expression (DC5; ‘AS DCs’). A subdivision of cDC2s reveals DC3 and 
DC4, identified using CD1c in combination with CD32B, CD36 and CD163. Both subsets are 
potent inducers of T cell proliferation. DC4 was defined by a CD1c-CD141-CD11c+ and CD16+ 
surface marker expression and shares gene signatures with monocytes (Villani, Satija et al. 
2017). This research highlights the importance in the accurate identification of DC subsets when 
assessing gene signature and function. However, due to the recent publication, the remainder 
of this thesis discusses the traditional cDC1, cDC2 and pDC classification. 
Characterisations of human DCs, nomenclatures and lineages in tissue have been limited. This 
has been mainly owing to difficulties obtaining human tissue, low cell numbers and a lack of 
distinctive markers. Therefore, most characterisation work has been carried out on circulating 
blood DCs, although characterisation of DCs in a number of tissues are now being studied 
(MacDonald, Munster et al. 2002, Haniffa, Gunawan et al. 2015). 
 
1.5 Monocytes 
Monocytes are a heterogeneous population of multi-functional mononuclear leukocytes 
contributing to ~10% of circulating blood mononuclear cells (Ziegler-Heitbrock, Strobel et al. 
1992, Geissmann, Jung et al. 2003). They have a high cytoplasm to nucleus ratio, irregular cell 
shape, cytoplasmic vesicles and kidney shaped nuclei (Qu, Brinck-Jensen et al. 2014). 
Monocytes contribute to the innate immune response by phagocytosis, antigen presentation and 
cytokine production. As previously discussed, circulating monocytes were originally thought 
to play a major role in replenishment of macrophages in tissue (van Furth & Cohn, 1968). 
However, other than some specific tissues, it has been shown that most tissue-resident 
macrophages are actually self-renewing populations originating from embryonic stem cells. 
(Hashimoto, Chow et al. 2013, Gomez Perdiguero, Klapproth et al. 2015). This opens up the 
debate for monocytes’ additional functions. Jakubizick et al. suggest that monocytes share the 
tissue surveillance characteristics of DCs as well as supporting antigen presentation and 
adaptive immunity.  They suggest that monocytes do this without becoming professional 
antigen presenting cells themselves, and instead act as a surveillance and effector cell in tissues, 
complementary to DCs (Jakubzick, Gautier et al. 2013).  However, in vitro, monocytes can 
10 
 
acquire DC-like and macrophage-like characteristics, under the appropriate culture conditions. 
The conditions in vivo which contribute to circulating monocytes entering tissues and acquiring 
these DC- and macrophage-like characteristics are the subject of much discussion. 
1.5.1 Monocyte subsets 
In humans, three subsets of circulating monocytes have been identified by CD14 and CD16 
expression, these are; CD14++CD16- ‘classical’, CD14++CD16+ ‘intermediate’ and 
CD14+CD16+ ‘non-classical’ (Cros, Cagnard et al. 2010, Ziegler-Heitbrock, Ancuta et al. 2010, 
Wong, Yeap et al. 2012). The classical CD14++CD16- subset is the major population of 
monocytes, contributing to ~85% of human circulating monocytes (Wong, Yeap et al. 2012). 
Wong et al. carried out microarray analysis of this classical (CD14++CD16-) subset, revealing 
that a gene signature involved in tissue repair and sensing receptors, in addition to expression 
of inflammatory S-100 proteins (Wong, Tai et al. 2011). This demonstrates a broad range of 
functions. Passlick et al. described the non-classical (CD14+CD16+) fraction of blood 
monocytes. With different functional capabilities to classical monocytes, they account for 
approximately 10% of circulating monocytes (Passlick, Flieger et al. 1989, Wong, Yeap et al. 
2012). They can stimulate T cells and patrol endothelium of blood vessels producing an 
inflammatory response to viral nucleic acids through TLRs 7 & 8 (Cros, Cagnard et al. 2010). 
It was demonstrated that this CD14+CD16+ monocyte subset is a truly independent subset 
through genome wide expression profiling, rather than a DC subset expressing CD16, as 
previously reported (Ancuta, Liu et al. 2009, Cros, Cagnard et al. 2010). The intermediate 
(CD14++CD16+) fraction accounts for ~5% of circulating monocytes and has a role in reactive 
oxygen species (ROS) production as well as angiogenesis and T cell proliferation (Wong, Tai 
et al. 2011). Zawada et al. suggested these cells are predisposed for antigen presentation and 
subsequent T cell proliferation due to higher expression of MHCII (Zawada, Rogacev et al. 
2011). Furthermore, this subset is thought to produce the largest amounts of tumor necrosis 
factor-alpha (TNF-α) and IL-1β after stimulation by LPS. 
1.5.2 Monocyte differentiation in tissue 
It has been demonstrated that the extent of monocyte differentiation in tissues is unclear. How 
the synovial tissue may mediate monocyte differentiation is also unknown. Kawanka et al. 
indicate that circulating monocytes are activated by excess cytokines into a CD16+ phenotype, 
before entry into the synovial compartment. Cytokines involved in this process include TGFβ1, 
macrophage colony stimulating factor (M-CSF) and IL-10 (Kawanaka, Yamamura et al. 2002). 
This coincides with early findings by Burmester et al. that monocytes infiltrate synovial tissue, 
and that the cytokines produced by CD16+ cells contribute to the pathogenesis of RA 
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(Feldmann, Brennan et al. 1996, Burmester, Stuhlmuller et al. 1997). This leaves the idea of a 
feedback loop, in which infiltrating monocytes are activated by cytokines including TNF-α and 
IL-1β. Once activated by these cytokines, monocytes then contribute to this TNF-α and IL-1β 
production.  
In sequence with recent investigations of monocyte differentiation in tissues, McGovern et al. 
challenged the classification of a dermal CD14+ ‘DC’ population in steady-state tissues, 
classified as DC on the basis of their MHCII expression and ex vivo migratory behaviour. They 
demonstrate that their gene-expression profile overlaps with that of circulating monocytes and 
tissue macrophages. Additionally their inability to stimulate naïve T cells suggests that they 
more closely resemble a monocyte-derived tissue resident macrophage population (McGovern, 
Schlitzer et al. 2014).  
Monocytes may enter tissue, carrying out specialised functions and change their phenotype 
entirely. However, contrasting arguments suggest that monocytes do not differentiate in tissue 
and instead survey the environment and migrate back out. This level of conflict in literature 
highlights the importance of research into monocyte functions, with special regard to their role 
once migrated to tissue from blood. Overall, further investigation needs to be carried out to 
advance the understanding of monocyte activation and differentiation in tissues. 
 
1.6 The Musculoskeletal System 
The human musculoskeletal system provides support and stability, in addition to allowing 
controlled movement of the body. It is primarily composed of the skeletal and muscular 
systems, in addition to a range of connective tissues including cartilage, tendons, ligaments and 
other connective tissues within the joint space. Synovial joints are indirectly connected by 
ligaments. These ligaments are lined by a synovial membrane, which secretes synovial fluid to 
lubricate the joint.  
Musculoskeletal disorders cause acute and chronic pain and are one of the largest burdens to 
global morbidity. Between 1990-2010, musculoskeletal disorders had one of the largest (88%) 
global increases in incidence out of non-communicable diseases (Global Burden of Disease, 
2010). There are over 200 musculoskeletal disorders including fibromyalgia, ankylosing 
spondylitis, idiopathic lower back- and neck-pain and arthritis (Arthritis Research UK, 2017). 
The two most common forms of arthritis are OA and RA, both causing joint stiffness, pain and 
inflammation. However, the causal mechanisms of disease pathogenesis differ greatly between 
these two arthritides. 
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The normal synovial membrane is relatively acellular, only 1-2 cells thick across the intimal 
layer (Smith, 2011). The sublining consists of mainly fat cells and fibroblasts, although 
macrophages and lymphocytes can be identified in lesser quantities. Conversely, macrophages 
are the main cell type in the intimal layer. 
 
1.7 Inflammatory Arthritis 
Throughout this thesis, inflammatory arthritis (IA) is a term that will be used to describe 
classically inflammatory arthritic conditions, when being used as a control or comparator. 
Although this mainly encompasses RA, it also includes other inflammatory conditions such as 
Psoriatic arthritis (PsA). When disease-specific mechanisms or research are being discussed, 
IA will not be used and instead, the disease-specific abbreviation. 
RA is thought to be a chronic autoimmune disease inducing synovial inflammation and joint 
destruction resulting in significant disability, morbidity as well as increased mortality compared 
to the general population (Chen, Wang et al. 2006, Lebre, Jongbloed et al. 2008, Pieringer and 
Pichler 2011, Koo, Kim et al. 2013). RA is a systemic disease and can lead to diffuse 
inflammation in the lungs, heart membrane, whites of the eyes and nodular lesions in the skin 
(McInnes and Schett 2011). Autoimmunity is an aberrant immune response to ‘self’ cells and 
tissues. Central and peripheral tolerance are immunological mechanisms developed to prevent 
autoimmunity. Central tolerance involves the deletion of self-reactive T- and B-cells during 
their development in primary lymphoid organs. However, not all auto-reactive cells are deleted 
by this process. Therefore, additional mechanisms of tolerance operate within peripheral 
tissues. These mechanisms include the induction of anergy through antigen presentation in the 
absence of co-stimulatory signals, or through active suppression by cells such as Tregs. It is 
thought that a break in central tolerance leads to the generation of auto-reactive T cells, whereas 
a break in peripheral tolerance may lead to the aberrant activation and expansion of pre-existing 
auto-reactive T cells. A failure of either of these mechanisms may contribute significantly to 
RA pathogenesis (Chen, Wang et al. 2006). 
The antigen-specific reaction in RA remains unclear. In seropositive disease, post-translational 
modifications may result in citrullinated peptides (Burska, Hunt et al. 2014).  Indeed, the 
clinical presentation of RA includes production of the autoantibodies rheumatoid factor (RF) 
and anti-citrullinated protein antibody (ACPA)), as well as synovial inflammation and 
hyperplasia, and joint destruction (McInnes and Schett 2011). Genetics factors have been shown 
to contribute ~60% variation in liability to RA, with environmental factors such as smoking 
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also playing a role (MacGregor, Snieder et al. 2000). As treating RA early results in a more 
beneficial outcome, there is much research being carried out into early biomarkers for RA as 
well as defining predictors for drug response (Isaacs and Ferraccioli 2011). Unlike OA, there 
are disease-modifying medications available for RA, including anti-inflammatory drugs, such 
as steroids, which may suppress symptoms and inflammation. Non-steroidal anti-inflammatory 
drugs (NSAIDs), are potent suppressors of disease activity, but may have many unwanted side 
effects over time. DMARDs, such as non-biologic methotrexate, used first line, and biologics 
such as anti-TNF, aim to stop the progression of disease activity and have proved effective in 
many patients. However, the pathogenesis of RA is yet to be fully understood.  
RA is characterised by the inflammation of the synovial tissue. In RA, joint damage initiates 
within the synovial tissue, where vasculitis and immune cell infiltrate, predominantly T- and 
B-cells, result in synovitis. Antigen presentation and cytokine production within the synovial 
tissue further exacerbate this inflammation and angiogenesis. The formation of an invading 
synovial pannus may cause erosions of nearby bone. Subsequent production of pro-
inflammatory cytokines and metalloproteinases (MMPs) by synoviocytes and chondrocytes 
causes cartilage degradation. Although many of the mechanisms of joint destruction in PsA are 
similar to RA, there are key differences. These include a T cell predominance in PsA synovium, 
absence of circulating autoantibodies in PsA and the early expression of vascular growth factors 
and distinct vascular pathology in PsA (Veale and Fearon 2015). PsA is associated with the 
development of psoriasis. Similarly, a number of other arthritic conditions can be associated 
with co-morbidities. These include enteropathic arthritis and inflammatory bowel disease, gout 
and the build up of sodium urate crystals in the joint, and reactive arthritis after infection. 
 
1.8 Osteoarthritis 
OA has historically been viewed as a wear and tear disease. However, it is becoming recognised 
that synovial inflammation may be a key mediator in disease pathogenesis. The understanding 
of synovial cellular mechanisms in OA pathogenesis is lagging behind the detailed 
understanding of how synovial cells perpetuate RA pathogenesis. This may be partly explained 
by the relatively recent recognition of these inflammatory processes in OA. Figure 1.3 
demonstrates the recent increase in ‘Osteoarthritis’ research articles being published.  
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1.8.1 National Institute for Health and Care Excellence (NICE) guidelines for diagnosis of 
OA 
OA is characterised by the progressive degradation of articular cartilage and subchondral bone 
(Fig. 1.4). This leads to the pain, stiffness and inflammation of the associated joint. The primary 
sites of OA are synovial joints, including knees, hips and hands.  
A diagnosis of OA can be made without investigation if the patient is over 45, has activity- 
related joint pain, and has either no morning joint-related stiffness or morning joint-related 
stiffness that lasts no longer than 30 minutes. Signs of OA joint involvement include joint pain, 
stiffness, effusion, tenderness, crepitus and locking. A holistic approach assesses the disease 
effect on a patient’s quality of life, summarised in Figure 1.5. Imaging can also be used to aid 
in the diagnosis of OA. X-rays, magnetic resonance imaging (MRI) and ultrasound are used to 
identify joint space narrowing and the presence of osteophytes (Braun and Gold 2012). 
OA is a multifactorial disorder with risk factors including, age, ethnicity, sex, nutrition, obesity, 
genetics and local injury (Felson, Lawrence et al. 2000). OA can be further characterised into 
primary and secondary OA. Primary OA is used as a classification for patients where there is 
no clear cause for their disease development, including the aging population. Secondary OA is 
used for patients who have an associated risk factor which is the probable cause such as local 
injury, obesity, genetics and inflammation in the joint (Felson, Lawrence et al. 2000). 
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Figure 1.3: Published research relating to rheumatoid arthritis, osteoarthritis and psoriatic arthritis 
PubMed was used to search for articles with the terms ‘Rheumatoid arthritis’, ‘Osteoarthritis’ or ‘Psoriatic 
Arthritis’ (18/09/2017). Lists of publications by year were downloaded and plotted in GraphPad Prism.1876 
and 1938 are the first recorded publications for RA and OA listed on PubMed, respectively. In 1992, there was 
a difference of 1492 articles between RA and OA, whereas in 2016 this difference has reduced to 139 articles. 
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Figure 1.4: Key characteristics of healthy, osteoarthritis and rheumatoid arthritis joints 
The healthy synovial joint is mainly composed of the bone ends lined with cartilage. These are connected by 
the synovial membrane and joint capsule. The joint space is filled with synovial fluid secreted by the synovial 
membrane. Osteoarthritis (OA) is characterised by narrowing of the joint space, degradation of cartilage and 
osteophyte formation. Rheumatoid arthritis (RA) is characterised by synovial inflammation and bone 
destruction. 
Figure 1.5: Holistic approach to OA diagnosis and management 
A holistic approach to the diagnosis and management of osteoarthritis (OA) is taken to assess the effect of 
disease on the patients overall quality of life. Key factors include health, social and occupational impacts 
in addition to range of other issues depicted above. 
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1.8.2 Pathogenesis of Osteoarthritis 
Risk factors of OA can be distinguished by two mechanisms initiating the early stresses on the 
joint. These are the abnormal loading on a normal joint structure or the normal loading on an 
abnormal joint structure (Goldring and Goldring 2010). Alongside cartilage degradation, 
subchondral bone sclerosis occurs and subsequent biochemical and biomechanical changes 
disrupt joint homeostasis, affecting other local tissues. This joint damage is associated with the 
overproduction of cytokines and growth factors. It has been previously shown that synovial 
macrophages play a key role in the overt production of TNF-α and IL-1β in OA synovium 
(Bondeson, Wainwright et al. 2006). These can subsequently influence the production of 
aggrecanases and collagenases such as MMP1, MMP13, a disintegrin and metalloprotease with 
thrombospondin (ADAMTS4) and ADAMTS5, contributing to cartilage destruction. 
Proteoglycans and type II collagen fragments produced during cartilage breakdown enter the 
synovial fluid. This in turn elicits an immune response resulting in synovitis. Whether this 
synovitis is primary or secondary to disease remains unclear. The resultant expression of MMPs 
and cytokines from joint damage are catabolic, resulting in a positive feedback loop promoting 
the further production of these catabolic factors and cartilage destruction (Fig. 1.6). Although 
the extent of joint damage in OA is known, the underlying pathology, particularly at the cellular 
level, remains poorly understood.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Pathogenesis of joint destruction and disease modifying strategies for OA 
Joint destruction in OA is led by a number of mechanisms. These include the secretion of adipokines by the 
fat pad, and cytokines by cells in the synovial membrane. Cartilage degradation promotes the further 
upregulation of MMPs, PGE2 and NO further contributing to cartilage destruction. Proteoglycans and type II 
collagen fragments enter the synovial fluid. It remains unclear whether associated synovitis is primary or 
secondary to disease. A number of disease modifying treatments have targeted specific pathways in OA, but 
have had disappointing results (Philp, Davis et al. 2017). 
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1.8.3 Management and treatment of OA 
Similar to diagnosis, a holistic approach is taken with the management and treatment of a patient 
with OA. Currently, there are no disease modifying treatments in use clinically, and instead, 
symptoms and pain are managed. 
Non-pharmacological treatments include exercise, weight loss, diet improvement, 
thermotherapy, acupuncture and physical aids such as adaptive footwear, external braces and 
walking sticks. Pharmacological treatments encompass mainly NSAIDs in the form of oral 
analgesics and topical treatments. Selective cyclooxygenase 2 (COX-2) inhibitors can also be 
used. For severe pain, articular corticosteroid injections may be administered. Surgical 
intervention will be considered if previous management strategies fail, but before the patient 
has prolonged functional limitation and severe pain. Patients who are referred for surgery 
typically experience joint pain, stiffness, and reduced joint function, all having a substantial 
impact on their quality of life. Although total joint replacement can provide therapeutic relief, 
they are only suitable for end-stage disease, provide reduced function compared to a healthy 
joint, and can ‘wear out’ over time. 
In a meniscal tear model of OA in rats, an autologous protein solution was shown to decrease 
collagen and cartilage degradation (King, Bendele et al. 2017). This solution contained white 
blood cells, platelets, concentrated plasma and anti-inflammatory IL-1Rα, sIL-1RII and sTNF-
RII. Although this did not have a completely regenerative effect, it did demonstrate that this 
autologous treatment had a disease-modifying effect in this model of OA. 
1.8.4 Inflammation in Osteoarthritis 
It is now becoming clear that inflammatory processes may be a key mediator in the pathogenesis 
of OA (Sellam and Berenbaum 2010, Scanzello and Goldring 2012). Synovial inflammation in 
OA exhibits synovial hypertrophy and hyperplasia, a mixed leukocyte infiltrate and is present 
in 50-70% of OA patients (Sellam and Berenbaum 2010, Kapoor, Martel-Pelletier et al. 2011, 
Scanzello and Goldring 2012, Moradi, Rosshirt et al. 2015). Elevated levels of pro-
inflammatory mediators including TNF-α, IL-1β, IL-6, IL-15, IL-17, IL-18 and nitric oxide 
(NO) have been reported in the serum and synovial fluid of OA patients compared to healthy 
controls (Benito, Veale et al. 2005, Kapoor, Martel-Pelletier et al. 2011). However, 
inflammation is usually local and low grade, not resulting in systemic inflammation as observed 
in RA patients. Correlations between OA synovial inflammation and clinical symptoms of OA, 
including pain, swelling, reduced joint mobility and cartilage damage, have been reported 
(Ayral, Pickering et al. 2005, Torres, Dunlop et al. 2006, Baker, Grainger et al. 2010, Conaghan, 
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D'Agostino et al. 2010, Roemer, Crema et al. 2011, Scanzello, McKeon et al. 2011). The 
presence of synovitis in early OA has been observed before radiographic joint damage can be 
detected, suggesting it plays an active role in subsequent damage. However, it remains unknown 
whether this inflammation is causal or consequential. Understanding these early mechanisms, 
and how they interlink, will be essential to fully understanding the underlying causes of joint 
damage in OA. 
Although it has been shown in animal models that targeting synovitis slows OA progression 
and reduces symptoms, clinical trials for OA patients with anti-inflammatory drugs have shown 
limited success (Frisbie, Ghivizzani et al. 2002, Schelbergen, Geven et al. 2015, Philp, Davis 
et al. 2017). These have included TNF-α inhibition, IL-1β inhibition, arachidonic acid pathway 
inhibitors and NO inhibitors. However, there is a range of alternative strategies currently 
undergoing in vitro and in vivo pre-clinical validation. These target a range of cytokines (IL-7, 
IL-15, IL-17), p38 mitogen-activated protein kinases (MAPKs), TLR2 & 4, adipokines (leptin), 
TNF-α siRNA and pan cytokine siRNA (Fig. 1.6) (Philp, Davis et al. 2017).  
When studying inflammation and synovitis in OA, it may also be important to consider disease 
pattern.  For example, it has been demonstrated that the cellular infiltrate differs between uni-
compartmental (UC) and bi-compartmental (BC) OA of the knee (Moradi, Rosshirt et al. 2015). 
BC OA had a high inflammatory profile driven by both CD14+ macrophages and CD4+ T cells, 
whereas in UC OA, CD14+ macrophages were the predominant cell type. Another consideration 
will be the analysis of synovial tissue from different joint sites. Although differences have been 
observed phenotypically and through RNA-sequencing of gene expression, these differences 
were deemed acceptable, and the use of tissue from multiple joints suitable when necessary 
(Kraan, Reece et al. 2002, Frank-Bertoncelj, Trenkmann et al. 2017). This is discussed further 
in Chapter 4. 
The disappointing early results in clinical trials testing disease modifying drugs for OA could 
be due to the known heterogeneity of OA patients, and a lack of appropriate patient 
stratification. Indeed, through assessment of historical clinical trial data, it was found that OA 
patients have not been previously stratified on the basis of synovitis or other inflammatory 
biomarkers (Philp, Davis et al. 2017). A more comprehensive understanding of the cellular and 
molecular mechanisms that govern low-grade synovial inflammation in OA will be 
instrumental in identifying patients that could be targeted for clinical benefit. 
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1.8.5 Synovial macrophages in OA 
Although there is extensive research focussed on the pathogenesis of OA, there is limited 
information about the roles of immune cell subsets in the synovial tissue. Early studies showed 
that macrophages are a key contributor to the pathogenesis of RA within the inflamed synovial 
joint, where they are found in abundance and produce pro-inflammatory cytokines including 
IL-1β, TNF-α, IL-18 and GM-CSF (Gracie, Forsey et al. 1999, Kinne, Brauer et al. 2000, Liew, 
Wei et al. 2003). Much of this research has included histological analysis (Haywood, 
McWilliams et al. 2003, Kennedy, Fearon et al. 2011, Manferdini, Paolella et al. 2016). 
Additionally, a recent non-invasive imaging study with a folate receptor-β-based agent has 
shown that the quantity of activated macrophages in the knee of OA patients correlated with 
disease severity and progression (Kraus, McDaniel et al. 2016).  
Macrophages in OA synovial tissue are thought to respond to DAMPs, and as a consequence, 
contribute to cartilage destruction and osteophyte formation through the production of MMPs 
and cytokines including IL-1β, TNF and TGFβ (Blom, van Lent et al. 2004, van Lent, Blom et 
al. 2004, Bondeson, Blom et al. 2010). Further evidence of the macrophages’ role in 
pathogenesis is the histological observation of enhanced numbers in OA synovium correlating 
with the degree of synovial angiogenesis, in line with the previously mentioned findings from 
the folate receptor imaging study (Haywood, McWilliams et al. 2003, Benito, Veale et al. 2005, 
Manferdini, Paolella et al. 2016). Furthermore, it has been shown that depletion of macrophages 
from synovial tissue cultures in vitro eliminates IL-1β and TNF production, in addition to 
downregulation of fibroblast produced cytokines and MMPs (Bondeson, Wainwright et al. 
2006). It was also shown that, unlike in RA, IL-1β production was independent of TNF-α in 
OA. 
It has been shown that depletion of macrophages in animal models reduces osteophyte 
formation (Blom, van Lent et al. 2004, van Lent, Blom et al. 2004). This study used a collagen 
induced OA model and chlodronate depleted macrophages. The authors suggest that 
macrophages may be the pivotal cell in the synovium mediating OA pathology including 
fibrosis and osteophyte formation. In contrast, results from a meniscal-tear induced OA model 
demonstrated no mitigation of cartilage degeneration, and instead enhanced joint synovitis, 
characterised by an infiltration of CD3+ T cells and neutrophils (Wu, McNeill et al. 2017). 
Although osteophyte formation was similarly reported to be reduced, this was only to the same 
level as the non-macrophage depleted control. This may be owing to the decreased levels of 
TGFβ1 measured in the serum. These decreased levels of TGFβ1 were mirrored by an increase 
of pro-inflammatory cytokines in both serum and synovial fluid. It was hypothesised that in the 
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setting of obesity, macrophages are vital for modulating homeostasis of immune cells, and that 
the targeted depletion of specific macrophage subsets may mitigate inflammation and OA in 
obesity. It has additionally been reported that a mix of both pro- and anti- inflammatory M1 
and M2 macrophages are present in the synovium of OA patients (Manferdini, Paolella et al. 
2016).  
These studies demonstrate the possible heterogeneity of macrophage function in OA. Despite 
the evidence of macrophages contribution to OA pathogenesis, it is likely that their role is more 
complex than causing just inflammation through production of various pro-inflammatory 
factors, or just contributing to tissue regulation. Macrophages are heterogeneous cells with wide 
ranging anti-inflammatory functions relevant to OA, including tissue repair, phagocytosis and 
dampening down of inflammation. A traditional model for the study of macrophages is the 
discussed M1/M2 paradigm. This macrophage model has been useful for understanding the 
roles macrophages play in inflammation and repair, but it is becoming recognised that this 
paradigm does not accurately represent macrophage activation in vivo, and rather demonstrates 
extreme examples of macrophage activation (Xue, Schmidt et al. 2014). There is a need to 
further understand the role of macrophages in OA pathogenesis. This will aid in the design of 
therapies that potentially target only a subset of macrophages. 
During tissue remodelling after injury, pro-inflammatory macrophages remove necrotic 
material, kill pathogens if present, and may promote proliferation of new tissue cells. 
Subsequently, anti-inflammatory macrophages dampen down inflammation, promote 
differentiation of newly recruited or expanded cells, and stimulate depositions of new 
extracellular matrix. The recognition of both pro- and anti-inflammatory macrophages playing 
roles in tissue remodelling has been previously observed (Novak and Koh 2013, Brown, Sicari 
et al. 2014). However, the specific processes involved in these roles will depend on the specific 
tissue environment, and will likely differ greatly between different tissues and types of tissue 
injury. Although both pro- and anti-inflammatory macrophages are thought to be crucial in 
tissue repair, the transition from these states is key to resolution and avoidance of associated 
complications (Sindrilaru, Peters et al. 2011). 
There is a substantial body of evidence to suggest the presence of activated synovial 
macrophages in OA, and their correlation with disease progression. However, the specific 
mechanisms of action are yet to be fully understood. In the context of the synovium in OA, it 
is unknown whether macrophages are pro- or anti-inflammatory, or a mixture, fluctuating 
between different stages of disease. Despite this lack of knowledge, it is likely that an imbalance 
between pro- and anti-inflammatory macrophages contributes to low-grade chronic 
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inflammation, subsequently progressing OA disease activity. To fully understand these 
polarisation states, it is first necessary to establish the full phenotypes of macrophages present 
in OA synovium.  
Previously conducted gene expression work in synovial macrophages has been mostly by 
candidate polymerase chain reaction (PCR) in RA. RNA-sequencing has been previously 
conducted on synovial fibroblasts, likely owing to their relative abundance, and ease of 
expansion ex vivo. Again, this has been mostly conducted in RA, but with some studies using 
OA as controls. The only evidence of RNA-sequencing on macrophages in the context of 
arthritis is CD14+ cells isolated from peripheral blood of healthy donors. These cells were 
differentiated ex vivo into a macrophage phenotype (Heruth, Gibson et al. 2012, Donlin, 
Jayatilleke et al. 2014, Wang, Xia et al. 2014, Shepherd, Skelton et al. 2015, Mizoguchi, 
Slowikowski et al. 2017). Although previous studies on the synovium of arthritis patients have 
been mostly histology- and imaging-based, the use of tissue digestion, flow cytometry and gene 
expression has been shown to be achievable (Kraan, Reece et al. 2002, Van Landuyt, Jones et 
al. 2010, Frank-Bertoncelj, Trenkmann et al. 2017). An accurate and in-depth analysis of the 
cellular mechanisms in OA synovial tissue, particularly those involving macrophages, will be 
key to progress our understanding of the role that synovial inflammation plays in this disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
1.9 Hypothesis and aims 
It is has become recognised that synovial inflammation contributes to the pathogenesis of OA. 
However, it is unclear what the role of synovial immune cell subsets in driving and regulating 
this process is. This is partly due to technical barriers. 
1.9.1 Hypothesis 
I hypothesise that there is heterogeneity at the cellular and molecular level in the synovial tissue 
of osteoarthritis patients, particularly within synovial macrophages. Heterogeneity within these 
synovial macrophages will be important to address as this likely reflects heterogeneity in the 
specific tissue environment of these arthritic joints. 
1.9.2 Aims 
To investigate this hypothesis, a set of three overarching aims were outlined, summarised 
below. These aims are discussed in detail in the subsequent three results chapters.  
(1) Develop technical protocols to allow the successful isolation, identification and purification 
of immune cell populations from synovial tissue. This will encompass the isolation of a single 
cell suspensions from synovial tissue with high cell viability, large yields, and minimal surface 
marker cleavage. The design of a flow cytometry panel will allow the purification of multiple 
cell subsets by fluorescence-activated cell sorting. 
(2) Enumerate the immune cell subsets present in the synovial tissue of OA and IA patients. To 
achieve this, methods for the accurate quantification will be assessed and confirmed with 
computational analyses. 
(3) Conduct an in-depth analysis of synovial macrophages in OA. Highly purified synovial 
macrophages from OA and IA patients will be extensively phenotyped and functionally 
assessed. The gene expression profiles of synovial macrophages will be determined by RNA-
sequencing. 
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Chapter 2. Materials and Methods 
2.1 Ethical Approval 
Osteoarthritis synovial tissue and peripheral blood samples were obtained through the 
Newcastle Bone and Joint Study (NBJS) after suitable elective patients were identified by 
designated research nurses (Freeman Hospital). Informed consent was obtained and patients 
enrolled as study participants. In line with patient confidentiality, samples were allocated 
anonymised NBJS numbers. Ethical approval was granted by the Newcastle and North 
Tyneside Research Ethics Committee (REC reference number 09/H0906/72). 
IA synovial tissue and peripheral blood samples were obtained from the Newcastle Early 
Arthritis Clinic (NEAC). Ultrasound-guided synovial tissue biopsies were collected by Dr. 
Arthur Pratt. Informed consent was obtained and patients enrolled as study participants. In line 
with patient confidentiality, all samples were allocated anonymised Early Arthritis (EA) 
numbers. Ethical approval was granted by the Newcastle and North Tyneside 2 Research Ethics 
committee (REC reference number 12/NE/0251). 
Healthy peripheral blood samples were obtained from volunteers following informed consent 
from the Newcastle Academic Health Partners Bioresource. Ethical approval was granted by 
the Newcastle and North Tyneside Research Ethics Committee (REC reference 12/NE/0395). 
Leucocyte Reduction System (LRS) cones from platelet donations by healthy volunteers were 
purchased from the National Blood Service (Newcastle upon Tyne). 
 
2.2 Tissue Culture 
All cell cultures were carried out in RF10: (RPMI 1640; Sigma Aldrich) supplemented with 
10% (v/v) Fetal Bovine Serum (FBS; Gibco), 100U/ml penicillin, 100μg/ml streptomycin, and 
2mM glutamine (All Sigma-Aldrich) at 37oC, 5% CO2. Cell washes were carried out with 
Hanks Balanced Salt Solution (HBSS Ca2+ and Mg2+ free; Lonza) supplemented with 1% (v/v) 
FBS. All cell counts were carried out using trypan blue (Sigma Aldrich) exclusion on a Burker 
counting chamber (Mairenfel-Superior). The average of three counts over 25 squares in a grid 
was taken as the cell count.  The cell count was multiplied by 104 to account for the chamber 
volume, and the dilution factor, to gain cells/ml. 
 
24 
 
2.3 Cell isolation 
2.3.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Fresh peripheral blood was collected in EDTA (Ethylenediaminetetraacetic acid; Fischer 
Scientific) vacutainers (Greiner Bio-One). Peripheral blood was diluted 1:1 (LRS Cones 1:2) 
with room temperature HBSS +2mM EDTA. PBMCs were isolated using density gradient 
centrifugation over Lymphoprep (Axis Shield). 20ml diluted blood was layered over 15ml 
Lymphoprep and centrifuged for 30 mins at room temperature (895g). PBMCs were recovered 
from the interface and washed for 7 mins at 4oC (600g) to remove any contaminating 
Lymphoprep. PBMCs were then washed for 7 mins at 4oC (250g), twice, to remove any 
platelets. Final cell suspension was filtered through a 70µm nylon filter to remove any debris, 
and counted as previously described. 
2.3.2 CD14+ Monocyte Isolation 
CD14+ monocytes were positively selected using magnetic assisted cell sorting (MACS®) with 
anti-CD14 magnetic microbeads (Miltenyi Biotec). PBMCs were washed and resuspended in 
ice-cold MACS buffer (Phosphate Buffered Saline (PBS; Lonza), + 2mM EDTA, + 0.5% FBS) 
at 80µl per 10x106 PBMC. 10µl CD14 MicroBeads per 10x106 PBMCs were added with gentle 
agitation. PBMCs were incubated on ice for 20 mins with gentle agitation every 5 minutes. 
PBMCs were washed with MACS buffer for 7 mins at 4oC (400g) to remove any unbound 
microbeads. Cell pellet was resuspended in 3ml MACS buffer. PBMCs were added to an LS 
column mounted in a MACS® magnetic separator (Miltneyi Biotec), pre-rinsed with MACS 
buffer. Columns were washed through 3 times with 3ml ice-cold MACS buffer. CD14+ labelled 
cells are retained by attraction to the magnetic beads in the column, and CD14- cells are washed 
through. LS column was removed from separator and CD14+ cells flushed out with 5ml MACS 
buffer. Cells were washed in ice-cold MACS buffer and resuspended in cold culture media. An 
average yield of 15-20% CD14+ monocytes was expected from the PBMC population. 
2.3.3 Synovial tissue mononuclear cell isolation 
Synovial tissue was stored overnight (<18 hours) in RF10 at 4oC. Where possible, any visible 
fat was carefully removed from the synovial tissue. Synovial tissue was mechanically digested 
into 1mm fragments using scissors, scalpel and forceps. During mechanical digestion, tissue 
was always submerged in RF10 to avoid drying. Tissue and media was transferred to a 20ml 
universal tube and topped up to 10ml with warm RF10. Liberase TM (Roche) was added at a 
final concentration of 15μg/ml and DNase (Roche) at 30μg/ml. Tube was transferred to a 
shaking incubator and shaken for 45 mins at 37oC (260rpm). Additional manual vigorous 
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shaking was applied every 15 mins during incubation. Solution was filtered through a 100μm 
filter and filtrate immediately placed on ice to inhibit enzymatic digestion. Any remaining tissue 
was subjected to a second repeated mechanical and enzymatic digestion with filtering. A third 
digestion on any remaining tissue was carried out. The three filtrates were pooled, washed and 
counted. 
 
2.4 Generation of monocyte-derived macrophages (moMac) 
CD14+ monocytes were cultured at a concentration of 0.5x106cells/ml RF10 in 24-well plates 
(Corning) for 6 days. Cells were cultured with 50ng/ml M-CSF (Peprotech). On day 3 media 
was refreshed by removal of 450μl media, and addition of 500μl warm RF10 supplemented 
with 100ng/ml M-CSF. After 6 days, cells were incubated on ice for 1 hour to loosen from the 
plate. Cells were then harvested, washed three times and resuspended in appropriate media. 
 
2.5 Generation of monocyte-derived dendritic cells (moDC) 
CD14+ monocytes were cultured at a concentration of 0.5x106cells/ml RF10 in 24-well plates 
for 6 days. Cells were cultured with 50ng/ml IL-4 (Immunotools) and 50ng/ml GM-CSF 
(Immunotools). On day 3, media was refreshed by removal of 450μl media, and addition of 
500μl warm RF10 supplemented with 100ng/ml IL-4 and 100ng/ml GM-CSF. After 6 days, 
cells were incubated on ice for 1 hour to loosen from the plate. Cells were then harvested, 
washed three times and resuspended in appropriate media. 
 
2.6 Flow Cytometry 
2.6.1 Cell surface staining 
For cell surface staining, single cell suspensions were resuspended at either 1x106 cells or entire 
tissue digest (≤5x106 cells) per 100µl staining buffer (PBS + 3% FBS, + 2mM EDTA, + 0.1% 
sodium azide (Sigma-Aldrich)). Cells were incubated for 30 mins on ice with 2.5µl human IgG 
per 1x106 cells, and selected flow cytometry antibodies (Table 2.1). Titration of antibodies for 
optimised flow cytometry panel (Chapter 3) were carried out on PBMCs (data not shown), and 
efficacy confirmed on synovial tissue cells. Additional antibody titrations were carried out by 
members of the Musculoskeletal Research Group, or antibodies used at manufacturers 
recommended dilution. Dilutions of all antibodies are listed in table 2.1. After incubation, cells 
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were washed twice in staining buffer for 7 mins at 4oC (400g) and resuspended in a final volume 
of 200μl staining buffer. 7-Aminoactinomycin D (7-AAD) viability dye (BD Biosciences), was 
added at 20µl/1x106 cells, 10 mins prior to data acquisition on an LSR Fortessa X20 (BD 
Bioscience). Flow cytometry data were analysed using FlowJo (TreeStar) software and 
CytofKit bioconductor package for R. In addition, tSNE, SPADE and CITRUS analyses were 
performed in Cytobank on flow cytometry data sets. 
 
2.6.2 Fluorescence activated cell sorting (FACS) 
Cell suspensions were prepared following the same methods outlined in 2.6.1, and resuspended 
at ≤5x106 cells/ml staining buffer. Cell subsets were isolated on a BD FACSAria FUSION cell 
sorter (BD Biosciences) at 4oC using the gating strategy discussed in Chapter 3. Gates were 
applied using fluorescence minus one (FMO), such as CD45 described in Chapter 3.5. 
Additional examples are demonstrated in Appendix 2.1. During FACS sorting, the stream of 
cells is separated into single cell droplets, to which electrical charges are applied according to 
their fluorescent parameters. These droplets then pass through oppositely charged plates, 
guiding them into assigned eppendorfs. For all sorts, the FACS sorter was operated on the 
highest purity configurations. For downstream applications involving cell culture, cells were 
sorted into 4oC RF10. For genomic analysis, cells were sorted directly into RLT buffer (Qiagen) 
+1% Beta-Mercaptoethanol (Sigma Aldrich), vortexed and immediately frozen on dry ice. 
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Antibody Dilution Fluorophore Clone Company 
CCR2 1:50 BV421 48607 BD Biosciences 
CCR7 1:20 APC 150503 R&D Systems 
CD1c 1:50 PE L161 Biolegend 
CD1c  1:50 PE-Cy7 L161 Biolegend 
CD11b 1:50 BV785 ICRF44 Biolegend 
CD11c 1:50 BV421 B-ly6 BD Biosciences 
CD11c 1:50 V450 B-ly6 BD Biosciences 
CD14 1:50 APC-Cy7 HCD14 Biolegend 
CD16 1:20 BV711 3G8 Biolegend 
CD16 1:50 BV605 3G8 Biolegend 
CD172a/Sirp-α 1:50 PerCP-Cy5.5 SE5A5 Biolegend 
CD19 1:100 PE-Cy5.5 SJ25cl eBiosciences 
CD19 1:50 AF700 HIB19 BD Biosciences 
CD20 1:100 PE-Cy5.5 2H7 eBiosciences 
CD20 1:50 AF700 2H7 BD Biosciences 
CD206 1:50 BV786 19.2 BD Biosciences 
CD206 1:50 APC 15-2 Biolegend 
CD3 1:20 BV786 UCHT1 BD Biosciences 
CD3 1:100 AF700 UCHT1 BD Biosciences 
CD3 1:20 APC UCHT1 Biolegend 
CD4 1:200 PE-Cy7 RPA-T4 Biolegend 
CD4 1:200 PE SK3 Biolegend 
CD45 1:10 V500 HI30 BD Biosciences 
CD64 1:50 APC 10.1 Biolegend 
CD64 1:50 PE 10.1 Biolegend 
CD83 1:50 PE-Cy7 HB15E Biolegend 
CD86 1:50 PerCP-Cy5.5 IT2.2 Biolegend 
CD90 1:50 APC 5E10 BD Biosciences 
FOLR2 1:50 PE EM-35 EXBIO 
HLA-DR 1:50 APC G-46-6 BD Biosciences 
HLA-DR 1:20 PerCP L203 R&D Systems 
Viability Dyes Concentration Detection Clone Company 
DAPI 3µm 355nm 379/28 - Life Technologies 
7-AAD 20µl/1x106 Cells 561nm 780/60 - BD Biosciences 
Table 2.1: Flow cytometry antibodies used for surface staining 
 
 
 
 
 
 
 
28 
 
2.7 Microscopy Slide Preparations 
2.7.1 Cytospins and Giemsa Stain 
After FACS sorting, cell populations were washed once and re-suspended in 50µl FBS. Glass 
Cytoslides were loaded into Cytoclips with filter cards and Cytofunnels (All ThermoFisher 
Scientific). Cell suspensions were transferred to Cytofunnels and centrifuged in a CytospinTM 
4 Cytocentrifuge (ThermoFisher Scientific) for 8 mins at room temperature (600g). Slides were 
dried overnight. Cells were fixed by submersion in ice-cold methanol for 30seconds. Slides 
were then stained on a Siemens Advia S60 Autoslide system with Hematek® Wright-Giemsa 
Stain PAK. Glass coverslip was applied with DPX (Sigma-Aldrich). Slides were stored at 4oC 
in the dark. 
2.7.2 CellTAK Fluorescent Preparations 
For fluorescent microscopy, cell suspensions were prepared using CellTAK (Corning) and 
Millicell EZ slides (Merck millipore – 8 well), both kindly gifted by Dr. Nicola Maney. A 1X 
HEPES neutral buffer solution was prepared. The amount of Cell-TAK solution required was 
calculated by multiplying 25µg/ml Cell-Tak solution by cm2 surface area of slide. Required 
amount of Cell-Tak (12.5µl) was diluted with neutral buffer solution (1ml). 100µl of Cell-Tak 
solution was added to each well within 10 mins. Slides were incubated for 3 hours at 37oC. 
Cell-Tak solution was aspirated and wells washed with sterile water to remove bicarbonate. 
50,000 cells were added per well in 200µl of media and incubated for 30 mins at 37oC. Media 
was aspirated and wells washed with PBS. Chambers were removed from the slides, and glass 
cover slip (Corning) mounted with 2 drops of DAPI-containing Vectorshield (Vector 
Laboratories). Slides were stored at 4oC in the dark. 
 
2.8 Phagocytosis 
To measure the phagocytic activity of macrophages, 1μm fluorescent (λex ~470 nm; 
λem ~505 nm) latex beads (Sigma Aldrich – L4655) were added to either moMac or moDC on 
day 6 of culture, synovial tissue mononuclear cells at 0.5x106cells/ml RF10 in 24-well plates 
or FACS sorted synovial macrophages at 0.5x104cells/ml RF10 in 96 well round bottom plates. 
An optimal bead dilution of 1/4000 was determined by Jane Langford (MRes), and used for all 
experiments. Cells were incubated for 3 hours at 37oC. After incubation cells were harvested 
and washed 3 times with PBS to ensure removal of unbound beads or beads on the cell surface. 
Viability dye 7-AAD was added at 20µl/1x106 cells and bead uptake measured by flow 
cytometry. Slide preparations were carried out as described in section 2.7.2. Confocal 
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microscopy (Section 2.9) was used to confirm the beads had been engulfed by the phagocytic 
cells as opposed to attaching to the cell surface.  
 
2.9 Microscopy 
Cytospin preparations were imaged using an Olympus CKX41 inverted phase contrast 
microscope with Olympus CAMEDIA C-7070 digital camera.  Fluorescent microscopy was 
carried out using an EVOS FL Cell Imaging System (Life Technologies). Prepared slides were 
imaged in bright field, phase contrast and merged with green and blue channels in ImageJ 1.8.0 
(ImageJ). Microscopy was carried out at 4X, 10X and 100X magnification, with scale bars 
generated. Confocal microscopy was performed using a Leica TCS SP8 confocal microscope 
and LAS X Software with the assistance of Dr. Rolando Berlinguer-Palmini at the Newcastle 
University Bio-imaging Facility. Fluorescent latex beads were detected at ~505nm. For analysis 
of bead internalisation, ‘Z stacks’ were generated. As the thickness of a single focal plane is 
less than that of a cell within the sample, multiple focal planes can be imaged with sensitive 
microscopes. Z stacks were generated by recording multiple images taken at incremental focal 
planes throughout the sample. Projections of these Z stacks were then created using LAS X 
software and ImageJ. This allowed the visualisation of latex bead internalisation by phagocytic 
cells (Section 2.8). 
 
2.10 Genomic Analyses 
2.10.1 Isolation of RNA 
RNA was isolated from purified peripheral blood and synovial tissue cells using QIAGEN 
Micro RNeasy kit according to the manufacturers protocol. Cell lysates were stored in RLT 
buffer at -80oC. After defrosting, lysates were homogenised by centrifugation for 2 min (full 
speed) in a QIAshredder spin column. One volume of 70% ethanol was added, transferred to a 
MinElute spin column and centrifuged for 15 secs (8000g), discarding flow-through. 350µl 
Buffer RW1 was added to the MinElute spin column and centrifuged for 15 secs (8000g), 
discarding flow-through. DNase I incubation mix (DNase I & buffer RDD) was added to the 
MinElute spin column membrane and incubated at room temperature for 15 mins. 350µl buffer 
RW1 was added to the MinElute spin column and centrifuged for 15 secs (8000g), discarding 
flow-through. 500µl Buffer RPE was added to the MinElute spin column and centrifuged for 
15 secs (8000g), discarding flow-through. 500µl 80% ethanol was added to the MinElute spin 
column and centrifuged for 2 mins (8000g), discarding flow-through. MinElute spin column 
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was centrifuged for 5 min (full speed), discarding flow through. 14µl RNase-free water was 
added to the MinElute spin column and centrifuged for 1 min (full speed) to elute RNA. RNA 
was stored at -80oC until RNA-sequencing was performed. 
 
2.10.2 RNA sequencing 
Next generation RNA-sequencing was carried out at the Newcastle University Genomics Core 
Facility (GCF) led by Dr. Jonathan Coxhead. Using RNA isolated following procedures in 
section 2.10.1, quantification and quality control was carried out using High Sensitivity RNA 
Screentape (Agilent Technologies) on an Agilent 2200 Tapestation. Samples were diluted 
accordingly to normalise quantities of RNA. Smart-seq v4 (Clonetech) amplification was 
performed on samples due to low RNA quantities and Nextera XT DNA library prep kit for 
sequence library. Sequencing was performed on an Illumina NextSeq 500 at a 10 million, 75 
base pair read depth. 
 
2.11 Statistical analyses 
2.11.1 Basic Statistics 
Statistical analyses were carried out in Prism 5.03 (Graphpad Software), Minitab 17 Statistical 
Software (Minitab Inc) and R Studio (R Studio Inc). 
2.11.2 Bioinformatic analyses 
Quality control of sequencing was carried out with FastQC. Read trimming was performed with 
trimmomatic, mapping and alignment with STAR and quantification with HTSEQ. SeqMONK 
was ran to account for any DNA contamination. Counts were filtered to remove those of low 
number (<0.5 Counts Per Million) followed by assessment of batch effect and library sizes. All 
high level analysis of RNA-sequencing data was performed in R studio. After Limma-Voom 
normalisation of data, differential gene expression was performed using Limma, with an 
adjusted p-value threshold of <0.05 based upon Benjamini-Hochberg correction, and Log fold 
change (LogFC) of >1.5. Exploratory Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
pathway analysis was performed on differentially expressed genes. 
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Chapter 3. Isolation of immune cell populations from synovial tissue 
3.1 Introduction 
In inflammatory forms of arthritic diseases, the synovial membrane is a site for disease activity. 
As previously discussed, in inflammatory arthritides there is a well-described cellular infiltrate 
(Tak, Smeets et al. 1997). However, the extent to which this occurs in OA is less clear. To date, 
a large amount of research carried out in arthritis is on peripheral blood samples, owing to their 
non-invasive collection and availability, in addition to research on mouse models. This has 
yielded a wide range of knowledge, advancing our understanding of the pathogenesis of these 
diseases, and giving rise to therapeutic strategies and biomarkers. 
The extent of research conducted on human synovial tissue is demonstrated in current published 
literature. There are 294,297 ‘arthritis’ termed research articles listed on Pubmed, with 135,815 
matching the query ‘patient’. Out of these 135,815, only 15.34% match the query ‘synovial 
tissue’ or ‘synovium’. In contrast, 44.19% of these articles match the query ‘blood’. 
Furthermore, research which has been carried out on synovial tissue is largely histology based. 
52.50% of research articles listed under ‘arthritis’ AND ‘synovial tissue’ return the query 
‘histology’ (all Pubmed queries conducted on 17/08/17). There is an increased interest in 
studying disease at the relevant tissue site, because that is the place disease process takes place. 
In order to investigate the disease site in arthritis, the synovium, appropriate methods of tissue 
digestion need to be applied.  
There is a range of published and established digestion protocols, encompassing varying 
different methodologies (Loewi, Lance et al. 1975, Kohem, Brezinschek et al. 1996, Fearon, 
Mullan et al. 2006, Nagai, Miyamoto et al. 2006, Miller, Manning et al. 2009, Connolly, 
Marrelli et al. 2010, Ng, Biniecka et al. 2010, Sakuraba, Fujimura et al. 2015). However these 
can result in poor cell viability, low cell yields, biased isolation of different cell subsets and 
cleavage of extracellular proteins. ‘Walk out’ assays are an example of cell isolation, whereby 
the tissue explants are left in appropriate media at 37oC, and cells migrate from the tissue into 
the media (Loewi, Lance et al. 1975, Fearon, Mullan et al. 2006, Nagai, Miyamoto et al. 2006, 
Connolly, Marrelli et al. 2010, Sakuraba, Fujimura et al. 2015). However, with this approach 
only migratory cells will leave the tissue, and the subsequent single cell suspension would not 
be representative of the entire tissue cell population.  
Most digestion protocols involve mechanical digestion, and some include additional enzymatic 
digestion. These protocols typically involve the mechanical mincing of tissue into small 
fragments, allowing more efficient enzymatic activity. Conversely, the use of a homogeniser is 
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an example of a purely mechanical digestion method often used for the isolation of murine cells. 
Enzymatic digestion protocols have a range of different approaches, but there is little 
justification for the specific choice or concentration of enzymes. Many of these described 
protocols are not truly optimised for human, or synovial tissue, and are adopted from digestion 
protocols of other tissues or species.  
There is a need for a protocol that is specifically optimised for the digestion of human synovial 
tissue. A common protocol would also be extremely useful to the field of arthritis research, 
specifically in the interest of understanding the cellular mechanisms within synovial tissue. This 
would reduce technical ‘noise’ between experiments. The careful and accurate identification of 
cell subsets would be an additional aspect to this process. 
3.2 Aims 
The successful isolation and identification of immune cell populations from synovial tissue is 
a crucial step in understanding the pathogenesis of joint disease in inflammatory and non-
inflammatory arthritis. I therefore aimed to: 
 Develop a digestion protocol specific for human synovial tissue which results in 
sufficient cell yields for downstream analyses, high cell viability and does not cleave 
extracellular antigens 
 Design a multi-colour flow cytometry panel for the accurate identification of multiple 
immune cell subsets within the synovial tissue 
 Apply the digestion protocol and flow cytometry panel to FACS to purify immune cell 
subsets for downstream analyses 
3.3 Assessment of established protocols for tissue digestion 
To assess the suitability of different synovial tissue digestion protocols, CD14+ myeloid cells 
and cDC2s were initially identified (Fig. 3.1). My initial interest of synovial tissue cell 
populations was cDC2s, owing to their antigen presenting capacity in disease pathogenesis. In 
addition, I was interested in CD14+ monocytes and how they may contribute to the synovial 
myeloid compartment.  
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Firstly, cell debris was gated out using the FSC-A and SSC-A properties of the synovial tissue 
cell suspension. Non-viable cells were gated out by their expression of DAPI, and synovial 
leukocytes identified by expression of common leukocyte antigen CD45. T- & B-cells and 
natural killer (NK) cells were excluded by gating on cells lacking CD3 (T cells), CD19, CD20 
(B-cells) and CD56 (NK cells), and gating on the remaining cells expressing MHC-II (HLA-
DR; human leukocyte antigen – D related). CD16+ monocytes were excluded by gating on the 
CD16- negative cells, followed by exclusion of pDCs and cDC1s by gating on the CD11chi 
expressing cells. Finally, cDC2s were identified by their expression of CD1c, and CD14+ 
myeloid cells were identified by their expression of CD14 (Fig. 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
I initially assessed an in-house digestion protocol for synovial tissue, which involved the 
mechanical digestion of tissue, and then incubation with Collegenase IV (1mg/ml, Thermo 
Fisher) at 37oC for either 2 hours (Fig. 3.2 A) or 24 hours (data not shown). Both of these 
protocols resulted in loss of CD16, CD14 and CD11c expression (Fig. 3.2 A), in addition to 
poor cell yields and viability (data not shown). To improve cell yield and viability, the 2-hour 
digestion with Collagenase IV (1mg/ml) was repeated but after digestion the cells were rested 
overnight at 37oC, a common step in published protocols (Fig. 3.2 B). This was successful in 
improving the yield of CD45+ cells and cDC2s, however there was still cleavage of CD16, 
Figure 3.1: Preliminary gating strategy for identification of synovial CD14+ myeloid cells and cDC2s 
Synovial tissue from OA total knee replacement was digested using a sub-optimal digestion protocol 
(Collagenase P; 10µg/ml – 2 hours) to obtain single cell suspension. Cell surface expression for markers 
indicated in the figure were identified by flow cytometry. Viability was determined by staining with DAPI. 
The gating strategy applied to identify CD14+ myeloid cells and cDC2s is depicted. Data is representative 
of two independent experiments. 
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CD14 and CD11c (Fig. 3.2 B). It was concluded that the enzymatic aspect of this protocol 
resulted in the cleavage of these surface proteins. I therefore tested a synovial tissue digestion 
protocol from the Institute of Infection, Immunity and Inflammation at Glasgow University 
(Fig. 3.2 C). This protocol involved reducing synovial tissue to 1-2mm3 fragments followed by 
incubation with Liberase (150µg/ml) (Roche) at 37oC for 1.5-2hours while rotating on a 
Miltenyi MACSmix tube rotator. Although this protocol resulted in greater cell yield and 
viability, cleavage of CD16 and CD11c was still apparent (Fig. 3.2 C).  
Collagenase P (Sigma Aldrich) was trialled as an alternative enzyme. After mechanical 
digestion, Collagenase P was added at either 1mg/ml (Fig. 3.2 D) or 10µg/ml (Fig. 3.2 E), both 
for 2h at 37oC. Both concentrations showed reduced cleavage of surface proteins, most 
prominently in the 10µg/ml concentration, in contrast to previous attempts with alternative 
enzymes (Fig. 3.2 D&E).  The final enzymes trialled were based on a protocol for digestion of 
mouse small intestine and colon, with the enzymes kindly gifted by Prof Simon Milling, 
Glasgow University. The mix incorporated Collagenase VIII (1mg/ml, Sigma-Aldrich), 
Collagenase D (1.25mg/ml, Roche), Dispase (1mg/ml, Gibco) and DNase (30ug/ml, Roche) 
(Fig. 3.2 F). This protocol also involved mechanical digestion, but was followed by enzymatic 
digestion carried out in a shaking incubator at 37oC for 40-60mins (260RPM), with additional 
shaking every 15 minutes. This protocol resulted in high viability assessed by DAPI staining, 
and moderate cell yield, however cleavage of extracellular CD14 and CD16 was still present. 
In addition to these protocols, a number of others were also tested, but due to a lack of 
reproducibility in creating a single cell suspension, were not taken forward (data not shown). 
In contrast to enzymatic methods, a protocol involving a homogeniser and no enzymes was also 
trialled (Fig. 3.2 G). Although no cleavage of extracellular proteins was observed, there was 
poor cell yield. Synovial tissue digestion results are summarised in Table 3.1. 
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Figure 3.2: Comparison of different digestion methods on synovial tissue 
The following digestion protocols were tested on synovial tissue from OA total knee replacements. A: 
1mg/ml Collagenase IV added to mechanically digested tissue and incubated for 2 hours. B: 1mg/ml 
collagenase IV added to mechanically digested tissue, incubated for 2 hours, washed and rested in incubator 
overnight. C: 150µg/ml Liberase added to mechanically digested tissue and incubated for 2 hours. D: 
1mg/ml Collagenase P added to mechanically digested tissue and incubated for 2 hours. E:  10µg/ml 
Collagenase P added to mechanically digested tissue and incubated for 2 hours. F:  1mg/ml Collagenase 
VIII, 1.25mg/ml Collagenase D, 1mg/ml Dispase and 20µg/ml DNase added to mechanically digested tissue 
and transferred to a shaking incubator for 45 mins. G: Tissue mechanically digested using a homogeniser. 
All incubations took place at 37oC. CD14+ myeloid cells and cDC2s were identified for each digestion 
method by flow cytometry; gating strategy shown in Figure 3.1 was applied. Data are representative of two 
independent experiments. 
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To conclusively determine whether these enzymatic digestion protocols were cleaving surface 
markers, three of the protocols were tested on a peripheral blood sample, and compared to the 
same blood sample not subjected to any digestion (Fig. 3.3). Both methods using Collagenase 
showed reduced expression of CD16, CD14 and CD1c (Fig. 3.3 C&D and Fig. 3.4 A). The 
protocol using Liberase showed a similar level of viability to the other protocols, but reduced 
expression of HLA-DR (Fig. 3.3 B and Fig. 3.4 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The assessment of these established tissue digestion protocols showed mixed results (Table 
3.1), most notably, low cell yield and viability, cleavage of surface markers, or both. Despite 
these limitations, some aspects of these protocols worked well. These aspects could potentially 
allow for the development of an optimal protocol for synovial tissue digestion. 
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Figure 3.3: Effect of tissue digestion methods on identification of CD14+ myeloid cells and cDC2 in 
PBMC 
Three tissue digestion methods from Figure 3.2 were applied to PBMC obtained from a healthy donor. A: 
PBMC not subjected to digestion. B: 150ug/ml Liberase added to PBMC and incubated for 2 hours. C: 
1mg/ml Collagenase IV added to PBMC and incubated for 2 hours. D:  1mg/ml Collagenase IV added to 
PBMC, incubated for 2 hours, washed and rested in an incubator overnight. All incubations took place at 
37oC. CD14+ myeloid cells and cDC2s were identified for each digestion method by flow cytometry; gating 
strategy shown in Figure 3.1 was applied. Data are representative of two independent experiments. 
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Figure 3.4: Viability and CD16 surface marker preservation of PBMC undergoing different tissue 
digestion methods 
Three tissue digestion methods from Figure 3.2 were applied to PBMC obtained from a healthy donor. 
The following digestion methods were used: 150ug/ml Liberase added to PBMC and incubated for 2 
hours; 1mg/ml Collagenase IV added to PBMC and incubated for 2 hours; 1mg/ml Collagenase IV added 
to PBMC, incubated for 2 hours, washed and rested in an incubator overnight. All incubations took place 
at 37oC. A: CD16 expression was determined by flow cytometry. Left plot summarises the gating strategy. 
Right plot depicts expression of CD16 within the CD11c+ population. B: Viability is depicted as % DAPI- 
cells. Data are representative of two independent experiments. 
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3.4 Development of an optimal digestion protocol for synovial tissue 
After assessment of established protocols, I decided that an optimised synovial tissue digestion 
protocol needed to be developed, to allow greater cell yield, minimal cleavage of surface 
markers, and acceptable cell viability. 
From the established protocols tested, a new protocol was developed using a low concentration 
of Liberase (15ug/ml) and multiple mechanical digestions (Fig. 3.5). Although Liberase 
previously showed low cell yields and surface marker cleavage, the extent of this was lesser 
than that of the other digestion protocols. By lowering the concentration of Liberase, it was 
hypothesised that surface marker expression would be preserved and viability would be 
increased. However as a result it was likely that cell yield would be affected owing to a lower 
efficiency of enzymatic digestion. To overcome this, I decided to attempt multiple mechanical 
digestions with the lower concentration of Liberase. The adapted Liberase protocol involved 
reducing synovial tissue to 1-2mm3 fragments with sterile scissors and scalpel followed by 
incubation with Liberase (15ug/ml) and DNase (30ug/ml) in a shaking incubator at 37oC for 
45mins (260RPM), with additional shaking every 15 minutes. After incubation, the cell 
suspension was filtered and filtrate immediately placed on ice to inhibit enzymatic digestion. 
Any remaining tissue was subjected to a second digestion following the same steps. On any still 
remaining tissue, a third and final digestion was carried out (Fig. 3.6).  
The optimised digestion approach resulted in high cell yields (Fig. 3.5 & 3.7 A), and when 
tested on PBMC (Fig. 3.5 & 3.7 B), viability and surface marker preservation were comparable 
to undigested PBMC. When compared with all previous digestion protocols, this protocol 
achieved one of the highest cell viabilities, in addition to the highest yield of CD14+ myeloid 
cells and cDC2s (Fig. 3.7 A&B). Figure 3.5 & 3.7 C demonstrates lack of surface marker 
cleavage using this optimised protocol. 
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analyses 
Figure 3.6: Optimised synovial tissue digestion protocol 
Illustration of optimised synovial tissue digestion protocol. Synovial tissue from either total knee replacement 
or ultrasound guided biopsy is subjected to mechanical digestion and subsequent low concentration enzymatic 
digestion (150µg/ml; Liberase) in a shaking 37oC incubator for 45 mins (260RPM). After filtering, any 
remaining tissue is subjected to one or two more digestion cycles. Filtrates were pooled, washed and single cell 
suspension used for downstream analysis. 
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Figure 3.5: Effect of optimised digestion protocol on synovial tissue and PBMC 
The optimised digestion protocol was applied to synovial tissue from OA total knee replacement and PBMC 
obtained from healthy donor. A: Optimised digestion protocol applied to synovial tissue: 15ug/ml Liberase 
and 30ug/ml DNase added to mechanically digested synovial tissue and transferred to a shaking incubator 
for 45 minutes. After filtering, any remaining tissue was subjected to one or two more cycles of digestion. 
B: PBMC not subjected to digestion. C: Optimised digestion protocol applied to PBMC. All incubations 
took place at 37oC. CD14+ myeloid cells and cDC2s were identified by flow cytometry; gating strategy 
shown in Figure 3.1 was applied. Data are representative of two independent experiments. 
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3.4.1 Storage of synovial tissue 
Total knee arthroplasty surgeries take place throughout the day, and samples are often not 
available until late in the day. Owing to this, it was assessed whether storing samples overnight 
with isolation carried out the following day would have an adverse effect on the sample quality. 
A synovial tissue sample was divided in half, with one half digested fresh and analysed by flow 
cytometry. The other half was placed in RF10, stored overnight at 4oC, and subsequently 
digested and analysed the following day (Fig. 3.8). Although viability was lower, this was only 
marginal (2%), and the identification of cell subsets and surface marker proteins was not 
affected (Fig. 3.8). Therefore, it was deemed feasible to leave samples overnight (stored at 4oC 
in RF10) for digestion and analysis the following day. 
 
 
Figure 3.7: Verification of optimised digestion protocol 
Optimised digestion protocol was tested on synovial tissue from OA total knee replacement and PBMC 
obtained from a healthy donor. This was compared to previous digestion methods. A:  Cell numbers of 
CD14+ myeloid cells and cDC2s achieved from synovial tissue by each digestion method. Gating strategy 
used to identify is shown in Figure 3.1. B: Viability of cells isolated from synovial tissue is depicted as % 
DAPI- cells. C: CD16 expression on PBMC sample as determined by flow cytometry. Left plot summarises 
the gating strategy. Right plot depicts expression of CD16 within the CD11c+ population. Data are 
representative of two independent experiments. 
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3.4.2 Composition and yield of cell isolates 
As the optimised digestion protocol involved multiple stages of digestion, I assessed whether 
cell subsets were preferentially isolated in different stages of digestion. For this, media was 
taken from tissue storage as well as from the three separate digestion filtrates. All four samples 
were analysed by flow cytometry (Fig. 3.9). This experiment demonstrated that it is necessary 
to carry out three stages of digestion in order to generate cell yields sufficient for carrying out 
functional analyses (Fig. 3.9 A). Once this protocol had been repeated it was expected that after 
three digestions stages, no or very little tissue would remain to undergo a fourth digestion. 
When comparing the cell yields as a percentage of their sum, it was observed that the CD4+ T 
cell compartment had a much higher yield during the ‘walk-out’ stage of digestion, when the 
tissue is stored in media (Fig. 3.9 B). This higher yield of CD4+ T cells suggests that out of the 
cells analysed, they have the highest capacity to non-specifically migrate out of tissue. During 
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Figure 3.8: Storage of synovial tissue 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in 
Figure 3.6. A: Synovial tissue was digested immediately. B: Synovial tissue was left in RF10 at 4oC 
overnight. Tissue was digested the following day. Gating strategy shown in Figure 3.1 was applied. 
Viability was determined by staining with DAPI. Data are representative of one experiment. 
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the subsequent three digestion stages, the percentages of different cell subsets did not alter 
greatly, suggesting that the relative yields would not be affected or cell subsets preferentially 
isolated. (Fig. 3.9 B). An expected decrease of viability was observed between the digested 
filtrates and the storage media (Fig. 3.9 C). However this was not a major difference, and was 
consistent across all three isolates.  
By analysing the composition and yield from each of the cell isolates, I have demonstrated that 
it is necessary to carry out three digestion stages in addition to retaining media from tissue 
storage, in order to achieve sufficient cell yields for carrying out functional analyses. In 
addition, this experiment has shown that throughout the three digestion stages, there is no 
preferential isolation of the cell subsets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Composition and yield of cell isolates 
Synovial tissue from OA total knee replacement was stored overnight in RF10 at 4oC and media removed the 
following day. Tissue was digested using the optimised protocol shown in Figure 3.6, but filtrates not pooled 
and analysed separately. A: Cell subset count analysed by flow cytometry. B: Cell subset counts from A as a 
percentage of their sum. Gating strategy shown in Figure 3.17 was applied. Data are representative of one 
experiment. C: Proportion of live (DAPI-) cells in each filtrate. 
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3.5 Identification of peripheral blood and synovial tissue immune cell subsets 
As previously discussed, my initial interest of synovial tissue cell populations was cDC2s, 
owing to their antigen presenting capacity in disease pathogenesis. In addition, I was interested 
in CD14+ monocytes and HLA-DR+CD14+ macrophages and how they may contribute to the 
synovial myeloid compartment. However, since there was potential to sort five populations 
from one tissue sample, I decided to also identify stromal cells as well as CD4+ T cells, to 
understand their corresponding role to the myeloid cells. To identify these cell subsets within 
the same sample, a multi-colour flow cytometry panel was optimised. 
3.5.1 FACS 
For FACS, an Aria Fusion (BD Biosciences) cell sorter was available. This allows the sorting 
of four cells populations simultaneously using electrical charges applied to the cell droplets. 
During the period of setting up this flow cytometry panel, the flow cytometry core facility 
announced the purchase of an additional cell sorter, a MoFlo Astrios EQ (Beckman Coulter). 
The advantages of this system over the Aria Fusion are increased speed of sorting, increased 
cell viability due to the sorting mechanics (‘jet-in-air’ system rather than electrical charges), 
and the ability to sort six cell populations from a single sample. One limitation of this system 
was that it did not have a UV laser, and therefore the flow cytometry panel had to be modified 
as cell viability was measured by DAPI at 355nm. Instead, 7AAD was used as an alternative 
viability dye, which could be measured on the same wavelength as the lineage cocktail, PE 
Cy5.5. Figure 3.10 shows original flow cytometry panel, and modified panel to accommodate 
additional cell subset markers, and compatibility with MoFlo Astrios cell sorter. 
When comparing a synovial tissue sample on both the Aria Fusion and on the MoFlo Astrios, 
the cells have different FSC-A properties, but similar levels of viability (Fig. 3.11 A&B). It is 
difficult to distinguish CD45+ and CD45- populations on the MoFlo Astrios. In addition, auto-
fluorescence, used for the identification of tissue macrophages, was also difficult to identify on 
the MoFlo Astrios (Fig. 3.11 A&B). CD3+ T cells were well resolved, but HLA-DR+ cells, and 
subsequent CD14+ monocytes and cDC2s were not possible to identify (Fig. 3.11 A&B). 
Cytospins were performed on cell populations sorted from the MoFlo Astrios to check purity 
and cell morphology (data not shown). Although some cells could be found matching expected 
morphology for macrophages, T cells and monocytes, there was a large amount of debris and 
cell death present (data not shown). This flow cytometry panel was attempted with full set-up 
and compensation three additional times on synovial tissue and peripheral blood samples (data 
not shown). Although the identification and resolution of some cell subsets was improved, it 
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was not possible to identify auto-fluorescence. For these and the above reasons, I decided to 
discontinue the optimisation of a panel for the MoFlo Astrios, and to carry out all future cell 
sorting on the Aria Fusion. 
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Figure 3.11: Comparison of synovial tissue acquisition on Aria Fusion and MoFlo Astrios cell sorters  
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Single cell suspension was divided into two before acquisition. A: Synovial tissue single cell suspension 
acquired on Aria Fusion cell sorter. B:  Synovial tissue single cell suspension acquired on MoFlo Astrios 
cell sorter. Gating strategy shown in Figure 3.17 was applied. Data are representative of four independent 
experiments. 
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3.5.3 CD3 & CD90 
As there was not an extra channel in the current flow cytometry panel to put a stromal marker 
in, CD3 and CD90 were initially used with the same conjugated fluorophore, APC (Fig. 3.12). 
As these two cell types should be split by their CD45 expression, it was hypothesised there 
should not be an issue with their identification. An experimental control was carried out to 
ensure there was no cross-contamination of either the T cell or stromal cell populations (Fig. 
3.12). Figure 3.12 A is the view of CD45- stromal and CD3+ T cell populations when both CD3 
and CD90 antibodies are used. Figure 3.12 B demonstrates that there is no contamination of 
CD3+ cells within the CD45- fraction, where CD90+ stromal cells would be identified. However, 
in the HLA-DR- CD3+ cell fraction, there was contamination by CD90+ cells (Fig. 3.12. C). 
Owing to this, CD3 and CD90 were measured on separate fluorophores. 
3.5.4 pDC and cDC1 contamination check 
Although the optimised digestion protocol yields high enough cell numbers of cDC2s for 
functional and genomic analyses, I was unable to isolate sufficient numbers of cDC1s or pDCs. 
I therefore decided not to include any markers of these DC subsets in the flow cytometry panel. 
To confirm they would not contaminate the cDC2 or monocyte populations, CD123, a marker 
of pDCs, and CD141, a marker of cDC1, were added to a synovial tissue sample to identify 
where these two DC subsets fall in my gating strategy (Fig. 3.13). Furthermore, when assessing 
the expression of CD123 on cDC2s and pDCs there is distinguishable expression suggesting no 
contamination (Appendix 3.1). Although the expression of CD141 between cDC1 and cDC2 
was not as clear, there was distinguishable expression of CD11c (Appendix 3.1). This 
demonstrates that these DC subsets fall in the cDC2 and CD14+ monocyte gating strategy up 
until the CD11c and CD16 gate. At this point, they both fall within the CD11clo population, 
which is excluded when identifying cDC2s and CD14+ monocytes. 
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Figure 3.12: Combination of CD3 & CD90 on APC 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in 
Figure 3.6. Single cell suspension was divided into three before flow cytometry antibody staining. A: 
Single cell suspension was stained with both CD3 and CD90 (both APC). B: Single cell suspension was 
stained with CD3 (APC). C: Single cell suspension was stained with CD90 (APC). Left hand panels 
depict CD45- population. Right hand panels depict CD3+ population. Gating strategy shown in Figure 
3.17 was applied. Data are representative of one experiment. 
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3.5.5 CD45 FMO 
As the distinction of CD45+, CD45- and debris was not completely clear, an FMO was carried 
out to identify the true CD45- population, debris, and where gating should be applied for the 
CD45+ population (Fig. 3.14 A&B). Although the FMO assisted in the identification of the 
CD45+ cell population, an alternative antibody was tested on APC-Cy7 to see if this yielded a 
clearer distinction (Fig. 3.14 C). The resolution of cell populations using APC-Cy7 (Fig. 3.14 
C) was not as clear as the original V500 antibody (Fig. 3.14 B), therefore CD45 on V500 was 
used for the final panel. 
 
 
 
Figure 3.13: Identification of pDC, cDC1, cDC2 and CD14+ monocyte  
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Flow cytometry panel shown in Figure 3.16 was used with the addition of CD123 (PerCP-Cy5.5) and 
CD141 (PE-Cy7) in place of CD4 (PE-Cy7). Gating strategy shown in Figure 3.17 was applied. Data are 
representative of one experiment. 
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3.5.6 Auto-fluorescence for the identification of synovial macrophages 
When considering the approach for the identification of macrophages, there are many different 
methods in the literature. One strategy is the use of CD64hi, CD11b+, HLA-DR+ cells taken as 
synovial macrophages. However when I tested this, a small (2.31%) amount of cDC2 
contamination was found (Fig. 3.15 A). Although this is a relatively small amount, it equated 
to >50% of the total cDC2 population within synovial tissue. As I was interested in sorting 
synovial cDC2s in addition to macrophages from the same sample, this gating strategy would 
not yield the number of DCs required, or the purity of macrophages desired. When analysing 
synovial tissue single cell suspensions by flow cytometry, auto-fluorescence occurs in the FITC 
channel, which is not present with peripheral blood single cell suspensions (Fig. 3.15 B). This 
allowed me to assume that the cells auto-fluorescing were larger and with more structure, and 
most likely tissue specific cells. With this, and the addition of HLA-DR+ and CD14+ gating, I 
could achieve highly pure synovial tissue macrophages. It was shown that cDC2s express CD64 
in addition to macrophages, resulting in the cDC2 contamination of the macrophage population 
(data not shown). 
 
 
Figure 3.14: CD45 flow cytometry antibody validation 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Single cell suspension was divided into three before flow cytometry antibody staining. A: Flow cytometry 
panel shown in Figure 3.16 was used with the exception of CD45. B: Flow cytometry panel shown in Figure 
3.16 was used. C: Flow cytometry panel shown in Figure 3.16 was used with the exception of CD45 (V500) 
and addition of CD45 (APC-Cy7). Gating strategy shown in Figure 3.17 was applied. Data are representative 
of one experiment. 
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3.5.7 Full gating strategy 
In brief, the full identification of all cell subsets was achieved using the panel in Figure 3.16 
and gating strategy in Figure 3.17. Firstly, debris was excluded using the FSC-A and SSC-A 
profile and dead cells and B cells excluded using 7AAD, CD19 and CD20 (Fig. 3.17 A&B). 
CD45+ cells were gated on to exclude stromal cells in tissue, in addition to debris. In synovial 
tissue, auto-fluorescent cells were gated on, and cells expressing HLA-DR and CD14 identified 
as synovial macrophages (T4). The auto-fluorescent negative population was split by 
expression of HLA-DR and CD3, with identification of CD4+ (CD14-) T cells within the CD3+ 
fraction (B1 & T1). CD11c+, CD16- cells were gated on in the HLA-DR+ cell fraction, and 
CD14+ monocytes (B2 & T2) and cDC2s (B3 & T3) identified by the respective expression of 
CD14 and CD1c. An additional FMO of CD1c was performed to ensure there were no auto-
fluorescencent monocytes contaminating this gate (Appendix 3.2). Full surface marker 
phenotypes of synovial cell subsets are listed in Table 3.2. 
Figure 3.15: Auto-fluorescence for the identification of MØ  
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Single cell suspension was divided into two before flow cytometry antibody staining. A: Gating strategy 
shown in Figure 3.17 was applied with the exception of macrophage identification. Alternatively CD64, 
CD11b and HLA-DR were used as positive identification markers. B: Gating strategy shown in Figure 3.17 
was applied. Right hand panels depict CD1c expression on macrohages. Data are representative of two 
independent experiments. 
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Owing to the problems experienced with the MoFlo Astrios cell sorter, it was decided that 
CD90+ stromal cells would not be sorted in future samples to maximise the yields from the other 
subsets, when sorting four ways on the Aria Fusion cell sorter. 
Here, a multi-colour flow cytometry panel has been carefully developed to allow the 
simultaneous and accurate identification of HLA-DR+CD14+ macrophages, CD4+ T cells, 
CD14+ monocytes and cDC2s. Although the set up of this panel was attempted on the MoFlo 
Astrios cell sorter, this was not successful. Therefore all future sorts were carried out on the 
Aria Fusion. 
Figure 3.16: Optimised flow cytometry panel 
Flow cytometry panel for the identification of CD14+ monocytes, cDC2s, CD4+ T cells and HLA-
DR+CD14+ MØ from synovial tissue and PBMC. Panel was set up on BD Fortessa X20 and BD Aria 
Fusion cell sorter. 
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Figure 3.17: Gating strategy for identification of cell subsets from synovial tissue and peripheral blood 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Matched PBMC was obtained from corresponding OA total knee replacement patient. A: PBMCs isolated 
from peripheral blood stained with flow cytometry panel shown in Figure 3.16. B: Single cell suspension from 
synovial tissue (digested following optimised protocol shown in Figure 3.6). Stained with flow cytometry panel 
shown in Figure 3.16. 
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3.6 Immune cell subset morphology 
After successful FACS sorting of cell subsets from peripheral blood and synovial tissue, 
cytospins were carried out to assess the morphology of these subsets, in addition to ensuring 
the populations were pure. Both blood and synovial tissue T cells shared similar expected 
morphology of a relative small size, with small amounts of cytoplasm (Fig. 3.18 B1 & T1). 
They could further be distinguished from any potential contaminating NK cells by their lack of 
cytoplasmic granules.  
CD14+ monocytes isolated from blood were spherical with the presence of small membrane 
ruffles (Fig. 3.18 B2). Those isolated from tissue had a more irregular cell shape compared to 
their blood counterparts (Fig. 3.18 T2).  Both exhibited ‘indented’ shaped nuclei and lack of 
cytoplasmic granules, discriminating them from both neutrophils and NK cells.  
cDC2s isolated from peripheral blood had irregular cell shapes, ruffled cell membranes and the 
appearance of small dendrite structures (Fig. 3.18 B3). cDC2s isolated from synovial tissue had 
similar irregular cell shapes, but with larger and more prominent dendrite structures (Fig. 3.18 
T3). Both blood and tissue cDC2s could be discriminated from macrophages due to their 
absence of any prominent phagocytic vacuoles, in addition to their shape and cell structure as 
previously discussed. Macrophages isolated from synovial tissue were large with membrane 
ruffles and increased cytoplasmic vacuoles compared to monocytes (Fig. 3.18 T4). There were 
no potential contaminating cells detected in all cell populations. 
Confirmation of microscopic morphology assessment was carried out by comparing the SSC-
A and FSC-A profiles of blood- and tissue-derived cDC2s and CD14+ monocytes (Fig. 3.19 
A&B). The SSC-A mean fluorescence intensity (MFI) of both cell types is significantly 
increased in tissue-derived cells compared to those from blood, suggesting that the tissue cells 
have more structural complexes (Fig. 3.19 A&B). This difference was not observed in the CD4+ 
T cells (Fig. 3.19 A). This corresponds with our microscopic observations of larger dendrite 
structures on the synovial DCs, and more irregular cell shapes of synovial tissue isolated CD14+ 
monocytes. The FSC-A MFI of both cell types suggests similar cell size from either blood or 
tissue (Fig. 3.19 B). 
The morphological assessment of these FACS sorted cell populations confirms their identity 
and purity. The higher SSC-A observed in tissue cells could be a result of liberase treatment. 
However matched tissue and blood cells which had both undergone liberase treatment had 
comparable SSC-A MFI (data not shown). Therefore these data suggest that tissue-derived 
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CD14+ monocytes and cDC2s contain more structural complexes than their peripheral blood 
counterparts. 
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Figure 3.18: Morphology of cell subsets isolated from synovial tissue and peripheral blood 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in 
Figure 3.6. Matched PBMC was obtained from corresponding OA total knee replacement patient. Single 
cell suspensions were FACS sorted following gating strategy shown in Figure 3.17. Cytospin slides 
were prepared with FACS purified cells.  A: Cytospin images of CD4+ T cells (B1), CD14+ monocytes 
(B2) and cDC2s (B3) from PBMC.  B: Images of CD4+ T cells (T1), CD14+ monocytes (T2), cDC2s 
(T3) and HLA-DR+CD14+ MØ (T4) from synovial tissue. Data are representative of three independent 
experiments. 
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Figure 3.19: SSC-A profile of CD14+ monocytes, cDC2s and CD4+ T-lymphocytes from synovial 
tissue and PBMC 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in 
Figure 3.6. Matched PBMC was obtained from corresponding OA total knee replacement patient. A: 
SSC-A of HLA-DR+CD14+ macrophages, CD14+ monocytes, cDC2s and T-Lymphocytes from 
matched synovial tissue and PBMC. B: SSC-A and FSC-A profiles OF CD14+ monocytes and cDC2s 
from matched synovial tissue and PBMC. Cell subsets were identified by flow cytometry; gating 
strategy shown in Figure 3.17 was applied. Data are representative of fourteen independent 
experiments. ***P≤0.001, ****P ≤0.0001. 
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3.7 Discussion  
Here I have outlined a method for the isolation, identification and purification of immune cell 
subsets from synovial tissue, summarised in Figure 3.20. A lack of clarity or clear development 
of these experimental aspects has limited research into the pathogenesis and cellular 
mechanisms at the disease site of arthritis, the synovial membrane. Owing to this and the 
invasive nature and limited availability of tissue samples, much current published research has 
been carried out on peripheral blood samples or mouse models.  In IA such as RA, symmetrical 
swelling of joints is persistent and characteristic (van der Helm-van Mil, Verpoort et al. 2005, 
Aletaha, Neogi et al. 2010). Commonly affected joints include wrists, elbows, knees and 
metatarsophalangeal (MTP) joints (van der Helm-van Mil, Verpoort et al. 2005, Aletaha, Neogi 
et al. 2010). Similarly, OA can affect multiple joints including those of the hand, however hips 
and knees are most commonly affected (Peat, Thomas et al. 2006, Haugen and Boyesen 2011, 
Fernandes, Hagen et al. 2013). Using tissue from these disease sites can aid in understanding 
the full cellular mechanisms and pathogenesis of these diseases. 
 
 
 
 
 
Figure 3.20: Illustrative summary of Chapter 3 results 
Depiction of the methods optimised in Chapter 3 for the isolation, identification and purification of 
mononuclear cells from synovial tissue. This involves the use of an optimised synovial tissue digestion 
protocol for isolation, multi-colour flow cytometry for identification and optimised FACs for purification. 
Purity and morphology of cell subsets were confirmed using cytospin preparations. 
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I have demonstrated that many published and established protocols for achieving single cell 
suspensions from synovial tissue have a number of limitations. Most notably, poor cell viability, 
low cell yields and cleavage of extracellular proteins. Owing to this, I have developed an 
optimal synovial tissue digestion protocol, which results in high cell yields, viability and little 
cleavage of extracellular antigens. This allows me to be confident in my cell identification by 
flow cytometry using these extracellular proteins, in addition to minimally manipulated isolated 
cells. When assessing the individual digestion stages of this protocol, no cell subsets were 
preferentially enriched, allowing for unbiased characterisation of cell subsets within the tissue.  
Although this optimised digestion protocol is improved on previous protocols, there remain 
limitations. Despite this protocol showing higher viability of cells, it is still likely that cells will 
be altered during this mechanical digestion process, especially with regard to gene expression. 
Because there is currently no clear alternative to studying these purified cell subsets, this 
limitation will be taken into consideration for future analyses. Furthermore, the involvement of 
enzymes will likely alter isolated cells, especially their surface marker phenotype. However, it 
is essential to include enzymes to achieve sufficient cell yields. I have further shown that there 
is minimal to no cleavage of surface markers (of those tested) with this protocol. 
Developing a well-tested, multi-colour flow cytometry panel for the identification of multiple 
cell subsets is an important, and often overlooked step in cellular analyses. When considering 
flow cytometry-based cell sorting and the cell subset downstream applications, it is vital that 
the accuracy and purification of these subsets is of the highest quality possible. Contaminating 
cell subsets in both functional assays and genomic analysis can mask the true function and 
phenotype of a cell population. Using structural properties of the cells, in addition to a 
comprehensive yet conserved panel of fluorescently labelled antibodies, I am able to identify 
and phenotype cDC2s, CD14+ monocytes, CD4+ T cells and HLA-DR+ CD14+ macrophages. 
This has been applied to FACS sorting and has resulted in high cell yields and successful use 
in functional and genomic analysis. Purity of FACS sorted cell subsets was confirmed by 
carrying out cytospins of these populations and manually checking for contaminating cells. 
Additionally, this also allowed the assessment of cell morphology, confirming their correct 
identification.  
Finally, I compared the morphology and structure of blood cell subsets with their tissue 
counterparts. From cytospin preparations, it was observed that although the blood monocytes 
had minor cell surface ruffles, the tissue monocytes had more irregular cell shapes. Tissue 
cDC2s appeared to have more pronounced dendrite structures compared to their blood 
counterparts. T cells between both blood and tissue showed no distinct differences. These 
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observations were mirrored when comparing the SSC-A profiles of the matched blood and 
tissue cells by flow cytometry, demonstrating no difference between T cells, but significantly 
higher SSC-A MFI measurements of tissue monocytes and cDC2s as compared to blood. This 
could suggest that unlike T cells, monocytes and cDC2s are more susceptible to influential 
changes from the tissue environment. Additionally, since both monocytes and dendritic cells 
are phagocytic, this could represent higher rates of engulfment within the tissue environment 
and therefore increased granularity. Indeed, macrophages are highly efficient at phagocytosis 
and were observed to have the highest levels of SSC-A. 
Taken together, this series of optimisation steps is essential to the accurate study of immune 
cell populations within the disease site of arthritis patients. Although there are established and 
published protocols being used, limitations could ultimately result in poor application in 
downstream studies. To allow comparable cellular data from synovial tissue between research 
laboratories, a common digestion protocol should be utilised to reduce technical differences 
between experiments. In our application, the pairing of this protocol with a carefully 
constructed flow cytometry panel has allowed the isolation of highly pure cell subsets. These 
techniques will now be used for the characterisation of immune cell subsets in synovial tissue, 
in addition to their purification for functional and transcriptomic analyses. 
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Chapter 4. Characterisation of immune cell populations in peripheral blood 
and synovial tissue of OA and IA patients 
4.1 Introduction 
There is an extensive body of research surrounding synovial inflammation in RA. During 
inflammation, there is cellular infiltration into the synovial sublining by T and B cells, 
macrophages, NK cells, and DCs (Tak, Smeets et al. 1997). Resultant angiogenesis exacerbates 
this infiltration allowing increased leucocyte migration, and the forming of a synovial ‘pannus’ 
(Reece, Canete et al. 1999). This pannus is thought to cause cartilage and bone destruction 
through expansion and invasion. Production of pro-inflammatory cytokines and MMPs can 
exacerbate this. 
Published literature has described OA synovium as limited to areas of fibrosis, hyper-
vascularization and cartilage fragments, with considerably less inflammation than seen in RA 
synovium (Petersson, Sandqvist et al. 1997, Struglics, Larsson et al. 2006, Remst, Blaney 
Davidson et al. 2015). OA has therefore often been used in research as a non-inflammatory 
comparator for RA. However, synovitis in OA is becoming more recognised. Synovial 
inflammation has been reported in over 50% of OA patients (Haywood, McWilliams et al. 2003, 
Attur, Samuels et al. 2010, Baker, Grainger et al. 2010).  
Cellular infiltration in the synovium of OA patients has been previously identified by 
histological methods. Angiogenesis and synovitic lesions have been reported, with infiltration 
of mononuclear cells, particularly CD68 macrophages (Ene, Sinescu et al. 2015). This synovitis 
was seen throughout OA patients with varying stages of radiographic joint damage. T cells in 
addition to macrophages have also been reported in OA synovium (Saito, Koshino et al. 2002, 
Rollin, Marco et al. 2008). The presence of pro-inflammatory mediators may also suggest a role 
for cellular synovitis in OA disease progression (Sellam and Berenbaum 2010, Scanzello and 
Goldring 2012). However, it is still not clear whether synovitis initiates, or is a consequence of 
OA joint damage. 
The cellular composition of the synovium can additionally act as a therapeutic biomarker. In 
1989, (Rooney, Whelan et al. 1989) showed that treatment with gold therapy resulted in a 
decrease of T and B cell numbers. Since then, macrophages have been the focus of many of 
these therapeutic biomarker studies. Numbers of macrophages have been shown to be decreased 
in the synovium after treatment with gold therapy, prednisolone, methotrexate and leflunomide 
(Yanni, Nabil et al. 1994, Kraan, Reece et al. 2000, Smith, Kraan et al. 2001, Gerlag, Haringman 
et al. 2004). Reports of lymphocyte numbers in patients have described mixed results. Other 
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studies have shown reductions in synovial CD3 T cells in addition to CD68 macrophages after 
treatment with infliximab, and B cells after treatment with rituximab (Tak, Taylor et al. 1996, 
Smeets, Kraan et al. 2003, Thurlings, Vos et al. 2008). In addition, there are a number of studies 
that suggest direct links between macrophages and RA disease progression, and the potential 
use of macrophages as a direct biomarker of disease activity (Haringman, Gerlag et al. 2005). 
Although histological methods are extremely useful, they also have limitations. One example 
is a lack of specificity owing to a restricted number of possible parameters. For example, most 
research identifying macrophages use the marker CD68. However, it has been well reported 
that this is not a specific macrophage marker and can be expressed by monocytes, monocyte-
derived DCs, fibroblasts and adipocytes (Kunz-Schughart, Weber et al. 2003, Khazen, M'Bika 
J et al. 2005, Gottfried, Kunz-Schughart et al. 2008, Pilling, Fan et al. 2009). Due to CD68 
expression on multiple cell types previous enumerations of synovial macrophages in disease 
using CD68 as a sole marker could be inaccurate. Additionally, it has been reported that the 
cellular composition of ‘healthy’ synovium is often not well represented (Smith, Barg et al. 
2003). This was attributed to variable architecture of the synovial membrane, including 
thickness and sub intimal cellular infiltrate. By using the whole synovium from OA total knee 
replacement (TKR), and unbiased IA synovial biopsies, the cellular content will be more 
representative.  
Recent advances in tissue digestion, flow cytometry and omics technologies have allowed new 
methods of studying the synovium in arthritic diseases. Studies using these approaches have 
characterised fibroblasts, macrophages, T and B cells  (Komatsu, Okamoto et al. 2014, Leipe, 
Schramm et al. 2014, Yeo, Lom et al. 2015, Yeo, Adlard et al. 2016, Mizoguchi, Slowikowski 
et al. 2017). However published research that use these techniques mostly focus on a single cell 
type within RA.  
The cellular composition of synovial tissue has proven to be extremely important. However, 
this research has been predominantly carried out in RA, and there has been a lack of similar 
research in OA. Furthermore, studies of cellular composition in OA have been limited to 
histological and imaging methods. Understanding the cellular compartment in both IA and OA, 
and identifying multiple subsets within the same tissue could lead to a better understanding of 
these disease mechanisms. 
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4.2 Aims 
The characterisation of immune cell subsets in the synovial tissue has been limited, especially 
in OA patients. Furthermore, most characterisation to date has been carried out by histological 
methods. This has been owing to difficulty in isolating cells from tissues at sites of disease 
activity, as discussed in Chapter 3. Now that a protocol has been optimised allowing the 
isolation and accurate identification of these cells, extensive analyses of the cellular content in 
arthritic synovial tissue can be conducted. I therefore aimed to: 
 Assess and select the most relevant method for the quantification of the immune cell 
subsets in synovial tissue 
 Identify the cellular compartments using flow cytometry data from the peripheral blood 
and synovial tissue of both OA and IA patients  
 Compare and contrast identified cellular compartments between OA and IA patients  
 Explore computational analysis techniques on flow cytometry data with a view to 
validating results of manual quantification 
 
4.3 Patient characteristics 
Peripheral blood and synovial tissue samples from OA and IA patients were used throughout 
the analyses described in Chapter 4. All OA samples were collected from elective TKR surgery. 
IA samples were collected from either elective TKR surgery, or ultrasound guided needle 
biopsy of the wrist. Patient information regarding basic clinical information, disease severity 
and treatment is summarised in Table 4.1. 
Between the two disease cohorts, patients were of similar age and sex. However, the Body Mass 
Index (BMI) of OA patients was significantly higher than that of IA patients. In OA patients a 
mean BMI of 32.7 (SD 5.6) was recorded. In adults, this is classed as obese by NICE guidelines 
(NICE, 2017). As Obesity is a known risk factor of OA, an obese patient cohort is not unusual 
(Davis, Ettinger et al. 1988, Cooper, Snow et al. 2000, Field, Coakley et al. 2001). The mean 
BMI of IA patients was 27.2 (SD 3.9), and whilst this is classed as overweight (NICE, 2017), 
it does not constitute obesity. As obesity may potentially play a causal role in the underlying 
cellular mechanisms, this significant difference was deemed acceptable when considering the 
comparative analyses performed throughout this chapter. 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are both routine clinical 
tests that non-specifically measure inflammation. CRP is an acute phase reactant produced in 
the liver. ESR is the sedimentation of erythrocytes, which during inflammation can become 
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denser owing to excess proteins, including fibrinogen, in blood. Additionally the can clump 
further increasing density. A higher sedimentation rate, measured in millimetres travelled in 
one hour (mm/hr), is an indicator of inflammation. Both CRP and ESR were significantly higher 
in the IA patients. This was expected as the clinical criteria for RA diagnosis includes abnormal 
ESR or CRP measurements (Aletaha, Neogi et al. 2010). Although it has been indicated that in 
OA, CRP and ESR levels are associated with local joint inflammation, this link is less clear 
(Pearle, Scanzello et al. 2007, Keenan, Swearingen et al. 2008, Hanada, Takahashi et al. 2016). 
These differences were therefore also deemed acceptable. This is justified, as the higher CRP 
and ESR levels are likely due to differences in disease mechanisms, of which I am aiming to 
compare in the cellular composition of the synovial tissue.  
OA specific data collected included Kellgren and Lawrence (KL) X-ray score, previous 
menisectomy or TKR, and disease patterns. The Kellgren and Lawrence system for 
classification of OA using radiographic images from X-rays is graded from 0-4. A score of 0 
suggests no radiographic features of OA present. Conversely, the most severe score is 4. The 
median score recorded in our OA patients was 3. This suggests active OA disease in our cohort, 
showing multiple, moderately sized osteophytes, definite joint space narrowing, some sclerotic 
areas and possible bony end deformity (NICE, 2017). 15% and 20% of OA patients had 
previously undergone a menisectomy or TKR, respectively. 
Of note, 32.95% of OA patients recruited were currently taking statins (Atorvastatin or 
Simvastatin). It has been suggested that statins can have modulatory roles in the context of 
immune cell subsets (Yilmaz, Reiss et al. 2006, Tuomisto, Lumivuori et al. 2008, Jameel, Ooi 
et al. 2013). In addition, 12.5% and 2.5% of OA patients also had clinical diagnosis of non-
insulin-dependent diabetes mellitus (NIDDM) and gout respectively. These data were taken 
into consideration when conducting comparative analyses. 
IA specific data collected included Disease Activity Score in 28 Joints (DAS28), Rheumatoid 
Factor (RF) and Cyclic Citrullinated Protein (CCP). Patients recruited showed a median DAS28 
of 3.42. A DAS28 score of 3.2-5.1 indicates moderate disease activity (Fransen and van Riel 
2005).  
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4.4 Characterisation of immune cell subsets in synovial tissue 
4.4.1 Immune cell infiltration in IA 
When quantifying immune cell infiltration in tissues, there are a number of different approaches 
that can be taken. One method often used in published literature is the number of cells isolated 
per gram of tissue. Using a calculation of cells per gram of tissue allows the normalisation for 
differing amounts of synovial tissue acquired from TKRs and wrist biopsies. When applied to 
my data set, there is a significantly higher proportion of live cells per gram of synovial tissue 
in IA compared to OA (Fig. 4.1 A). 
CD45, the leukocyte common antigen is expressed ubiquitously on all haematopoietic cells. As 
this encompasses human immune cells, and owing to the lack of expression on stromal cells, a 
greater quantity of CD45+ cells found within a tissue could be indicative of immune cell 
infiltration during inflammation. To calculate this in the flow cytometry data, dead cells and 
debris were gated out and the number of CD45+ and CD45- cells were determined (Fig. 4.1 B). 
Percentages of these two cell numbers were then calculated from their sum. In the synovial 
tissue samples of these two patient cohorts, a significantly higher proportion of CD45+ cells 
was observed in the IA patients and accordingly a significantly higher proportion of CD45- cells 
was observed in OA patients (Fig. 4.1 C). This difference was also observed when measuring 
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absolute CD45+ cell numbers per gram of synovial tissue (Fig. 4.1 D). This supports the 
observation of increased immune cellular infiltrate into the synovial tissue of IA patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Analyses of cellular infiltration in IA and OA synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A: Quantification of live cells (DAPI-) per gram 
of synovial tissue. B: Gating strategy for identification of CD45+ and CD45- cells. Left plot is representative 
of an IA sample, right plot is representative of an OA sample. C: Percentage of CD45+ and CD45- cells in IA 
and OA. D: CD45+ cells per gram of synovial tissue in IA and OA. Data are representative of >20 independent 
experiments. ****P ≤0.0001. 
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Using CD90, stromal cells can be identified within the CD45- population (Fig. 4.2 A). 
Morphology of these cells was assessed by cytospin (Fig. 4.2 B). Stromal cells are known to 
contribute to the pathogenesis of both OA and IA. However, as discussed in Chapter 3 the 
detailed investigation and isolation of this stromal cell population was not taken further.  
These initial comparisons have demonstrated a larger proportion of cells, particularly CD45+ 
immune cells, in IA synovial tissue. I next aimed to characterise the cell subsets within this 
CD45+ cell population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 Identification and quantification method of additional cell subsets 
For the analyses carried out in this chapter, the gating strategy for the identification of HLA-
DR+ macrophages, CD14+ Monocytes, cDC2s and CD4+ T cells discussed in Chapter 3 was 
used. In addition, for some analyses, additional cell subsets were taken into account. These 
include all CD3+ T cells and CD3+CD4- T cells, CD16+ monocytes and the CD11clo fraction of 
cells which cDC1s and pDCs are likely to contribute (Fig. 4.3). 
 
 
Gated on: Cells minus debris, DAPI-, CD45- 
Figure 4.2: Identification of CD90+ stromal cells 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and 
analysed by flow cytometry using techniques described in Chapter 3. Cytospin slides were prepared with 
FACS purified cells. A: Gating strategy for identification of CD90+ Stromal cells. B: Cytospin images of 
CD90+ stromal cells. Data are representative of three independent experiments. 
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Figure 4.3: Identification of immune cell subsets for quantitative analyses 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A: Identification of CD3+, CD4+ & CD4- T cell 
populations, CD11clo cells, CD16+ & CD14+ monocytes and cDC2s. B: Identification of HLA-DR+CD14+ MØ. 
Data are representative of both OA and IA samples from 22 independent experiments. 
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4.4.3 Quantification method immune of cell subsets 
When quantifying these multiple subsets, there are again a number of methods that could be 
used. As previously discussed, looking at the total event or cell number would not amount for 
biases in amount of tissue analysed. Therefore calculating cell number/g of tissue could be 
employed to these analyses (Fig. 4.4). Although this was a useful method, this did not control 
for anatomical source of tissue. For example, as it is difficult to control for the exact location 
from which tissue is taken, there may be large variations in the proportion of stromal cells to 
immune cells. An alternative is to calculate cell subset percentages from a total population of 
cells. I carried this out, calculating cell subsets as a percentage of either total events, cells minus 
debris, live cells or CD45+ cells (Fig. 4.4). All four of these methods of calculating percentages 
yield the same result in terms of relative cell subset quantification (Fig. 4.4). However, due to 
the high number of events, in some of these, differences between the less abundant cells subsets 
can be less clear as smaller percentages are produced. I therefore decided to use cell subset 
numbers as a percentage of the CD45+ cell population. This method will yield the same result 
as the other methods, but allow me to better compare differences at the subset level. 
Furthermore, as the flow cytometry panel was designed for identifying cells within the CD45+ 
cell fraction, this could also be seen as the most relevant calculation to make. 
4.4.4 Manual quantification of immune cell subsets in peripheral blood 
The initial analyses conducted between OA and IA was on peripheral blood samples obtained 
from these patients (Fig. 4.5). First, the T cell compartment was compared. Although there were 
higher levels of CD3+ T cells and CD4+ T cells in IA patients, this difference was not significant 
(Fig. 4.5 A). There was no clear difference in the CD4- proportion of the T cell compartment 
between OA and IA (Fig. 4.5 A), or when comparing CD4 T cells as a percentage of CD3+ T 
cells (Appendix 4.1). There was no difference in the percentages of monocytic populations 
between OA and IA (Fig. 4.5 B & C), or when analysed as total monocytes (Appendix 4.1). 
However, there were significantly higher levels of cDC2s in the OA group (Fig. 4.5 C). 
Conversely, there were significantly higher levels of CD11clo cells in the IA group (Fig. 4.5 C). 
Although, it is likely the CD11clo population represents cDC1s and pDCs, it is important to 
note that these are not specifically identified.  
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A 
Figure 4.4: Quantification methods of immune cell subsets in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A: Results from six different quantification 
methods. Orange cells indicate lowest value for that analyses. Blue cells indicate highest value for that 
analyses. B: Data of percentage quantifications from A plotted. %Total events, %Cells minus debris and 
%Live cells plotted on left Y-axis. %CD45+ cells plotted on right Y-axis. In addition to cell subsets described 
in Figure 4.5, Total AF+, AF-, HLA-DR+ and CD11c+ populations are plotted. Data are representative of 22 
individual experiments. 
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B 
A 
C 
Figure 4.5: Quantification of immune cell subsets in peripheral blood 
PBMCs were isolated from peripheral blood of OA total knee replacement and IA ultrasound guided 
biopsy patients. PBMCs were analysed by flow cytometry using techniques described in Chapter 3. A: 
Proportion of CD3+, CD4+ and CD4- T-cells in IA and OA peripheral blood. B: Proportion of CD14+ and 
CD16+ monocytes in IA and OA peripheral blood. C: Proportion of cDC2 and CD11clo cells in IA and 
OA peripheral blood. All data presented as % of CD45+ cells. n=23. *P≤0.05, **P ≤0.01. 
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4.4.5 Manual quantification of immune cell subsets in synovial tissue 
The same set of comparisons conducted in Section 4.4.4 was conducted on the flow cytometry 
data from synovial tissue (Fig. 4.6, 4.7, 4.8). Within the T cell compartment, there were 
significantly higher levels of CD3+ T cells in the synovial tissue of IA patients compared to OA 
(Fig. 4.6 A). In the IA group there appeared to be four tissue samples that contained lower levels 
of CD3+ cells, akin to that of the OA group (Fig. 4.6 A). Conversely, there was a small number 
of OA tissue samples that had slightly higher levels of CD3+ T cells (Fig. 4.6 A). The lower 
levels of CD3+ T cells in the synovium of a number of IA samples was not mirrored by the level 
of CD3+ T cells in the matched peripheral blood samples (Fig. 4.6 B). Although there was no 
clear difference in the levels of CD3+ T cells between the matched blood and tissue of IA 
patients, there appeared to be significantly lower levels of these cells in the synovial tissue of 
OA patients, compared to matched blood samples (Fig. 4.6 B). When applied to the CD4+ and 
CD4- populations, higher levels were again seen in the synovial tissue of IA patients compared 
to OA patients (Fig. 4.6 C & E). Likewise, there was no clear difference between the tissue and 
blood of IA patients, but lower levels of these T cell populations were seen in the tissue of OA 
patients compared to matched blood (Fig. 4.6 D & F). A group of patients with levels of CD4+ 
T cells similar to OA was seen again in the IA patients, which too did not have distinct levels 
in the blood (Fig. 4.6 C). 
Next, these analyses were applied to the monocytic populations (Fig. 4.7). There were no clear 
differences in quantities of either CD14+ classical monocytes or CD16+ non-classical 
monocytes in the synovial tissue of the IA and OA groups (Fig. 4.7 A & B). There appeared to 
be an increase in CD14+ monocytes in the synovial tissue of OA patients compared to matched 
peripheral blood, not observed in the IA patient cohort (Fig. 4.7 B). A reduced quantity of 
CD16+ monocytes was seen in the tissue of IA patients compared to peripheral blood (Fig. 4.7 
D). This difference was not seen in the OA patients.   
Similarly, to the observation in blood, there were significantly higher levels of cDC2 in the 
synovial tissue of OA patients compared to IA (Fig. 4.8 A). However compared to matched 
blood, an increase in cDC2s was observed in the synovial tissue of both IA and OA patients 
(Fig. 4.8 B).  A greater proportion of the CD11clo population was observed in the synovial tissue 
of IA compared to OA (Fig. 4.8 C). Although an increase was seen in the tissue compared to 
matched blood in both IA and OA, this difference was only significant in the OA group (Fig. 
4.8 D). 
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Figure 4.6: Quantification of T cells in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
using techniques described in Chapter 3. PBMCs were isolated from matched peripheral blood. Single cell 
suspensions were analysed by flow cytometry using techniques described in Chapter 3. A: Proportion of 
CD3+ T cells in IA and OA synovial tissue. B: Proportion of CD3+ T cells in matched synovial tissue and 
peripheral blood. Left hand panel depicts IA. Right hand panel depicts OA. C: Proportion of CD4+ T cells in 
IA and OA synovial tissue. D: Proportion of CD4+ T cells in matched synovial tissue and peripheral blood. 
Left hand panel depicts IA. Right hand panel depicts OA. E: Proportion of CD4- T cells in IA and OA synovial 
tissue. F: Proportion of CD4- T cells in matched synovial tissue and peripheral blood. Left hand panel depicts 
IA. Right hand panel depicts OA. All data presented as % of CD45+ cells. n=23. *P≤0.05, **P ≤0.01, *** P 
≤0.001. 
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A 
Figure 4.7: Quantification of monocytes in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
using techniques described in Chapter 3. PBMCs were isolated from matched peripheral blood. Single cell 
suspensions were analysed by flow cytometry using techniques described in Chapter 3. A: Proportion of CD14+ 
monocytes in IA and OA synovial tissue. B: Proportion of CD14+ monocytes in matched synovial tissue and 
peripheral blood. Left hand panel depicts IA. Right hand panel depicts OA. C: Proportion of CD16+ monocytes 
in IA and OA synovial tissue. D: Proportion of CD16+ monocytes in matched synovial tissue and peripheral 
blood. Left hand panel depicts IA. Right hand panel depicts OA. All data presented as % of CD45+ cells. n=23. 
*P≤0.05, **P ≤0.01. 
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Figure 4.8: Quantification of dendritic cells in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
using techniques described in Chapter 3. PBMCs were isolated from matched peripheral blood. Single cell 
suspensions were analysed by flow cytometry using techniques described in Chapter 3. A: Proportion of cDC2 
in IA and OA synovial tissue. B: Proportion of cDC2 in matched synovial tissue and peripheral blood. Left 
hand panel depicts IA. Right hand panel depicts OA. C: Proportion of CD11clo cells in IA and OA synovial 
tissue. D: Proportion of CD11clo cells in matched synovial tissue and peripheral blood. Left hand panel depicts 
IA. Right hand panel depicts OA. All data presented as % of CD45+ cells. n=24. *P≤0.05, **P ≤0.01, *** P 
≤0.001. 
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Figure 4.9: Quantification of macrophages in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. Proportion of HLA-DR+CD14+ macrophages in 
IA and OA synovial tissue. n=50. Data presented as % of CD45+ cells. *** P ≤0.0001. 
The final analyses carried out was that of HLA-DR+CD14+ macrophages (Fig. 4.9). As these 
cells are primarily found in the tissue, and are extremely scarce and difficult to identify in the 
blood, the only comparison carried out was quantities in the synovial tissue between OA and 
IA. The quantity of these cells was significantly higher in OA compared with IA (Fig. 4.9).  
A number of interesting differences between IA and OA have been uncovered through these 
manual analyses. In particular, this has shown the need for investigating individual cell 
populations, and the benefits of using tissues at disease site. However, as these analyses have 
been carried out manually, in terms of flow cytometry gating, there are inherent biases and 
limitations. To validate these findings, unbiased computational methods were employed. 
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4.5 Computational analysis of flow cytometry data sets 
There are a number of computational analysis tools available which can be applied to this type 
of data. Although many have been designed for application with mass cytometry and single cell 
data, they can also be applied to flow cytometry data sets. Here I have applied three of these 
computational techniques to my data set, with two aims. The first was to explore these 
techniques and fully understand their potential benefits in the analyses of this type of data, in 
addition to uncovering any limitations. The second aim was to validate the results from the 
manual gating analyses (Section 4.4), in an un-biased and un-supervised manner. 
4.5.1 SPADE 
The first tool employed was the spanning tree progression of density normalized events 
algorithm, commonly referred to as SPADE. SPADE applies a density dependent down 
sampling taking into account regions of density in the sample, and removing events to normalise 
the full dataset, resulting in a consistent distribution of data, but with representation of 
abundance lowered. This technique is particularly useful for the identification of rare cell types. 
Hierarchical clustering of phenotypically similar cells was then performed, without the 
abundance of a dominant cell type affecting the analyses. (Saeys, Gassen et al. 2016). A 
minimal spanning tree (MST) algorithm then visualises these clusters. Although this tool aids 
in visualising similarities between these clusters, developmental relationships cannot be directly 
interpreted, as cells that are similar may not be close within the tree, and vice versa. 
SPADE was applied to the CD45+ cell population of an OA and an IA synovial tissue sample 
(Fig. 4.10). The MST produced shows a series of nodes representing cell clusters, all 
interconnected. The size of these nodes represents the abundance of that cluster in the sample. 
The colour of the nodes represents the relative expression of the chosen cell property or marker 
for each grid. From assessing abundance and phenotype, nodes can be manually grouped into 
cell types. Comparing the OA and IA samples, these analyses agree with a number of my 
manual analyses. There appears to be an increased quantity of macrophages and cDC2s in the 
OA sample (Fig. 4.10). Additionally, there appears to be a higher proportion of monocytes in 
the OA sample, which was not observed through manual analyses (Fig. 4.10). Furthermore, in 
agreement with my manual analysis, there was no clear difference in the T cell compartment 
between OA and IA (Fig. 4.10). 
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Figure 4.10: SPADE analyses of synovial tissue flow cytometry data set 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed by 
flow cytometry using SPADE. A: OA synovial tissue sample. B: IA synovial tissue sample. Data are 
representative of 5 independent analyses. 
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4.5.2 viSNE 
viSNE is based on the t-distributed stochastic neighbour embedding (tSNE) algorithm. This 
allows the mapping of high-dimensional cytometry data by reducing the data into two 
dimensions, whilst conserving high-dimensional structure (Amir el, Davis et al. 2013). The 
position of cells on the viSNE map reflects their proximity in high-dimensional space, and is 
therefore a powerful tool for the identification of cell subtypes. I applied viSNE analysis to the 
same OA and IA samples as the SPADE analyses (Fig. 4.11). Similarly to SPADE, viSNE maps 
use colour as a third dimension to display expression of cell property or marker (data not 
shown). Furthermore, using the cytofkit Bioconductor package in R, once analysis is 
completed, an analysed version of the original flow cytometry standard (FCS) file is created. 
This can then be used in traditional flow cytometry analysis software, such as FlowJo. 
Individual cells or clusters can be gated on and cell marker expression analysed to aid 
identification (data not shown). Using these data, clusters on the viSNE map can be assigned to 
cell types.  
The subsets identified in the OA viSNE analysis are demonstrated with conventional flow 
cytometry gating (Fig. 4.11 A). The viSNE map produced demonstrates a large proportion of 
macrophages, as observed in all previous analyses (Fig. 4.11 B). The progression of these 
subsets can be interpreted by producing progression maps. The number of cells are down-
sampled to remove potential influence from more abundant, dominant cell subsets. Diffusion 
maps plot the cells by marker expression patterns. This allows us to better examine the 
relationship between the cell subsets. The diffusion map plotted for this sample shows 
macrophages, cDC2s and monocytes clustered closely together (Fig. 4.11 C). CD4+ and CD4- 
T cells are separate from both each other, and myeloid cells (Fig. 4. 11 C). 
Within IA, a number of additional subsets were identified by the viSNE analyses. These are 
demonstrated with conventional flow cytometry gating (Fig. 4.11 D). From the viSNE map, it 
is clear that the CD4+ and CD4- T cells are the most abundant in this sample (Fig. 4.11 E). 
Furthermore, activated CD4+ and CD4- T cells (HLA-DR+) are identified separately, but closely 
related to their non-activated counterparts (Fig. 4.11 E). Macrophages and monocytes are the 
next dominant cell type. CD11clo cells are identified in addition to cDC2s (Fig. 4.11 E). When 
analysing the diffusion map, macrophages, cDC2s and monocytes are clustered closely together 
(Fig. 4.11 F). CD11clo are contiguous, but split into two different clusters, potentially reflecting 
the presence of both cDC1s and pDCs (Fig. 4.11 F). The CD4+ and CD4- T cells are separate 
from both each other, and the myeloid cells (Fig. 4.11 F). The activated CD4+ and CD4- T cells 
(HLA-DR+) are closely related to their non-activated counterpart (Fig. 4.11 F). 
78 
 
viSNE analyses was performed on these two samples separately. Comparisons can be made 
from this, such as the abundance of macrophages in the OA synovium, compared to T cells in 
the IA synovium (Fig. 4.11). However, to draw more robust conclusions, these two samples 
were subsequently analysed together (Fig. 4.12). This analysis of the combined samples 
confirms the previous suggestion of the relative abundance of macrophages and T cells in OA 
and IA synovium (Fig. 4.12 A). Again, the myeloid cells are clustered together on a diffusion 
map, and the CD4+ and CD4- T cells clustered separately, regardless of disease type (Fig. 4.12 
B). 
These analyses provide a useful overview of cell populations within the synovial tissue data, 
and allows for a more detailed exploration of the cell subsets and their relationships. 
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Figure 4.11: viSNE analyses of synovial tissue flow cytometry data set 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed by 
flow cytometry using techniques described in Chapter 3. A:  Manual gating of cell subsets in OA synovial tissue. 
B: viSNE map of OA synovial tissue. C: Diffusion map of IA synovial tissue. D:  Manual gating of cell subsets 
in IA synovial tissue. E: viSNE map of IA synovial tissue. F: Diffusion map of IA synovial tissue. Data are 
representative of 5 independent analyses. 
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Figure 4.12: visNE analyses of IA and OA synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A: viSNE map of IA and OA synovial tissue. 
Left hand panel depicts both samples. Right hand panels depict separated IA and OA samples. B: Diffusion 
map of IA and OA synovial tissue. Data are representative of 5 independent analyses. 
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4.5.3 CITRUS 
The previous analyses were carried out on one sample from each OA and IA group providing 
useful overviews of cellular content. However, to draw strong conclusions of differing cell 
quantitates between the two disease types, more comprehensive analyses needed to be 
undertaken. The CITRUS algorithm encompasses cluster identification, characterization and 
regression allowing a fully automated, unsupervised hierarchical clustering of cell populations 
in the entire dataset. 
The Significance Analysis of Microarrays (SAM) correlative association model was applied to 
a fluorescent dynamic range normalised dataset of 24 OA and 9 IA synovial tissue samples 
(Fig. 4.13). Using the strictest false discovery rate of 0.01, an abundance featurePlots 
visualisation is created, highlighting significant cell clusters in the tree (Fig. 4.13 A). Similarly 
to SPADE and viSNE, expression values can be visualised in a third dimension using colour, 
allowing the identification of each of these cell clusters (Fig. 4.13 B). From this, and the 
histograms generated for each cluster (data not shown), it can be concluded that each cluster 
represents the following: 
 Cluster 1 – Monocyte like cluster 
 Cluster 2 – Macrophage like cluster 
 Cluster 3 – T cell like cluster 
 Cluster 4 – DC like cluster 
 Cluster 5 – Unknown 
From this, abundance plots of cell clusters can be analysed (Fig. 4.13 C). The clusters 
representing monocytes are slightly higher in abundance in the OA samples than IA. Both the 
macrophage and DC clusters have significantly higher abundance in the OA than IA. The T cell 
like clusters were significantly higher in abundance in the IA samples than the OA samples. 
Finally, the fifth unknown cluster has higher abundance in OA than IA. These results agree 
with all results found in the manual analyses. 
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Figure 4.13: CITRUS analyses of synovial tissue flow cytometry data set 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. 24 OA and 9 IA synovial tissue samples were 
analysed. A: featurePlots visualisation of all samples analysed. Significant cell clusters identified are 
numbered 1-5. B: Visualisation of marker expression on featurePlots. C: Abundance plots of all nodes within 
significant cell clusters numbered 1-5. n.s.P>0.05, *P≤0.05, **P ≤0.01, ***P ≤0.001. 
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4.6 Histology and comparison with additional tissues 
It is difficult to obtain healthy synovial tissue samples. Sources for healthy synovial tissue 
include trauma patients, such as motor accidents or falls. However, the latter are unlikely to be 
healthy as individuals susceptible to falls can often be of old age or obese, both risk factors for 
OA. Another source is from limb salvage surgery of patients with osteosarcoma, a rare type of 
bone cancer. However, throughout the duration of the final experimental stages of this PhD, I 
was unable to recruit any healthy synovial tissue samples. Alternatively, I digested and analysed 
an adipose sample from a TKR, in addition to a healthy dermis sample kindly provided by Prof. 
Matthew Collin (Newcastle University). The aim was to have a representation of cell types 
identified in a healthy tissue using my flow cytometry panel. 
Although the OA adipose tissue is not representative of a healthy tissue, it is interesting to 
notice that the predominant cell type is also macrophages with very few of the other cell types 
measured (Fig. 4.14). There was a lot of debris in this sample, which may have skewed the 
proportion of the final cell percentages. However, through calculating cell percentages of 
CD45+ cells this effectively excludes the debris. The healthy dermis sample showed a large 
number of T cells, similar to that seen in the IA patients (Fig. 4.14 A). In addition, there was a 
larger number of cDC2s in dermis than both OA and IA (Fig. 4.14 A & B). 
One of my IA samples was sectioned and stained with haemotoxylin and eosin (Fig. 4.15 C). 
This was compared to a relevant OA TKR example from published literature (Ene, Sinescu et 
al. 2015) (Fig. 4.14 D). From these sections, there appeared to be increased cellular infiltration 
in the IA synovium. In addition, many of these were small in appearance. This could mirror my 
flow cytometry finding of increased proportion of T cells in IA synovium. However, no strong 
conclusions can be drawn from this until my samples have been analysed by histology, and 
compared with matched flow cytometry data. 
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4.7 Correlation of immunological and clinical data 
Although clinical data was not specifically recorded for this project, routine clinical information 
for both OA and IA cohorts was collected. When comparing two inflammatory markers with 
each other (CRP & ESR), a significant correlation was found within the IA cohort (p = 0.003; 
R2 = 0.50) (Fig. 4.15 A). This correlation was weaker in the OA cohort (p = 0.021; R2 = 0.13) 
(Fig. 4.15 A). When assessing CRP with measures of disease activity in each group (IA – 
DAS28; OA – KL X-ray Score), a correlation was only found in IA (p = 0.016; R2 = 0.42) (Fig. 
4.15 B). 
To investigate these clinical data in relation to my immunological data, I examined both of these 
datasets, and their relative importance to HLA-DR+CD14+ macrophages (% of CD45+). The 
variability of the top two factors for OA (Tissue weight and ESR) is clear when assessing 
individual linear correlation plots (Fig. 4.16 A). However, there is less variability in the IA 
linear regression of CD14+ monocytes and ESR, despite the smaller sample size (Fig. 4.16 A). 
When applying the bootstrapping method to this question, tissue weight and ESR are the two 
largest contributors in the OA cohort, explaining ~33% and ~22% of R2, respectively (Fig. 4.16 
B). In IA, CD14+ monocytes are the most important factor, contributing ~70% to R2 (Fig. 4.16 
B). The Bootstrapping technique involves the random sampling and replacement of values 
within the data range. In this instance 5000 iterations where employed. 
When assessing multiple regression models as predictors for HLA-DR+CD14+ macrophages (% 
of CD45+), the highest R2 value that can be achieved in OA is 0.55 (Fig. 4.17). In IA, this is 
improved with an R2 of 0.85 (Fig. 4.18). However, a multiple regression model should aim for 
an R2 value of >0.90 to be considered statistically acceptable, alongside a significant p-value.  
In OA, the best model involved age, BMI, disease duration, ESR, CD4+ T cells, CD14+ 
monocytes, cDC2s and tissue weight (R2 = 0.55) (Fig. 4.17). When reducing the factors of this 
model, the R2 is not proportionately effected. A model of age, BMI, ESR, CD14+ monocytes 
and tissue weight presents an R2 of ~0.53 (Fig. 4.17 A). As with the previous linear regression, 
tissue weight and ESR were the most contributory to the model, in addition to CD14+ monocyte 
levels. However, since all three of these factors had high variability of data, the regression is 
less reproducible. It is therefore possible that these are coincidental factors. When the best 
model and data are applied to a series of quality control plots, a non-linear relationship is 
observed (Fig. 4.17 B). This is demonstrated through the non-conformity in residuals v fitted 
values plot, and a curvature in the qqnorm plot, assessing data distribution (Fig. 4.17 B).  
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In IA, the best multiple regression incorporated age, gender, CRP, ESR, CD4+ T cells, CD14+ 
monocytes and tissue weight (R2 = 0.85) (Fig. 4.18). When removing age from this model, the 
R2 is reduced to ~0.73 (Fig. 4.18 A). When reducing this model further to disease duration, ESR 
and CD14, the R2 value is only reduced to ~0.65, suggesting that these additional factors do not 
contribute greatly and that CD14+ monocyte levels, ESR and disease duration are the most 
contributory factors. In the IA cohort, a non-linear relationship is again observed, but this is 
perhaps stronger after assessment of the scale-location plot and standardised residuals. 
However, it is possible that a small number of samples are skewing these data (Fig. 4.18 B). 
These analyses are ultimately limited by the sample size. 
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Figure 4.16: Correlation of clinical factors and immunological data 
Clinical data was collected for both IA and OA cohorts. A: Linear regression of contributing factors to 
HLA-DR
+
CD14
+
 macrophages. Left panels represent OA cohort, right panels represent IA cohort. B: 
Bootstrapping method assessing relative importance of variables to HLA-DR
+
CD14
+
 macrophages. 5000 
iterations were employed. Left panel represents OA cohort, right panel represents IA cohort. 
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Figure 4.17: Fitted model of Osteoarthritis clinical and immunological data 
Clinical data was collected for OA patient cohort. A: Fitted multiple regression models encompassing 
clinical and immunological variables. B: Fitted model with most relative importance for HLA-DR
+
CD14
+
 
macrophages applied to residuals vs fitted values plot (top left), qqnorm plot assessing data distribution 
assumptions (top right),  standardised residuals vs fitted values plots (bottom left), and standardised 
residuals against leverage plot (bottom right). 
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Figure 4.18: Fitted model of Inflammatory arthritis clinical and immunological data 
Clinical data was collected for IA patient cohort. A: Fitted multiple regression models encompassing 
clinical and immunological variables. B: Fitted model with most relative importance for HLA-
DR
+
CD14
+
 macrophages applied to residuals vs fitted values plot (top left), qqnorm plot assessing data 
distribution assumptions (top right),  standardised residuals vs fitted values plots (bottom left), and 
standardised residuals against leverage plot (bottom right). 
90 
 
4.8 Discussion 
In this Chapter, I aimed to characterise the cellular compartment of synovial tissue in both OA 
and IA. In addition, I aimed to explore computational approaches for the analyses of flow 
cytometry data. 
The patient cohorts used within these analyses were well matched between disease type with 
similar age and sex. Differences in BMI, CRP and ESR were deemed acceptable as these have 
all been identified as known risk factors, or disease-specific consequences. The OA group had 
active OA disease, assessed by Kellgren and Lawrence scoring of radiographic images. 
Likewise, the IA group had moderate disease activity measured by DAS28 score. 32.95% of 
the OA cohort were currently taking statins, known to affect immune cell subsets. Separate 
comparative analyses were conducted on this group and the remaining OA patients. No clear 
differences were found (data not shown). 
First, the cellular content of the synovial tissue was quantified. When calculating the number 
of live cells per gram of tissue, significantly more cells where observed in IA. Additionally, 
when calculating the quantity of CD45+ and CD45- negative cells, a significantly higher number 
of CD45+ cells were also observed in IA synovium. The CD45- cell population contains CD90+ 
stromal cells, in addition to other stromal cells including fibroblasts. As this was calculated as 
a percentage, it can be postulated that OA patients have a higher ratio of stromal cells than IA 
patients. Interestingly, a range of CD45+ cells was observed in OA. Although the extent of 
cellular infiltration is clear in IA, this does not consequently mean that there is no cellular 
infiltration in OA. Alternatively, there appears to be similar levels of cellular infiltration in 
some of these OA patients, and a lower level within the remaining patients. 
I next aimed to quantify multiple, individual cell subsets within these synovial tissue samples. 
Owing to a lack of similar published research, I first assessed the best method for this 
quantification. The most suitable method was to calculate each cell subset as a percentage of 
total CD45+ cells within that sample. It was shown that calculating the cell subset as a 
percentage of CD45+ or total events, cells –debris and live cells, yielded the same relative result. 
Furthermore, since the cell populations quantified were all CD45+, this would be the most 
relevant value to calculate from. 
When I conducted comparative analysis of peripheral blood from OA and IA, a limited number 
of differences were observed. The indication of increased quantity of CD3+ and CD4+ T cells 
in IA blood compared to OA again agrees with previously reported findings (Zhang, Li et al. 
2012, Leipe, Schramm et al. 2014, Lurati, Laria et al. 2015). Although no clear differences were 
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observed in the monocytic populations, contrasting quantities of cDC2s and CD11clo 
populations were observed. Work previously carried out in our group has identified an increase 
in the quantity of pDCs in early RA patient blood (Cooles et al, JACI, 2017, in press). There is 
little information on the quantity of cDC2s in OA patient blood. Here, I observed a significant 
increase of cDC2s in the peripheral blood of OA patients compared to IA. Similarly, a 
significant decrease of cDC2s in the blood of RA patients compared to healthy controls has 
been previously reported (Jongbloed, Lebre et al. 2006). OA patients were also reported to have 
higher levels of cDC2s in peripheral blood than RA patients in this study. I found both OA and 
IA to have significantly lower percentages of cDC2s compared to healthy controls (Appendix 
4.2). The authors later proposed a model whereby DCs migrate from the blood and traffic 
between the synovial fluid and tissue, accounting for this decrease in peripheral blood in RA 
patients (Lebre, Jongbloed et al. 2008). 
Studies using peripheral blood of arthritis patients have yielded much beneficial knowledge 
previously. However, when quantifying cell subsets within a small cohort size, peripheral blood 
does not prove an overly useful tissue when used alone. I have identified potential differences 
in the quantities of DC subsets in the peripheral blood of these two arthritis patient groups. 
However, conducting these analyses alongside synovial tissue data is likely to yield more 
informative results. 
The same set of comparisons were conducted in synovial tissue, in addition to comparing the 
relative cell quantities between matched blood and synovium samples. An increase of all T cell 
populations was observed in the synovial tissue of IA compared to OA. Two groups of IA are 
noticeable with high and low levels of T cells. Evidence for lymphoid, myeloid, fibroid and low 
inflammatory phenotypes of RA synovium have previously been described (Dennis, Holweg et 
al. 2014). Retrospective analyses of my data showed those samples with a lower percentage of 
T cells had higher percentages of myeloid cells than the samples with higher T cell percentages 
(data not shown). Additionally, a number of these samples had percentages of macrophages 
akin to that seen in OA. 
The percentages of T cells measured in OA synovium were significantly lower than those 
measured in matched peripheral blood, suggesting that these patients are not systemically 
deficient in T cells. Interestingly there is a range of OA patients with varying levels of T cells, 
suggesting that this group is heterogeneous. It is likely that there is an infiltration of T cells 
present within the synovium of IA patients, absent in OA. This has been previously reported, 
and there is substantial evidence for the role of T cells in RA (McInnes and O'Dell 2010, Pratt, 
Swan et al. 2012, Anderson, Pratt et al. 2016). Conversely, the levels measured in OA could 
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either be decreased, or due to the increase of another cell type. As no healthy synovium samples 
were collected, this cannot be conclusively stated. 
Similarly to blood, an increase of CD11clo cells was seen in the synovium of IA patients 
compared to OA. This has only been previously shown by histological methods (Lebre, 
Jongbloed et al. 2008). Interestingly, there was an increased proportion of cDC2 in the tissue 
of OA compared to IA. Additionally, an increase of cDC2s and CD11clo cells in OA synovial 
tissue compared to blood was not expected. Both cDC2s and CD11clo DCs have been described 
in OA synovium previously, but in low numbers compared to IA (Lebre, Jongbloed et al. 2008). 
As an increase of DCs has been previously associated with obesity, this could explain the 
heightened levels in my obese OA cohort (Wu, Perrard et al. 2010, Bertola, Ciucci et al. 2012, 
Stefanovic-Racic, Yang et al. 2012). However, these data are primarily from diabetes literature. 
I found no correlation between the quantity of cDC2s with BMI (Appendix 4.3). 
Finally, there was greater proportion of synovial macrophages observed in OA synovium 
compared with IA. In addition to a higher percentage of macrophages within the CD45+ cell 
population, the number of macrophages was higher per gram of synovial tissue (Appendix 4.4). 
As previously discussed, macrophages have been implicated in the pathogenesis, and identified 
in the synovium of both of these disease types. However, the increased proportion of 
macrophages in OA is notable. Furthermore, the OA patients are variable; some have high 
levels of macrophages whilst others have levels similar to IA. It has been suggested that 
adipokines and DCs promote monocyte recruitment into tissues, which can differentiate into 
macrophages (Nakamura, Fuster et al. 2014, Bai and Sun 2015). If this mechanism were present 
in OA, it would suggest obesity may not just add mechanical stress to the joint. However, I 
similarly found no correlation of macrophages and monocyte quantities with BMI (Appendix 
4.5). 
After these initial findings, I investigated computational approaches to analyse the same data. I 
first carried out SPADE analysis. This was a helpful first step for visualising these data in a 
different manner. Although this was used as an initial step, it did provide confidence in the 
observation of a relative increase in cDC2 and macrophage populations within OA, compared 
to IA. Similarly, viSNE was used to reduce high parameter biological data into two dimensions 
generating easy to interpret visual data. With this, I again confirmed a greater quantity of 
macrophages in OA, in addition to increased T cells in IA. There was a more even ratio of 
monocytes and macrophages in IA, not seen in OA. Diffusion maps demonstrated close 
relationships between myeloid cells, but clear differences between CD4+ and CD4- T cells. This 
suggests that the myeloid cells are relatively similar to one another, whereas CD4+ and CD4- T 
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cells are distinct from each another. As a method for visualising these types of data, I found 
viSNE easy to use, interpret and yielded additional information.  
After these visualisation steps, CITRUS was used to assess a broader range of both OA and IA 
samples. Unbiased cell cluster abundances were generated and compared between the two 
disease groups. Four cell clusters were identified pertaining to a monocyte, macrophage, T cell 
and DC-like clusters. Furthermore, macrophages and cDC2s were confirmed to be of greater 
abundance in OA synovium and T cells of greater quantity in IA synovium. 
The use of computational tools with these data proved useful for validation of my manual 
analyses. In addition, they present ways of visualising high dimensional data, in a more simple 
and easier to interpret format. 
One of the major limitations of these analyses was the lack of a healthy control tissue. Instead, 
a healthy dermis sample was analysed. Although this cannot be used as a direct comparator for 
healthy synovium, it was useful in understanding the cells identified in a healthy tissue by my 
flow cytometry panel. The large proportion of T cells identified in the dermis was initially 
unexpected. However, this finding agrees with current published literature (Wang, McGovern 
et al. 2014). In addition, a similar proportion of macrophages and DCs was also reported. The 
large proportion of macrophages observed in the adipose sample is similar to published research 
(Surmi and Hasty 2008). Additionally, increased infiltration of macrophages has been 
previously been reported in both obesity and OA (Weisberg, McCann et al. 2003, Clockaerts, 
Bastiaansen-Jenniskens et al. 2010). Although clinical data are not available for this patient, it 
was previously shown that our OA cohort is clinically classed as obese. This could be a 
contributing factor to the quantity of macrophages identified in this adipose tissue sample. 
From a number of these samples characterised by flow cytometry, tissue has been fixed and 
wax embedded for histological analyses. This would be a final step for the validation of our 
flow cytometry panel. The aim was to identify and quantify macrophage, CD3+/CD4+ T cells, 
CD14+ monocytes and cDC2s by both flow cytometry and histological methods. However due 
to time constraints this was not possible before the completion of my PhD. Although this 
experiment will be conducted in the near future, an alternative was to examine haematoxylin 
and eosin stained sections. The IA synovium used was one of my samples, compared with a 
relevant OA TKR synovium section found in published literature (Ene, Sinescu et al. 2015). 
This was a useful first step in validating our flow cytometry findings. Although quantities of 
specific immune cell types were not possible to enumerate, it was possible to suggest that there 
is a higher proportion of immune cell infiltrate in the IA synovium. Additionally, there appeared 
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to be a higher proportion of lymphocyte-like cells in the IA sample compared with the OA 
section. 
With the clinical information available for these patients, correlative analyses were conducted 
using both these clinical, and immunological data generated. Clinical data is extremely useful 
in monitoring disease progression and identifying mechanisms in a number of diseases. 
However, I demonstrated that in OA, systemic inflammatory markers may not be too useful as 
they do not correlate well with each other. Additionally, these markers did not correlate with 
measures of disease activity. This was not observed in IA. This could be because synovitis and 
inflammation in OA may be limited to the joint space, unlike systemic inflammatory diseases 
such as RA.  
Through multiple co-variate and linear regression analyses, it was found that the most important 
variables for the prediction of HLA-DR+CD14+ macrophages in OA were tissue weight, ESR 
and CD14+ monocytes. Although none of the variables reached great statistical acceptability, 
they could potentially have interesting biological meaning. As tissue weight was not seen as a 
contributing factor in IA analyses, this could suggest that it is not a technical co-founder. Since 
IA samples were mainly sourced from biopsies, and for OA samples, the whole synovial 
membrane was removed from the joint, a greater tissue weight in OA samples could be 
indicative of greater inflammation. Although it was shown systemic inflammatory markers may 
not be extremely useful in the analyses of OA data, tissue weight taken together with ESR could 
suggest that an increased proportion of macrophages is associated with increased inflammation 
in these patients. 
In the analysis of the IA cohort, CD14+ monocytes and ESR were the greatest contributory 
factors, and although had a better statistical certainty than the OA analyses, this was still not 
statistically acceptable. However, the importance of CD14+ monocytes in the synovium to 
macrophages, may agree with findings of a greater ratio of inflammatory, monocyte derived 
macrophages in IA, discussed in Chapter 5. 
In addition to the lack of healthy synovial tissue samples, another confounding factor in these 
analyses is the dissimilarity in the source of synovial tissue from these two disease groups. As 
mentioned, OA synovium was sourced from TKR surgeries, whereas IA synovium was largely 
acquired from ultrasound-guided biopsies of the wrist. A thorough search of the relevant 
literature yielded only one related article which attempted to examine differences in synovial 
tissue from multiple joints (Kraan, Reece et al. 2002). The authors suggested that factors 
including differences in mechanical stress, innervation and vascularity could influence features 
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of synovial inflammation between joint sites. This was conducted in RA patients and compared 
arthroscopic synovial tissue biopsies taken on the same day from the knee and either wrist or 
MCP joints. Comparing fibroblasts, macrophages, T cells and IL-6, good correlation was found 
between the large and small joints suggesting that biopsies from small and large joints can be 
used in a similar way. 
An additional limitation is that synovium from TKR is generally the whole synovial tissue, 
whereas tissue acquired from a biopsy is only a small sample and therefore may not be 
representative of the whole synovial tissue within the joint. To this end, it has been previously 
suggested that six tissue ‘pieces’ obtained by biopsy is representative of cell infiltration and 
whole tissue gene expression (Dolhain, Ter Haar et al. 1998, Smith, Kraan et al. 2001, Boyle, 
Rosengren et al. 2003). This concern was raised with Dr. Arthur Pratt who advised me that 
although these procedures were ultrasound-guided, they were just guided and that it was 
difficult to selectively sample inflamed areas only. Furthermore, during biopsy the aim was to 
acquire a representative range of tissue from the joint. Therefore the tissue recruited should 
have been done so in a fair, un-biased way. For all samples, 2-3 ‘pieces’ were fixed and wax 
embedded for histological study, and on post-examination of photographs, each sample 
analysed contained 7-15 biopsy ‘pieces’. 
Although it has been demonstrated that synovium from different joint sites is comparable there 
will inevitably be variances beyond disease mechanisms between these two groups. However, 
because the collection of synovial tissue from IA patients was a relatively new technique for 
our group, and due to the time-scale of this project, it would not have been possible to 
standardise these samples any further. 
Within this Chapter, I have been able to apply the optimised tissue digestion protocol and flow 
cytometry panel (Chapter 3) to a cohort of synovial tissue and peripheral blood samples from 
OA and IA patients. Through manual enumeration of the synovial tissue cellular compartment, 
in addition to exploration and validation with computational analyses, a number of thought-
provoking results have been generated, illustrated in Figure 4.19. Firstly, I observed increased 
immune cellular infiltration in the IA samples, a very well regarded feature of IA like diseases. 
Using the most appropriate quantification method for these analyses, quantification of 
individual cell subsets was conducted. Many of these findings agree with published literature, 
giving confidence in these methods for isolation and characterisation of synovial tissue cell 
subsets. However, some novel findings were generated, notably, the increased proportion of 
macrophages and cDC2s in OA synovial tissue compared with IA. Although disease and 
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cellular mechanisms were not explored here, this is an important initial step in refining which 
component of the synovium to explore further.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Illustrative summary of Chapter 4 results 
Depiction of the main findings from Chapter 4. Pie charts display data from Figure 4.14 (cell subsets as 
a percentage of CD45+ cell population). Visual representation of these results (bottom). 
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Chapter 5. Synovial macrophage phenotype, function and gene expression  
5.1 Introduction 
Macrophages are present alongside fibroblasts in normal synovium and are likely to be the front 
line cell ‘sensing’ joint damage (Smith 2011). In OA, macrophages contribute to cartilage 
destruction and osteophyte formation. This is through mechanisms such as cytokine production 
including but not limited to IL-1β, TNFα, TGFβ, and pro-matrix MMPs (Blom, van Lent et al. 
2004, van Lent, Blom et al. 2004, Bondeson, Blom et al. 2010). Depletion of macrophages from 
synovial tissue cultures in vitro showed the elimination of IL-1β and TNF production 
(Bondeson, Wainwright et al. 2006). In animal models, macrophage depletion reduces 
osteophyte formation (Blom, van Lent et al. 2004, van Lent, Blom et al. 2004). In line with my 
previous findings (Chapter 4, Figures 4.9-4.14), histological studies have demonstrated 
enhanced numbers of macrophages in the synovium of OA patients (Haywood, McWilliams et 
al. 2003, Benito, Veale et al. 2005). Increased numbers of activated macrophages have further 
been shown to correlate with the severity and progression of disease in OA patients (Kraus, 
McDaniel et al. 2016).  
Although macrophages have been implicated in the pathogenesis of OA, their role remains 
unclear. It is unlikely that macrophages are the single and direct cause of joint inflammation 
and destruction. Macrophages are heterogeneous cells with diverse functions including tissue 
repair, promotion and dampening of inflammation. A well-described paradigm in macrophage 
literature is that of the pro-inflammatory M1 and anti-inflammatory M2 macrophages. These 
were described based on in vitro responses to stimuli and have yielded a vast knowledge of 
macrophage activation. However, this paradigm reflects the polar extremes of macrophage 
activation, and may not truly represent tissue macrophages (Xue, Schmidt et al. 2014). Despite 
these macrophage states representing extremes of activation, they are both required for tissue 
remodelling after injury (Novak and Koh 2013, Brown, Sicari et al. 2014). Pro-inflammatory 
macrophages remove necrotic cellular material, kill pathogens and promote proliferation of new 
tissue cells. Anti-inflammatory macrophages subsequently dampen down inflammation, 
promote differentiation of newly recruited or expanded cells, and stimulate deposition of new 
extracellular matrix. It is thought that the timely and regulated transition from a pro- to anti-
inflammatory macrophage phenotype is essential for tissue regeneration (Sindrilaru, Peters et 
al. 2011, Novak and Koh 2013). It is unknown if synovial macrophages in OA have a pro- or 
anti-inflammatory phenotype and whether an imbalance between these types of macrophages 
is a protagonist of OA synovial inflammation. 
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High-resolution gene expression analyses such as RNA-sequencing have been previously 
conducted on whole synovial tissue, other synovial immune cell types, and monocyte-derived 
macrophages. However, to my knowledge this has not been previously been conducted on 
purified human OA synovial macrophages. The role of macrophages in the synovium of IA and 
OA has been previously discussed (Chapter 1 & 4). To summarise, despite their well-researched 
role in IA, macrophages have also been implicated in the pathogenesis of OA. Additionally, I 
have demonstrated their abundance in the synovium of OA patients compared with IA patients 
(Chapter 4). Much of the previously published research has been histology-based, and has 
lacked the specificity and advanced techniques which I have now developed. An in-depth 
analysis of these cells in the synovium of OA patients is required to gain a better understanding 
of how these cells contribute to OA pathogenesis. 
 
5.2 Aims 
Macrophages have been implicated in the pathogenesis of both IA and OA. I have further 
demonstrated an increased quantity of synovial macrophages in OA compared to IA. I therefore 
aimed to carry out an in-depth analysis on highly pure synovial macrophages from OA and IA 
patients. The main aims of this chapter were: 
 Phenotype the surface markers of synovial macrophages 
 Evaluate the functionality of synovial macrophages after digestion and FACs 
 Assess the gene expression profiles of synovial macrophages in OA 
 
5.3 Phenotyping of synovial macrophages 
I first carried out further phenotyping of synovial macrophages by flow cytometry. This 
involved exploring different gating strategies, and measuring specific surface marker 
expression on synovial macrophages from OA and IA. 
5.3.1 Resident and recruited macrophages 
After meeting with Professor Matthew Collin (Newcastle University), I tested a gating strategy 
developed for the identification of inflammatory and non-inflammatory monocytes and 
macrophages. Within his group, this gating strategy is applied to healthy dermis, and 
inflammatory samples from patients with graft versus host disease (Collin group, manuscript in 
preparation; Jahnsen et al., 2017).  
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After gating on CD45+ cells using the gating strategy described in Chapter 3, the first strategy 
involves gating on HLA-DR+ and CD14+ cells and then splitting this population based on CD14 
and CD11c expression (Fig. 5.1 A). From this, DCs could be identified as CD14-CD11c+ and 
macrophages as CD14+ CD11clo. The intermediate population could then be split by HLA-DR 
expression into two monocyte subtypes: ‘monocyte 1’ and ‘monocyte 2’. It is thought that the 
quantity of monocyte 2 within inflammatory conditions is increased. The second gating strategy 
is for the identification of resident and infiltrating monocytes/macrophages. HLA-DR+ (CD45+) 
cells were gated on and split by expression of CD14 and CD11c (Fig. 5.1 B). CD11cloCD14- 
cells are identified as pDCs and cDC1 and CD11cloCD14+ cells as ‘resident’ macrophages. 
CD11c+ cells were then identified as CD14+CD1c- ‘inflammatory’ macrophages, CD14+CD1c+ 
monocytes and CD14-CD1c+ cDC2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Identification of monocyte and macrophage subsets in dermis 
Dermal mononuclear cells were analysed by flow cytometry using techniques described in Chapter 3. A: 
Identification of Monocytes ‘1’ and ‘2’. B: Identification of resident and inflammatory macrophages. Data 
are representative of one experiment.  
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The first strategy was applied to OA and IA samples (Fig. 5.2 A) and monocytes 1 & 2 
quantified (Fig. 5.2 B).  The second strategy was also applied to OA and IA samples (Fig. 5.2 
C) and the ratio of resident and inflammatory macrophages quantified (Fig. 5.2 D). When back-
gating the ‘resident’ and ‘inflammatory’ macrophage populations to assess their auto-
fluorescence, it was noticed that contamination with non auto-fluorescent cells was present, 
most likely monocytes (Fig. 5.3 A). I therefore incorporated auto-fluorescence into the gating 
strategy to achieve purer ‘inflammatory’ and ‘resident’ macrophages populations (Fig. 5.3 B). 
As CD11c was not previously incorporated into macrophage phenotyping panels, the only 
activation marker of interest I had for these populations was CD86. Higher levels of CD86 
expression were measured on the inflammatory macrophages (Fig. 5.3 C).  
Although interesting preliminary data were generated from testing this gating strategy, this was 
conducted towards the end of my project and was therefore left for future work. The remainder 
of this chapter focusses on the previously defined HLA-DR+CD14+ synovial macrophages. 
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Figure 5.2: Identification and quantification of monocyte and macrophage subsets in synovial 
tissue  
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and 
analysed by flow cytometry using techniques described in Chapter 3. A: Identification of monocytes 
‘1’ and ‘2’ in synovial tissue. Top panels depict IA samples. Bottom panels depict OA samples. B: 
Quantification of monocytes ‘1’ and ‘2’ in synovial tissue. Left panel depicts % monocyte ‘1’. Right 
panel depicts % monocyte ‘2’. C: Identification of resident and inflammatory macrophages. Data are 
representative of 33 independent experiments. *P ≤0.05, ***P ≤0.001, ****P ≤0.0001. 
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5.3.2 Expression of ‘standard’ surface markers 
When measuring the MFI of the surface markers in my standard flow cytometry panel, there 
was no clear difference in levels of expression between OA and IA synovial macrophages (Fig. 
5.4). However, higher levels of CD14, CD45, CD16, CD11c and CD4 were measured in the 
healthy monocyte-derived macrophages compared to either OA or IA. Although these cells 
were generated from healthy blood, they likely better represent a monocyte-derived infiltrating 
macrophage, rather than a healthy tissue macrophage, due to their monocyte-derived in vitro 
culture. Importantly, synovial macrophages express expected markers (e.g. HLA-DR, CD14), 
and do not express other cell specific markers, such as CD1c or CD3. 
Figure 5.3: Identification of macrophage subsets in synovial tissue utilising auto-fluorescence 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed by 
flow cytometry using techniques described in Chapter 3. A: Auto-fluorescence of macrophage subsets. B: 
Identification of macrophage subsets utilising auto-fluorescence. C: CD86 expression of macrophage subsets. 
Data are representative of 3 independent experiments. 
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5.3.3 Expression of ‘activation’ surface markers 
To further characterise the surface marker phenotype of these synovial macrophages, antibodies 
that were not required for the identification of macrophages (CD3, CD4, CD11c, CD1c) were 
removed from the panel, and antibodies of interest added. This allowed the consistent 
identification of macrophages, and enabled specific questions to be addressed. 
Expression levels of CD86 were similar between OA and IA synovial macrophages, and 
monocyte-derived macrophages (Fig. 5.5 A). However, higher levels of CD172α (Sirp-α), 
CCR2 and CCR7 were measured in the moMacs compared with the OA and IA synovial 
macrophages. Although not expressed to the same extent as moMacs, higher levels of all three 
of these markers were observed in OA compared to IA (Fig. 5.5 A). CD206 and FOLR2 were 
expressed at similar levels by both moMacs and OA macrophages. By contrast, IA macrophages 
expressed these markers at lower levels than both moMacs and OA macrophages. CD64 
expression was similar between OA and IA, and although only measured on OA synovial 
macrophages, MCSF-R and CD83 were expressed (Fig. 5.5 A). When assessing the cell size 
(FSC-A) and structure (SSC-A) by flow cytometry, the OA macrophages had significantly 
higher FSC-A and SSC-A MFI as compared to synovial macrophages from IA patients (Fig. 
5.5 B).  
Figure 5.4: Expression of ‘standard’ surface antigens on synovial macrophages 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and 
analysed by flow cytometry using techniques described in Chapter 3. Expression of surface antigens 
included in FACS panel on healthy control (HC) monocyte-derived macrophages, OA and IA macrophages. 
Data are representative of 8-13 independent experiments. 
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Figure 5.5: Expression of ‘activation’ surface antigens on synovial macrophages 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A:  Expression of surface antigens on HC 
monocyte-derived macrophages, OA and IA macrophages. Data are representative of 1-4 independent 
experiments. B: Cell size and structure of HC monocyte-derived macrophages, OA and IA macrophages 
measured by FSC-A and SSC-A MFI. Data are representative of 17 independent experiments. *P ≤0.05, **P 
≤0.01, ***P ≤0.001. 
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5.4 Phagocytic capacity of synovial macrophages 
As future studies will likely address the functional differences between synovial macrophages 
in different disease states, I next determined whether synovial macrophages retained functional 
ability after tissue digestion and cell sorting. Because phagocytosis is a typical function of 
macrophages, I measured their phagocytic ability utilising latex beads. moDC, which should 
have low phagocytic capacity, and moMacs, which should have high phagocytic capacity, were 
used as comparators.  
5.4.1 Flow cytometry analysis of phagocytosis 
When assessing the amount of latex beads phagocytosed by flow cytometry, moDC had a very 
low level of bead uptake, similar to that of the no-bead negative control (Fig. 5.6 A). In contrast, 
the moMacs had high levels of bead uptake, similar to that of the positive control, beads alone 
(Fig. 5.6 A). Synovial tissue macrophages had similar levels of phagocytosis as moMacs (Fig. 
5.6 A). The levels of phagocytosis were next compared between moMacs and moDC generated 
from blood of either healthy controls or IA patients (Fig. 5.6 B). In both healthy and IA samples, 
moMacs had higher levels of phagocytosis than moDC (Fig. 5.6 B). IA moMacs had slightly 
lower levels of phagocytosis compared to healthy moMacs (Fig. 5.6 B). Unfortunately, I was 
unable to collect any OA blood at this stage of the project to carry out this experiment in parallel. 
When comparing OA synovial macrophages and cDC2, macrophages had a much higher 
efficiency for phagocytosis than cDC2 (Fig. 5.6 C). 
Phagocytosis of the latex beads could be observed in the culture wells by light microscopy, 
demonstrated in Figure 5.6 C. Beads can be seen engulfed by macrophages in the positive 
condition, whereas they are absent in the negative condition. However, the presence of vacuoles 
in the macrophages could obscure true quantification by this method. Additionally, the latex 
beads could have been simply adhering to the surface of the cell rather than being phagocytosed, 
giving a false positive result by both flow cytometry and examination under a light microscope 
during culture. 
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5.4.2 Immunofluorescent and confocal microscopy of phagocytosis 
To further assess latex bead engulfment by macrophages, immunofluorescence microscopy was 
conducted (Fig. 5.7). Interestingly, within the monocyte-derived macrophage condition, 
individual macrophages appeared to have different levels of phagocytosis (Fig. 5.7 A). A 
similar observation was seen with synovial macrophages (Fig. 5.7 B). Most of the beads were 
localized around the nucleus and within the outer membrane, suggesting that they were within 
the cell. However, as the presence of a small number of beads were overlaid with the nucleus, 
this again could suggest the possibly of beads simply adhering to the cell surface. To further 
confirm phagocytosis, confocal microscopy was conducted. 
First, imaging was conducted using differential interference contrast (DIC), to provide high 
resolution images of macrophages (Fig. 5.8 A). This allowed the confirmation that the beads 
were not stuck to the outside of the cell membrane, however they could still be resting on the 
top membrane. To eliminate this possibility, serial images were taken through the cell (Z-
stacks), and three-dimensional images recreated (Fig. 5.8 B & C). From examination of these 
re-constructed images, and the individual serial images (data not shown) it could be seen that 
the beads were located parallel to the nucleus, and within the cell membrane. This allowed me 
to confirm that these macrophages were indeed phagocytosing the beads. 
This was an import preceding step to my gene expression analysis experiments. Although care 
has been taken in isolating these cells from tissue and subsequent purification, these 
experiments have allowed me to confirm that the cells are still functional once isolated.  
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Figure 5.7: Phagocytosis of latex beads by synovial macrophages 
Synovial tissue from OA total knee replacement was digested using techniques described in Chapter 3. 
Monocyte-derived macrophages were cultured following technique described in Chapter 2. Slides were 
prepared following methods outlined in Chapter 2. A: Immunofluorescent imaging of slide preparation 
at x40 magnification. B: Immunofluorescent imaging of slide preparation at x100 magnification. Left 
panel depicts cells incubated without latex beads. Right panel depicts cells incubated with latex beads. 
Data are representative of 2 independent experiments. 
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Figure 5.8: Confocal microscopy of phagocytosis by monocyte-derived macrophages 
Monocyte-derived macrophages were cultured following techniques described in Chapter 2. Slides were prepared 
following methods outlined in Chapter 2. A: Confocal microscope image utilising differential interference 
contrast (DIC). Left panel depicts macrophages cultured without latex beads. Right panel depicts macrophages 
cultured with latex beads. B: Confocal Z stack reconstruction of 39 images. Blue areas indicate DAPI staining 
of nucleus. Green areas indicate latex beads. C: Confocal Z stack reconstruction  animation of 39 images. Blue 
areas indicate DAPI staining of nucleus. Green areas indicate latex beads. Grey areas indicate cell membrane 
(DIC). Data are representative of 2 independent experiments.  
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5.5 Gene expression of synovial macrophages 
I now know that these synovial macrophages are viable, pure, express expected surface markers 
and are functional after isolation. I next examined the transcriptomic profile of these synovial 
macrophages by RNA-sequencing. I aimed to do this by contrasting OA synovial macrophages 
with IA controls. This is a relatively new technique for our group and there are challenges 
associated with using tissue-derived cells. There were nine OA and three IA samples available 
for analysis. A summary of patient characteristics are presented in Table 5.1. The IA control 
group was heterogeneous, comprising one early and one established RA sample, and one PsA 
sample. Although this will inherently increase biological variance, the IA group was being used 
as an inflammatory control and therefore encapsulates a range of inflammatory arthritides. All 
IA samples were derived from wrist biopsies, whereas OA samples were taken from TKR 
surgery. The two disease cohorts were well matched for age, gender and BMI, with no 
significant differences (Table 5.1). However, the mean BMI of OA cohort, 36.3 (SD 4.7), is 
classed as obese, whereas the BMI of the IA cohort, 29.4 (SD 0.5) is classed as overweight. As 
previously discussed in Chapter 4, this will be taken into account during analyses, but was 
deemed as an acceptable difference owing to obesity being a risk factor for OA. 
Both CRP and ESR were significantly higher in the IA patients. Again, this was expected as 
the clinical diagnosis for RA includes abnormal ESR or CRP measurements, and are likely due 
to differences in disease mechanisms. The median KL X-ray score recorded in our OA patients 
was 3.44. This suggests active OA disease in our cohort, showing multiple, moderately sized 
osteophytes, definite joint space narrowing, some sclerotic areas and possible bony end 
deformity (NICE, 2017). 11% and 33% of OA patients had previously undergone a 
meniscectomy or TKR, respectively. IA patients recruited showed a median DAS28 of 3.0. A 
DAS28 score of <3.2 represents a low disease activity (Fransen and van Riel 2005). 
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5.5.1 Quality Control 
Data presented within this chapter are based on counts generated using methods outlined in 
Chapter 2. Counts with a low number (<0.5 Counts per million; CPM) were removed (data not 
shown). Counts per million were found to be consistent across disease groups (data not shown). 
No clear batch effect was present (Fig. 5.9 A). Next, I examined the library size (Fig. 5.9 B). 
Although all samples had good library sizes, X1_OA presents with a smaller library than the 
other samples. When plotting the relative log expression, X1_OA also shows an elevated ratio 
compared to the other samples (Fig. 5.9 C & D). RNA length was utilised as a covariate factor 
for pathway analyses. 
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A 
Figure 5.9: Quality control of synovial macrophage RNA-sequencing 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A: Assessment of batch effect plotting cumulative proportion of library size against number of 
features. B: Analysis of library size plotted using relative log expression. Left panel depicts library sizes pre 
gene exclusion based upon low CPM values. Right plot depicts library sizes post gene exclusion based upon 
low CPM values. C: Full (C) and minimal (D) relative log expression ratio. 
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Using these raw counts, multidimensional scale (MDS) plots were used to initially visualise 
these data (Fig. 5.10 A). Despite the biological variance, the IA group cluster together. The OA 
group is highly dispersed, although a small group cluster close to the IA samples. Sample 
X1_OA clusters away from both IA and the rest of the OA samples. Because of this, the MDS 
plot was repeated without sample X1_OA (Fig. 5.10 A). This again showed the IA samples 
clustering together, and a heterogeneous range of OA samples. X6_OA, X3_OA and X4_OA 
can be seen on the left side of the leading logFC dimension (1) with the IA samples. Repeating 
without the IA samples further demonstrates heterogeneity with the OA samples (Fig. 5.10 A). 
A principle component analysis (PCA) plot was next generated of the same data (Fig. 5.10 B). 
Although similar to MDS plots, a PCA plot preserves covariance of data, and is useful for 
demonstrating local variation between samples. MDS plots preserve distance dimensionality 
allowing the interpretation of distance between data points. MDS plots are useful for identifying 
outliers in data as they demonstrate large differences better than local similarities. The PCA 
plot demonstrated similar clustering of IA samples, and similar heterogeneity of OA samples. 
Subsequent components do not demonstrate such separation (data not shown). As component 
one accounts for 39% of the dimensionality, subsequent components would not be expected to 
be useful. Due to consistent abnormalities in the quality and presentation of X1_OA, this sample 
was removed from the remaining analyses. For further analyses, these counts were computed 
to counts per million and normalised with edgeR. Expression levels were generated using 
Limma’s ‘voom’ function. Counts per million were consistent pre-normalisation, and more so 
after normalisation (Appendix 5.1). Contrasts were built and differential expression analyses 
conducted using Limma. 
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Figure 5.10: MDS and PCA analyses of synovial macrophage RNA-sequencing 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. A: Multidimensional scale (MDS) plots of all samples (left panel), all samples minus X1_OA 
(middle panel), and OA samples minus X1_OA (right panel). B: PCA plot of all samples. Red text and circle 
identifies IA samples, blue text and triangle identifies OA samples. 
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5.5.2 Expression of known macrophage gene signatures 
As a final validation step, I evaluated the expression of known macrophage genes, and non- 
macrophage genes in my data. As demonstrated, all samples lacked expression of genes 
associated with cell types including B-cells (B-cell receptor; BCR), DCs (CD1c), NK cells 
(Nuclear adhesion molecule; NCAM1), stromal cells (THY1) and T cells (T cell receptor alpha 
constant; TRAC) (Fig. 5.11). In contrast, all samples expressed genes associated with 
macrophages, including CD14, CD68, CSF1R, HLA-DRA and MARCO (Fig. 5.11). 
Next, I considered the expression of known macrophage gene sets. Common M1 and M2 gene 
sets were composed from pre-existing gene sets and chemokine signatures (Martinez, Gordon 
et al. 2006, Beyer, Mallmann et al. 2012, Barros, Hauck et al. 2013, Italiani and Boraschi 2014, 
Roszer 2015, Saliba, Li et al. 2016, Gensel, Kopper et al. 2017). When addressing the 
expression of these gene sets by synovial macrophages isolated here, they do not clearly fit 
either M1 or M2 gene signatures (Fig. 5.12). Overall, all synovial macrophage samples appear 
to have lower levels of expression of M2 related genes compared to M1 (Fig. 5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Expression of macrophage and non macrophage genes by synovial macrophages 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. logCPM expression levels of macrophage genes (left panel) and B cell (BCR), DC (CD1c), 
NK cell (NCAM1), Stromal (THY1) and T cell (TRAC) genes (right panel). 
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5.5.3 CD16+ Macrophages 
Within the flow cytometry data, CD16+ macrophages were observed in IA samples, which were 
only present in some OA samples (Appendix 5.2). I initially conducted differential gene 
expression analyses of sequenced macrophage samples with high and low amounts of CD16+ 
macrophages. However, only one significantly differentially expressed gene (DEG) was 
observed (>1.5-FC; p<0.05, multiple test corrected) (Appendix 5.2). This gene was the non-
protein encoding gene RP11-12601.5 (Appendix 5.2). The distribution of p-values from this 
differential gene expression analysis was plateaued suggesting a null-hypothesis (Appendix 
5.2). Additionally, these samples did not cluster into CD16+ high and low macrophage groups 
by MDS or PCA plot analyses (data not shown). Because of the statistical uncertainty of the 
Figure 5.12: Expression M1 and M2 gene sets by synovial macrophages 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A: Hierachical clustering heat map based upon logCPM expression of M1 macrophages genes (left 
panel) and M2 macrophage genes (right panel). B: Hierachical clustering heat map with scaling of logCPM 
expression  values of M1 macrophages genes (left panel) and M2 macrophage genes (right panel). Colours 
indicate gene-wise expression across 11 samples as per key (right). Top colour bar indicates disease group and 
type as per key (bottom). 
A 
B 
M1 no scaling 
M2 scaled M1 scaled 
M2 no scaling 
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differences between these CD16+ high and low groups, it was decided to discontinue with this 
analysis.  
5.5.4 IA v OA (Question 1) 
The first question I addressed was the difference in gene expression between IA and OA. From 
this first comparison, three protein encoding DEGs were observed (>1.5-FC; p<0.05, multiple 
test corrected) (Fig. 5.13 A).  These genes were IGFBP5, LRRN4CL and TKSU, all under-
expressed (>-4.5 FC) in the IA samples compared to OA (Fig. 5.13 B). As this is differential 
gene expression, the inverse that these genes are over-expressed in OA samples is equally true. 
When examining the p-value distribution for this question, an anti-conservative distribution is 
observed (Fig. 5.13 C). These genes are visually represented in a hierarchical clustering heat 
map (Fig. 5.14). As expected, the IA and OA groups are distinctly branched from one another. 
To conduct pathway analyses, a larger set of DEGs was required. To achieve this, un-adjusted 
p-values (<0.05) were used (Fig. 5.15). Although this generates a greater array of significantly 
DEGs, these will only be used at an exploratory level due to the risk of false discovery. When 
presented in a heat map, this gene set also clusters IA separately to OA (Fig. 5.16). Additionally, 
samples X4_OA, X6_OA and X3_OA group separately from the other OA samples. Using 
these un-adjusted p-value DEGs, a range of significant (p <0.01) Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) perturbed pathways in IA are noted (Fig. 5.17). Although under- and 
over-expressed KEGG pathways were analysed, the under-expressed fell short of any statistical 
acceptability (data not shown). Encouraging results of KEGG analyses include, but are not 
limited to, cytokine-cytokine receptor interaction, TNF signalling pathway, NF-kappa B 
signalling pathway, NOD-like receptor signalling, chemokine signalling and rheumatoid 
arthritis. All pathways reaching adjusted p-value <0.01 are shown in Appendices 5.7 – 5.34. 
KEGG pathway maps help to demonstrate how genes contribute to a particular pathway. 
All of these analyses were repeated, removing the PsA sample from the IA disease group to 
reduce biological variation (data not shown). However, little difference in results were noted, 
and the PsA sample was included for all remaining analyses. 
 
 
 
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Question 1 (IA v OA) differential gene expression analyses 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. A: Volcano plot identifying DEGs (>1.5-fold change; p<0.05, multiple test corrected). B: 
Table (5.2) of DEGs, log fold change and adjusted p-value from Question 1. C: p-value distribution of all 
DEGs from Question 1. 
A 
B C 
Q1: IA v OA 
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Figure 5.14: Heat map visualisation of DEGs from Question 1 (IA v OA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A hierarchical clustering heat map based on DEGs (>1.5-fold change; p<0.05, multiple test-
corrected) from Question 1. Colours indicate gene-wise fold-change across 11 samples as per key (right). Top 
colour bar indicates disease group and type as per key (bottom). 
Figure 5.15: Un-adjusted differential gene expression analyses of Question 1 (IA v OA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Volcano plot identifying DEGs (>1.5-fold change; p<0.05, no multiple test correction).  
Q1: IA v OA (Un-adjusted) 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Heat map visualisation of all DEGS from Question 1 (IA v OA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A hierarchical clustering heat map based on DEGs (>1.5-fold change) from Question 1. Colours 
indicate gene-wise fold-change across 11 samples as per key (right). Top colour bar indicates disease group 
and type as per key (bottom). 
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5.5.5 Identification of OA subgroups 
When examining the top 500 variably expressed genes between all samples, two distinct 
clusters are present (Fig. 5.18 A). One cluster contains the IA samples with X4_OA, X6_OA 
and X3_OA. The other group consists of the remaining OA samples. This segregation of OA 
samples remains true when removing IA samples from the analyses (Fig. 5.18 B), and when 
reducing to only the top 25 variable genes (Fig. 5.18 C). Using flow cytometry data acquired 
during fluorescence-activated cell sorting of these samples, percentages of cell subsets were 
calculated using methods discussed in Chapter 4. When these values are visualised in a heat 
map, hierarchical clustering of these same subgroups is again present (Fig. 5.18 D). 
X3_OA, X4_OA and X6_OA, were also clustered closer to the IA samples in PCA and MDS 
plot analyses, based on the leading dimension (Fig. 5.10). To address the heterogeneity present 
with the OA group, I split the OA samples into two subgroups for the remaining analyses (Table 
5.3). Contrasts were designed for further differential gene expression analysis of these 
subgroups (Table 5.4). Samples X3_OA, X4_OA and X6_OA that clustered closely to the IA 
samples are named group OA_1. Conversely, samples X2_OA, X5_OA, X7_OA, X8_OA and 
X9_OA that clustered distantly from the IA samples are named group OA_0. 
Figure 5.17: KEGG pathway analyses of un-adjusted DEGs from Question 1 (IA v OA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Perturbed KEGG pathways based upon DEGs from Question 1 (>1.5-fold change; p<0.05, no 
multiple test correction). Colour indicates p-value of pathway as per key. 
Q1: IA v OA – Greater perturbed pathways (Un-adjusted) 
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Figure 5.18: Identification of OA subgroups in RNA-seq and flow cytometry data sets 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. Identification of cell subsets by flow cytometry was conducted following techniques described in 
Chapter 4. A: Hierarchical clustering heat map of the top 500 variable genes across all samples. B: Hierarchical 
clustering heat map of the top 500 variable genes across OA samples. C: Hierarchical clustering heat map of 
the top 25 variable genes across OA samples. Colours indicate gene-wise expression across samples as per key. 
D: Hierarchical clustering heat map of relative percentage (% of CD45+) of cell subsets in samples. Colours 
indicate percentage across samples as per key. 
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5.5.6 OA_1 v IA (Question 2) 
In previous analyses, OA_1 clustered closely with IA, and therefore differential gene expression 
analyses was unlikely to generate a great number of significant DEGs.  Indeed, a small number 
of significant DEGs were observed (>1.5-FC; p<0.05, multiple test corrected) (Fig. 5.19). The 
volcano plot visualisation shows a high degree of striation, which suggest poor calculation of 
p-values (Fig. 5.19 A). This is often due to poor design contrast, incorrect hypotheses, or 
insufficient data. Poor p-value distribution was also observed (Fig. 5.19 C). This showed a 
bimodal and conservative distribution with a peak present at both the low and high end of the 
spectrum. These observations are likely due to the similarity of the two groups being tested. 
Significant DEGs are displayed in a heat map, which clusters into IA, OA_0 and OA_1 (Fig. 
5.20). IGFBP5 and LRRN4CL are under expressed in the IA group, as they were in Question 1. 
Using un-adjusted p-values, KEGG pathway analyses was repeated (Fig. 5.21). As there were 
still a relatively small number of DEGs, only 9 significant (<0.01) perturbed KEGG pathways 
were discovered. Full pathways are shown in Appendices 5.35 – 5.43. 
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Figure 5.19: Question 2 (OA_1 v IA) differential gene expression analyses 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. A: Volcano plot identifying DEGs (>1.5-fold change; p<0.05, multiple test corrected). B: Table 
(5.5) of DEGs, log fold change and adjusted p-value from Question 2. C: P-value distribution of all DEGs 
from Question 2. 
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Figure 5.20: Heat map visualisation of DEGs from Question 2 (OA_1 v IA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A hierarchical clustering heat map based on DEGs (>1.5-fold change; p<0.05, multiple test-corrected) 
from Question 2. Colours indicate gene-wise fold-change across 11 samples as per key (right). Top colour bar 
indicates disease group and type as per key (bottom). 
Figure 5.21: KEGG pathway analyses of un-adjusted DEGs from Question 2 (OA_1 v IA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Perturbed KEGG pathways based upon DEGs from Question 2 (>1.5-fold change; p<0.05, no 
multiple test correction). Colour indicates p-value of pathway as per key. 
Q2: OA_1 v IA – Greater perturbed pathways (Un-adjusted) 
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5.5.7 OA_0 v IA (Question 3) 
I next carried out comparisons on the most distant groups, OA_0 and IA. Differential gene 
expression analyses yielded 138 DEGs (>1.5-FC; p<0.05, multiple test corrected) (Fig. 5.22). 
The p-value distribution for this question demonstrates consistent anti-conservative distribution 
(Fig. 5.22 C). When visualised in a heat map, three distinct groups are clustered matching those 
found in previous analyses (Fig. 5.23). Despite a higher number of DEGs, and a better statistical 
certainty in the question, KEGG pathway analyses was again conducted using un-adjusted p-
values (Fig. 5.24). 15 significant (<0.01) perturbed KEGG pathways were discovered. All 
pathways reaching adjusted p-value <0.01 are shown in Appendices 5.44 – 5.58. 
Owing to the greater number of significantly DEGs, gene set enrichment analyses could be 
performed using gene ontology database (GO). This used the adjusted p-values, and therefore 
has higher statistical significance than previous exploratory KEGG analyses. The p-value 
distribution of these GO terms demonstrated anti-conservative distribution (Appendix. 5.3). 
The DEGs and GO terms can then be linked using a Circos plot (Fig. 5.26). Circos plots 
visualise data in a circular layout, allowing the exploration between genes and GO term 
relationships. This demonstrates numerous genes involved in extracellular organisation, 
cartilage development, in addition to an array of other GO terms. In particular, it can be seen 
that individual genes such as IGFBP5 contribute to a range of GO terms. In contrast, genes such 
as TSKU and GPRC5A contribute to a singular or <3 GO terms. When plotting biological 
process GO terms in a network visualisation, it is indicated that the gene SMAD3 plays a role 
in many of these pathways (Fig. 5.26 A). Furthermore, when plotting these same networks in a 
different formation, it can be highlighted that the Extracellular Matrix Organisation pathway 
has the most interlinking roles with many of these additional pathways and genes (Fig. 5.26 B). 
Similarly, when plotting molecular function GO terms, the integrin binding and related 
pathways association with a smaller group of genes can be examined (Fig. 5.27). 
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Figure 5.22: Question 3 (OA_0 v IA)  differential gene expression analyses 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A: Volcano plot identifying DEGs (>1.5-fold change; p<0.05, multiple test corrected). B: Table (5.6) 
of DEGs, log fold change and adjusted p-value from Question 3. C: P-value distribution of top 25 (ordered by p-
value) DEGs from Question 3. 
A 
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Q3: OA_0 v IA 
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Figure 5.23: Heat map visualisation of DEGs from Question 3 (OA_0 v IA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A hierarchical clustering heat map based on DEGs (>1.5-fold change; p<0.05, multiple test-
corrected) from Question 3. Colours indicate gene-wise fold-change across 11 samples as per key (right). Top 
colour bar indicates disease group and type as per key (bottom). 
Q3: OA_0 v IA – Greater perturbed pathways (Un-adjusted) 
Figure 5.24: KEGG pathway analyses of un-adjusted DEGs from Question 3 (OA_0 v IA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Perturbed KEGG pathways based upon DEGs from Question 3 (>1.5-fold change; p<0.05, no 
multiple test correction). Colour indicates p-value of pathway as per key. 
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Figure 5.25: GO term circos plot of adjusted DEGs from Question 3 (OA_0 v IA)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. Perturbed GO terms passing adjusted p<0.05 and q-value FDR <0.25, based upon DEGs from 
Question 3 (>1.5-fold change; p<0.05, multiple test corrected). Pathway colour indicates GO pathway as per 
key (bottom). Gene colour indicates log fold change as per key (top). 
Q3: OA_0 v IA – Perturbed GO-terms (Adjusted) 
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5.5.8 OA_0 v OA_1 (Question 4) 
Finally, I compared both OA groups with each other. This yielded the biggest difference, with 
155 significantly DEGs identified (>1.5-FC; p<0.05, multiple test corrected) (Fig. 5.28). The 
p-value distribution for this question demonstrates consistent anti-conservative distribution 
(Fig. 5.28 C). Visible in a heat map, the expression of these genes is highly consistent between 
both OA_0 and OA_1 (Fig. 5.29). The IA group expression of these genes is mixed. Despite a 
higher number of DEGs, and a better statistical certainty in the question, KEGG pathway 
analyses was again conducted using un-adjusted p-values (Fig. 5.30). No pathways meeting a 
significant threshold of (<0.01) were discovered.  
As Question 4 also produced a larger array of significantly DEGs, gene set enrichment analyses 
was performed using adjusted p-values. The p-value distribution of these GO terms 
demonstrated anti-conservative distribution (Appendix. 5.4). The DEGs and GO terms can then 
be linked using a Circos plot (Fig. 5.31). This demonstrates numerous genes involved in cell 
cycle processes. Of note, TTK, CDT1, XRCC3 and PLK1 have roles in a large number of GO 
terms. It can be additionally visualised that ASPM, KMT5A and KIFC all have dual roles in 
mitotic cell cycle and cell cycle check point. When plotting these pathways and associated 
genes in a network visualisation, it is indicated the gene CDT1 plays a role in many of these 
pathways (Fig. 5.32 A). Furthermore, when plotting these same networks in a different 
formation, it can be highlighted that the Mitotic Cell Cycle pathway has the most interlinking 
roles with many of these additional pathways and genes (Fig. 5.32 B). 
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Figure 5.28: Question 4 (OA_0 v OA_1) differential gene expression analyses 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described in 
Chapter 2. A: Volcano plot identifying DEGs (>1.5-fold change; p<0.05, multiple test corrected). B: Table 
(5.7) of DEGs, log fold change and adjusted p-value from Question 4. C: p-value distribution of top 25 (ordered 
by p-value) DEGs from Question 4. 
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Q4: OA_0 v OA_1 
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Figure 5.29: Heat map visualisation of DEGs from Question 4 (OA_0 v OA_1)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods 
described in Chapter 2. A hierarchical clustering heat map based on DEGs (>1.5-fold change; p<0.05, 
multiple test-corrected) from Question 4. Colours indicate gene-wise fold-change across 11 samples as 
per key (right). Top colour bar indicates disease group and type as per key (bottom). 
Figure 5.30: KEGG pathway analyses of un-adjusted DEGs from Question 4 (OA_0 v OA_1)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods 
described in Chapter 2. Perturbed KEGG pathways based upon DEGs from Question 4 (>1.5-fold change; 
p<0.05, no multiple test correction). Colour indicates p-value of pathway as per key. 
Q4: OA_0 v OA_1 – Greater perturbed pathways (Un-adjusted) 
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Figure 5.31: GO term circus plot of adjusted DEGs from Question 4 (OA_0 v OA_1)  
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Perturbed GO terms passing adjusted p<0.05 and q-value FDR <0.25, based upon DEGs from 
Question 4 (>1.5-fold change; p<0.05, multiple test corrected). Pathway colour indicates GO pathway as 
per key (bottom). Gene colour indicates log fold change as per key (top). 
Q4: OA_0 v OA_1 – Perturbed GO-terms (Adjusted) 
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5.5.9 Overlap 
In order to determine the concordance of DEGs between questions, a Venn diagram was used 
to visualise the DEGs generated (Fig. 5.33). Between the comparison of whole OA and IA 
(Question 1), TSKU was shared with OA_0 (Fig. 5.33 B). IGFBP5 and LRRN4CL were both 
differentially expressed in Questions 1-3. However, these two genes were not significantly 
differentially expressed in Question 4, suggesting they are ubiquitously expressed by all OA 
samples (Fig. 5.33 C). The remaining genes were exclusive to each question. The 85 DEGs 
unique to Question 4 exhibited strong cell cycle functional pathways (Fig. 5.33 C). 75 DEGs 
from Question 3 were exclusive to OA_0, representing extracellular matrix and cartilage 
development related pathways and SMAD/RUNX functioning (Fig. 5.33 C). 61 DEGs were 
shared between Question 3 & 4, and although did not have a strong consistent pathways 
signature, again showed cell cycle related pathways, in addition to RNA III Polymerisation 
(Fig. 5.33 C). 
 
5.6 Clinical analyses 
To assess whether the distribution of samples by gene expression could be explained by clinical 
factors, a density plot was used to demonstrate these relationships (Fig. 5.34). None of the 
clinical factors collected demonstrated a log10 variance of 1 (100% variance), and all samples 
present values above this threshold suggesting negative percentage variance. Although ESR 
presented with a proportionately large density, this remains relatively low, explaining <15% of 
variance. Additionally, ESR did not demonstrate a log10 variance of 1. Overall, this co-variate 
analysis demonstrates that none of the clinical data collected have a substantial explanatory 
power for the genes measured and variances observed in this data-set. 
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Figure 5.33: Concordance of DEGs identified across all questions 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. A: Table (5.6) of DEGs, log fold change and adjusted p-value from all questions.  B: Venn 
diagram depicting degree of concordance between DEGs (>1.5-fold change; p<0.05, multiple test corrected) 
identified in questions  1, 2 & 3. C: Venn diagram depicting degree of concordance between DEGs (>1.5-
fold change; p<0.05, multiple test corrected) identified in Questions  2, 3 & 4. 
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Figure 5.34: Density plot of variance explained by clinical data 
Density plot of the percentage variance (log10) normalised counts across all genes. Each line corresponds to a 
clinical factor and represents the distribution of percentages. Those aligning with the dashed line corresponding 
to log10 1 on the X axis demonstrate 100% variance. Those with a  high proportion of density demonstrate 
hierarchical clustering of samples based on gene expression data, such as seen in PCA analyses. 
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5.7 Discussion 
Within Chapter 5, I set out to examine the phenotype, function and gene expression of synovial 
macrophages in OA patients. This encompassed wide-ranging and advanced techniques 
including, flow cytometry, FACs, in vitro assays, RNA-isolation and RNA-sequencing. 
Through this, I aimed to provide a novel in-depth analysis of synovial macrophages in OA 
synovial tissue. 
The gating strategy for the accurate identification and purification of synovial macrophages had 
already been developed, discussed in Chapter 4.  However, for Chapter 5 I began by testing a 
gating strategy developed by Professor Matthew Collin for the identification of inflammatory 
monocyte and macrophage subsets in healthy and inflammatory (graft-versus- host disease; 
GvHD) dermis. The first method was the identification of an inflammatory monocyte subset. 
Although my flow cytometry panel was not optimised for this gating strategy, I was still able 
to identify these monocyte subsets in previously acquired samples. When applied to OA and IA 
synovium samples, a larger proportion of monocyte ‘2’ were identified in the IA samples 
compared to OA. This matches the observation seen in healthy versus GvHD dermis. A second 
strategy allows the identification of resident and inflammatory macrophages based on CD11c 
expression. This demonstrated a higher proportion of resident macrophages in OA synovium 
samples and conversely a higher proportion of inflammatory macrophages in IA samples. With 
the inclusion of auto-fluorescence into this strategy, I was able to eliminate non-auto-
fluorescent cell contamination, likely monocytes and DCs. Although I only had data for one 
additional surface marker for these samples, it was shown that ‘inflammatory’ macrophages 
indeed had higher expression of CD86, a co-stimulatory marker often associated with 
inflammation. This gating strategy may present a novel method that will aid in our 
understanding of resident macrophages and, potentially, monocyte-derived inflammatory 
macrophages. As this strategy was recently developed, it was left for future work. 
When examining the surface markers within my FACs panel on synovial macrophages, they 
expressed macrophage- and myeloid-markers and did not express markers associated with other 
cell types. This aided in confirming the purity of these cell-sorted synovial macrophages. 
Healthy moMacs expressed higher levels of CD14, CD45, CD16, CD11c and CD4. As this cell 
type represents a monocyte-derived macrophage, it is interesting to note higher levels of 
CD11c, the marker used in the previous analyses for the identification of inflammatory 
macrophages. Furthermore, when assessing a select panel of ‘activation’ markers, monocyte-
derived macrophages also had increased expression of CD172α, CCR2 and CCR7. These have 
all previously been reported as markers of moMacs, giving me confidence in these data (Italiani 
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and Boraschi 2014, Yang, Zhang et al. 2014, Bian, Shi et al. 2016). Folate receptor 2 (FOLR2) 
has been previously used as a marker of activated synovial macrophages in an imaging study 
(Kraus, McDaniel et al. 2016). Here I measured increased expression in both my moMacs and 
OA macrophages compared to IA. A similar observation was also recorded for CD206, 
mannose receptor, which is associated with tissue repair-like M2 macrophages (Martinez and 
Gordon 2014). 
Although care was taken in optimising the isolation and purification of these synovial 
macrophages, it was important to ensure that these cells were still functional once isolated. 
Through incubation of macrophages with latex beads, I was able to measure phagocytic 
capacity by flow cytometry. Using confocal microscopy, I confirmed engulfment of latex beads 
as opposed to adherence to the cell membrane. Healthy moMacs, IA moMacs and OA synovial 
macrophages were shown to have a superior capacity of phagocytosis than their DC 
counterparts. This data overall demonstrated that despite the stresses of mechanical and 
enzymatic digestion, in addition to FACs, once isolated these macrophages are still functional. 
For gene expression analyses, patient cohorts were matched well between disease type with 
similar age and sex. Differences in BMI, CRP and ESR were deemed acceptable, as these have 
been identified as known risk factors or disease-specific consequences. The OA group had 
active OA disease, assessed by KL scoring of radiographic images. The IA group had a low 
disease activity score of 3.0 (SD: 0.3). However this was close to a moderate disease activity 
score, classed as between >3.2 and ≤5.1. 
Through both MDS and PCA analyses, the three IA samples grouped together, away from the 
OA samples. However, the OA samples could be split along the leading dimension in all 
analyses. These analyses suggest heterogeneity within the OA samples. This heterogeneity is 
not seen in the IA samples, despite the biological variation of disease types. Secondly, a group 
of OA samples appear to cluster closer to the IA samples, and further from the remaining OA 
samples. Together, these observations suggest the macrophages isolated from OA patients are 
heterogenous, and that a subset of these macrophage samples may have a gene signature more 
closely matched to those isolated from IA patients. 
Subsequently, I assessed whether these synovial macrophages had a gene signature homologous 
to previously described macrophage phenotypes. When addressing M1 and M2 macrophage 
gene signatures, no clear conformity was found of either all synovial macrophages, or 
discrimination between OA and IA samples. X9_OA, X5_OA, X7_OA and X8_OA (all from 
the OA_0 group) had high expression of a number of these M1 genes. Notably, all IA 
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macrophage samples had lower levels of expression of genes commonly associated with 
inflammation and RA such as TNF, IL6 and IL1B, whereas the OA samples had higher levels 
of expression of these genes. Conversely, most synovial macrophages did not express M2-
related genes, however two IA samples had higher levels of expression of a small group of these 
M2 genes. Although IA is an inflammatory condition, the macrophages present in the synovium 
may not actively express these inflammation-related genes. Overall, these data suggest that 
while the M1/M2 macrophage activation paradigm is useful, it may not be relevant in the 
context of tissue-derived macrophages from our samples. 
I next assessed the differing gene signatures of synovial macrophages isolated from OA and IA 
patients. After performing differential gene expression analysis, there were three significantly 
DEGs after Benjamini-Hochberg correction. These were under-expressed in the IA samples and 
therefore over-expressed in the OA samples. Although I expected to find greater numbers of 
significantly DEGs between these groups, the p-value distribution of the DEGs did not suggest 
a null-hypothesis. The three significantly DEGs were IGFBP5, LRRN4CL and TSKU. 
To conduct exploratory pathway analyses, unadjusted p-values were used to generate a large 
enough repository of logFC DEGs. When all unadjusted DEGs were visualised in a heat map, 
the IA samples clustered separately as expected due to the question design. However, it was 
noted that the same three OA samples observed in the MDS and PCA analyses again clustered 
separately from the remaining OA samples. From this visualisation, the heterogeneity of OA 
samples, and homology of IA samples is clear. 
The KEGG pathways generated that were statistically significant were all over expressed in the 
IA group. 28 pathways were statistically significant (p<0.01). It is important to consider that 
this was performed on un-adjusted p-values and is exploratory. However, a number of pathways 
generated are already implicated in the pathogenesis of IA and give confidence in this data. 
These include cytokine-cytokine, TNF, NF-kappa B, IL-17, NOD-like receptor, chemokine, 
toll-like receptor, rheumatoid arthritis, MAPK and JAK-STAT pathways. Results such as 
malaria, and cancer related pathways should be treated with caution. These could be significant 
due to the nature of using un-adjusted p-values. However, especially in the cancer field, there 
is often a greater array of data in these diseases, and their presentation in this analyses rather 
reflects a component of this pathway being active within our samples. For example, when 
examining the pathview of inflammatory bowel disease, this suggests an over expression of 
MHCII, TLRs, cytokines and STAT signalling, all relevant in the context of macrophages and 
IA. As this analysis was exploratory, it was not considered in any more detail. 
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Owing to the lack of significant differences observed between the IA and OA samples, I 
hypothesised that this was limited due to the heterogeneity observed within the OA samples. It 
was thought that the biological variation within the OA samples was masking the difference 
with the IA samples. Paired with the observation that a subgroup of OA samples appeared more 
similar to IA, I decided to investigate this heterogeneity further. 
Through visualising the top 500 and 25 genes, with and without inflammatory samples, this 
same clustering of three OA samples was present. In these analyses, these samples clustered 
within the IA samples, rather than in their own cluster. When this analyses was applied to the 
flow cytometry dataset for these samples, a similar clustering was observed (Fig. 5.17). Due to 
the consistent evidence for heterogeneity in OA, and the appearance of a sub group consisting 
of X3_OA, X4_OA and X6_OA, three additional question were asked. The aim of these 
questions was to segregate the OA samples and compare with the IA samples. This allowed me 
to reduce the biological variation within the OA samples when comparing with IA. In addition, 
I aimed to identify gene expression differences between these two OA groups. 
The first question was to compare the OA_1 group that had previously clustered closely with 
IA samples, to the IA samples. Although this resulted in 11 significantly over expressed genes, 
visualisation of the data and analysis of the p-value distribution suggested that this question 
was designed poorly. This could be owing to a high similarity between the two groups, or a 
lack of repeats. However, within the significantly DEGs, IGFBP5 and LRRN4CL were again 
up regulated in the OA samples. The most statistically significant DEG was E2F8. E2F8 has 
roles in the regulation of cell cycle, promoting cell proliferation and has been previously 
reported in OA chondrocytes (Ye, Guo et al. 2016, Alshenibr, Tashkandi et al. 2017). Other 
genes overexpressed include TMEM98 and RSPO2. TMEM98 is a regulator of MMPs, can 
promote Th1 cells and can regulate cell invasion and migration (Fu, Cheng et al. 2015, Mao, 
Chen et al. 2015). RSPO2 is a member of the R-spondin family, which have been widely 
implicated in OA (Abed, Chan et al. 2011, Jin and Yoon 2012, Nakajima, Kou et al. 2016). 
Exploratory pathway analyses was performed again on un-adjusted p-values. 9 statistically 
significant KEGG pathways were generated. Again, those that are immediately relevant to the 
experiment as a whole include cytokine-cytokine receptor and NF-kappa B. Pathways such as 
AGE-RAGE, inflammatory bowel disease, malaria, cancer transcription and other 
inflammatory diseases that were observed in the previous question are again perturbed here. It 
is again likely that this is a result of the exploratory nature of these analyses, or generic cell 
mechanisms which are cross relevant to this experimental set-up. Of note, Cell cycle pathway 
was the highest significant result in the OA samples, similarly to the GO term analyses. 
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Within Question 2, it is likely that a lack of statistical significance is due to the similarity of 
this OA sub group (OA_1) and the IA samples. Although the results are not of the highest 
statistical significance, these help to validate this data set as a whole and give confidence in its 
quality.  
Question 3 addressed the difference between the second OA group (OA_0) the IA group. It was 
clear after visualisation of the data and p-value distribution, that there were a greater number of 
significant differences between these two groups. There were 138 significantly DEGs 
(adjusted). This would again suggest that the OA samples are heterogeneous, and that the 
biological variation within all OA samples was masking the difference in Question 1 (IA v OA). 
True to the hypothesis, many of the DEGs were very biologically relevant with roles in either 
OA, cartilage development, RA, macrophages or cell signalling.  
Despite the greater amount of significantly DEGs, KEGG pathway analyses again required a 
greater number of genes to reach statistical significance. Many of the previously relevant 
pathways were again observed in this analysis. Although KEGG analyses were performed on 
un-adjusted p-values, a number of significant GO terms were found based on the adjusted p-
value DEGs. Many of these GO terms are relevant to OA, including extracellular matrix and 
structure organisation, osteoblast proliferation, cartilage and connective tissue development and 
roles in other tissue engineering. When network analysis was performed on the GO terms, the 
relation of the most significant GO terms and genes can be more intuitively visualised. Once 
more, we see many tissue engineering pathways in addition to binding pathways. Utilising 
network visualisations, SMAD3 was highlighted as having roles in many of the GO terms, in 
addition to the importance of the Extracellular Matrix Organisation pathway in this question. 
Additionally, IGFBP5 was again identified, and was associated with integrin and insulin 
binding pathways. 
The final question addressed the difference between the two OA groups. This yielded the largest 
amount of significantly DEGs, 155, with a good p-value distribution. Once again, despite the 
greater amount of significantly DEGs, KEGG pathway analyses required a greater number of 
genes to reach statistical significance. In this analysis, there were no pathways that fell below a 
significant value of 0.01. Although KEGG analyses were performed on un-adjusted p-values, a 
number of significant GO terms were found based on the adjusted p-value DEGs. Interestingly, 
when performing GO term analyses, a strong cell cycle gene signature was present in the 
pathways, which was again seen in network analyses. CDT1 was highlighted as having roles in 
many cell cycle processes. CDT1 encodes the DNA replication factor Cdt1 protein, involved in 
the formation of the DNA pre-replication process. The CDT1 gene is involved in the cell cycle 
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and has been previously been reported to be highly expressed in scleroderma patients (Milano, 
Pendergrass et al. 2008). 
The analysis of Question 4 strongly supports the premise that there are two distinct groups 
within the OA samples. Interestingly, there were greater differences measured between these 
two OA groups, than when contrasting OA_1 against IA, or contrasting all OA samples against 
IA. Question 3 yielded a similar result to Question 4 with a relatively large amount of significant 
DEGs presenting between OA_0 and IA. These differences again suggest that the biological 
variation in OA samples, or the similarity of IA and OA_1, was masking differences in previous 
analyses.  
All of these data highlight a level of heterogeneity in OA synovial macrophages. IGFBP5 and 
LRRN4CL were significantly over-expressed in all OA groups tested as compared to IA, 
suggesting these genes are uniquely expressed in the OA macrophages. Previously published 
literature on LRRN4CL are limited to its generic expression in human tissues. However, there 
is much research surrounding insulin growth factor binding proteins (IGFBP).  
IGFBP5 has roles in controlling cell survival, differentiation and apoptosis and is often 
implicated in tumour biology (Salih, Tripathi et al. 2004, Sureshbabu, Okajima et al. 2012). 
The role of IGFBPs in OA is unclear. In a canine model of OA, inhibition of IGFBP5 proteases 
improved the structure of the joint during OA development (Clemmons, Busby et al. 2002). It 
was suggested that the inhibition of complement C1s in human OA synovial fluid reduced  
IGFBP5 cleavage and that this mechanism may promote a cartilage repair response (Busby, 
Yocum et al. 2009). Conversely, IGFBPs have been found increased in chondrocytes in human 
OA, with a positive correlation of histological joint destruction and IGFBP levels (Olney, 
Tsuchiya et al. 1996). Downregulation of IGFBP5 has also been associated with the 
upregulation of TNFα-induced NF-kappa B signalling in synovial fibroblasts, promoting IL6 
production (Hong, You et al. 2017). Furthermore, in an animal model of sepsis, and in response 
to LPS stimulation, IGFBP5 expression was shown to be reduced (Lang, Krawiec et al. 2006). 
There is less research surrounding the specific function of IGFBP5 in macrophages, and to my 
knowledge, none in the context of synovial macrophages in OA. In murine macrophages, 
IGFBP5 has been shown to reduce expression of inflammatory markers and oxidative stress, 
including F4/80, MAC1 and TGFβ mRNA (Sokolovic, Montenegro-Miranda et al. 2012). 
Similarly, IGFBP5 has been shown to reduce local inflammation in animal models of 
periodontitis through the negative regulation of NF-kappa B signalling (Liu, Wang et al. 2015). 
As IGFBP5 was over-expressed in OA macrophages, and therefore under-expressed in IA 
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macrophages, this could reflect a less inflammatory environment in OA compared to IA. 
Furthermore, in Question 3, IGFBP5 had the highest logFC change (LogFC = 9.51) 
representing a significant overexpression in OA_0 compared with IA. As OA_0 macrophages 
consistently clustered separately from both IA and OA_1 macrophages, this large over 
expression could again reflect a less inflammatory environment. Perhaps the expression of 
IGFBP5 seen in these OA macrophages, particularly OA_0, is a cellular mechanism 
contributing directly to the reduction of local synovial inflammation. Conversely, these 
macrophages could simply be reflecting the inflammatory or non-inflammatory environment in 
which they are found. 
High temperature requirement serine protease A1 (HTRA1) is a serine protease previously 
considered to degrade IGFBP5. However, it is now thought that the high affinity of C1s for 
IGFBP5 results in this degradation (Clemmons, Busby et al. 2002, Busby, Yocum et al. 2009). 
Nevertheless, upregulation of HTRA1 has also been demonstrated following cartilage damage 
in animal models of OA (Tsuchiya, Yano et al. 2005, Grau, Richards et al. 2006). Although the 
primary source of HTRA1 in the synovium is thought to be fibroblasts, HTRA1 is upregulated 
(non-statistically significant) in OA macrophages compared to IA macrophages (Question 1 – 
LogFC = -3.16), and significantly upregulated in OA_0 macrophages (Question 3 - LogFC = 
3.71; p value = 0.03, multiple test corrected). In agreement with this, HTRA1 has previously 
been measured at higher levels in the synovial fluid of OA patients compared to RA patients 
and non-arthritic controls (Grau, Richards et al. 2006). Treatment of synovial fibroblasts with 
HTRA1 increases the production of cartilage catabolic MMP1 & 3 (Grau, Richards et al. 2006). 
This induction of MMPs was generated directly, and indirectly through the production of 
fibronectin fragments through fibronectin degradation. The immunohistochemical expression 
of HTRA1 in synovial tissue has been used as a biomarker for OA progression, specifically 
cartilage damage (Grau, Richards et al. 2006, Larkin, Kartchner et al. 2013). However, the 
mechanism for HTRA1 upregulation, and its cellular source in OA is unknown. Perhaps an 
increased expression of HTRA1 in OA macrophages, particularly macrophages from OA_0 
synovium in this instance, induces MMP production by synovial fibroblasts, which in turn 
contributes to the cartilage destruction characteristic of OA. 
EFEMP1, also referred to as fibulin-3, was significantly over-expressed in OA_0 macrophages 
compared with IA macrophages. EFEMP1 has been reported to inhibit angiogenesis, as well as 
being a negative regulator of chondrogenesis (Albig, Neil et al. 2006, Wakabayashi, Matsumine 
et al. 2010). A correlative link between EFEMP1 and OA progression has been previously 
reported (Henrotin, Gharbi et al. 2012). Furthermore, the detection of fibulin-3 fragments has 
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shown to be a prognostic biomarker for the development of knee OA in overweight and obese 
middle age women (Runhaar, Sanchez et al. 2016). However, the role of EFEMP1 in 
macrophages in synovial tissue remains unclear. EFEMP1 expression in the OA_0 
macrophages may function as a negative regulator of chondrogenesis, and therefore a failing 
repair mechanism after cartilage destruction through chronic mechanical damage and other 
catabolic factors such HTRA1 signalling and MMP production previously discussed. 
SMAD3 was also over-expressed in OA_0. SMAD3 functions as a transcriptional modulator 
coding for an intracellular molecule that translocates TGF-β signal to the nucleus. Previous 
work in our department (Musculoskeletal Research Group) has investigated a molecular 
SMAD3 SNP loss of function mutation in OA knees and hips (Raine, Reynard et al. 2014). An 
increase of SMAD3 expression was observed in OA knees compared with hips. They postulated 
allelic expression effects of relevance to OA. Indeed, there is much molecular literature 
investigating the association of SMAD3 and OA (Yao, Wang et al. 2003, Aref-Eshghi, Zhang 
et al. 2014, Su, Yang et al. 2015). SMAD3 and TGFβ signalling have also been implicated in 
tissue repair M2-like macrophages, particularly in environments of fibrosis and tissue damage 
(Kalinina, Agrotis et al. 2004, Gong, Shi et al. 2012, Rocher and Singla 2013, Eichenfield, 
Troutman et al. 2016, Loboda, Sobczak et al. 2016). Treatment with Bone morphogenetic 
protein-7 (BMP-7), a TGF-β signalling protein, in an animal model of OA resulted in improved 
cartilage repair through reduction of catabolic factors of cartilage destruction (MMPs and 
aggrecanase) (Badlani, Oshima et al. 2009). The loss of SMAD2/3 signalling in favour of 
SAD1/5/8 further progresses OA joint damage through chondrocyte differentiation (van der 
Kraan, Blaney Davidson et al. 2009). SMAD2/3 signalling is thought to inhibit RUNX2, a 
contributing factor for this chondrocyte differentiation (van der Kraan, Blaney Davidson et al. 
2009). RUNX2 is under-expressed in OA_0 macrophages in both Questions 3 and 4 (Q3: 
LogFC = -1.39; Q4 LogFC = -2.12). Although these changes in expression are not statistically 
significant, they are consistent with the negative association of SMAD3 with RUNX2, in 
addition to the negative regulation of chondrogenesis by EFEMP1. The upregulation of SMAD3 
in the synovial macrophages of OA_0 is likely a tissue repair response to chronic mechanical 
joint damage. However, this may be an additional failing mechanism since these patients are at 
end stage OA. 
In contrast, the top GO terms from Question 4 (OA_0 vs OA_1) yielded a consistent cell cycle 
phenotype. The top genes contributing to this were mostly over-expressed in the OA_1 group. 
Notably, MKi67 gene was highly over-expressed by this group (LogFC -7.2 in OA_0). MKi67 
encodes for Ki67, a nuclear protein associated with cell proliferation. Although Ki67 has been 
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previously shown to be correlated with OA Research Society International (OARSI) 
histological grading, no correlation was shown with CD68 macrophages in OA (Koller, 
Waldstein et al. 2017). This was attributed to the inclusion of only biomechanical degenerative 
joint disease, suggesting a lack of inflammatory involvement in these samples. To confirm 
synovial macrophages isolated from OA synovium expressed Ki67, I stained for Ki67 by flow 
cytometry (Appendix 5.6). Positive expression was seen, but this was not clear. As Ki67 is a 
nuclear marker and requires permeabilisation of cells, it can be difficult to stain by flow 
cytometry. This staining of Ki67 would need to be repeated with an optimised staining protocol. 
Additionally, many other genes with involvement in cell cycle and proliferation were 
upregulated in OA_1 macrophages compared to OA_0 macrophages including E2F8 and CDT1 
which have been shown promote cell proliferation through modulation of G1/S phase (Deng, 
Wang et al. 2010, Zhang, Xing et al. 2012, Pozo and Cook 2016, Ye, Guo et al. 2016). It is 
likely that OA_1 macrophages are undergoing proliferation. The tissue environment which may 
be modulating this is unclear. The CTRL gene encodes the enzyme Chymotrypsin-like protease 
(CTRL-1), and is highly overexpressed in OA_1 compared to OA_0. CTRL has been shown to 
be enhanced after stimulation with LPS. Additionally, when CTRL stimulation is blocked, 
macrophages reduce their expression of inflammatory mediator genes, Nitric Oxide (NO) 
production and TNF-α secretion (Maa, Chang et al. 2008, Reis, Guan et al. 2011). As CTRL is 
highly expressed in OA_1 macrophages, this could be in response to an inflammatory 
environment, and these macrophages then subsequently contribute to this inflammatory 
environment through the CTRL dependent production of inflammatory mediators. Local 
proliferation of macrophages in tissue, rather than monocytic recruitment from blood, has been 
reported to be Th2/IL-4-type inflammation driven (Jenkins, Ruckerl et al. 2011). This could be 
further mediated by factors such as CTRL expression controlling enhanced production of 
inflammatory mediators, providing a positive feedback loop further contributing to this 
inflammatory environment. Taken together, these analyses are suggestive of a cell cycle gene 
signature in OA_1 macrophages, which is likely to be driven by a specific, potentially 
inflammatory tissue environment in this group of OA patients. 
Unc-51 like-kinase 1 (ULK1) is a protein encoding gene which is a key inducer of autophagy, 
through mTOR signalling (Zhang, Vasheghani et al. 2015). In OA, it is thought that mTOR 
regulation of ULK1 may contribute to catabolic and anabolic factors in cartilage, however these 
specific mechanisms are unclear (Zhang, Vasheghani et al. 2015). In contrast, it has been 
reported that this ULK1 mediated authophagy is protective of cartilage, and that an ageing 
related loss of expression results in OA development (Carames, Taniguchi et al. 2010). In RA, 
expression of ULK1 has previously been associated with disease activity, and measures of 
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ULK1 and RUNX2 being used as predictors and measures of response to rituximab and 
methotrexate (Tchetina, Pivanova et al. 2016, Tchetina, Demidova et al. 2017). ULK1 is 
significantly over expressed in both IA and OA_1 macrophages when compared with to OA_0 
macrophages. This difference is not seen when contrasting IA and OA_1 macrophages. 
Additionally as previously mentioned, RUNX2 is overexpressed (LogFC = -2.12) in OA_1 
macrophages compared to OA_0 macrophages, although not statistically significantly. These 
observations again suggest a similarity between OA_1 macrophages and IA macrophages. 
Furthermore, with further validation, expression of ULK1 may prove a useful tool for 
identifying OA patients which may respond treatments commonly used in RA.  
Previous research into ULK1 expression in the tissues of OA patients has been limited to 
histological analysis of cartilage and western blotting of chondrocytes (Carames, Taniguchi et 
al. 2010). The authors suggest that in the quantification of ULK1 expression in cartilage, the 
assessment may be conflicted by cell clusters localised in the middle and deep zones. This 
yielded inconsistent results with western blot analyses. Overall, reduced expression of ULK1 
was measured in both mild and established OA groups compared the healthy controls. However 
histological analysis of cartilage showed lowest ULK1 expression in mild OA, whereas through 
western blotting of chondrocytes, ULK1 expression in established OA was significantly lower 
than both mild OA and normal controls. It could be postulated that this is due to technical 
variances in measurement, as well as the biological variance of measuring whole cartilage 
expression and expanded chondrocytes. This was not discussed by the authors. A significant 
decrease of ULK1 was observed after surgically induced OA compared to sham surgery in 
murine knee joints. In my analyses of synovial macrophages, ULK1 is highly over-expressed 
in both IA and OA_1 macrophages in differential gene expression analyses. Although this over-
expression in OA_1 and IA macrophages was the primary interest, when examining gene reads, 
ULK1 is absent from all OA_0 samples, with counts measured in all OA_1 and IA samples. 
Since all OA samples were derived from end stage OA patients, and there was no significant 
variation of age between OA groups, this is unlikely to be an age or disease activity associated 
decrease of ULK1 expression in OA_0. It could be postulated that a previous lack of OA patient 
stratification (other than disease activity or age), results in inaccurate data. Rather than OA 
patients having decreased expression of ULK1, a subset of OA patients may completely lack 
expression in synovial macrophages (OA_0). It would be interesting to see if these patients 
additionally lack ULK1 expression in cartilage and chondrocytes. Since ULK1 is an inducer of 
autophagy, a complete lack of ULK1 expression in OA_0 patients could result in reduced levels 
of autophagy and subsequent increased chondrocyte cell death. It has been previously suggested 
that Rapamycin, a specific inhibitor of mTOR signalling, could enhance autophagy and prevent 
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chondrocyte death (Li, Zhang et al. 2016). By stratifying patients via lack of ULK1 expression, 
this treatment could potentially restore autophagy functioning in these patients and prevent OA 
cartilage damage. 
A limitation of this gene expression experiment is the sample size. In RNA-sequencing 
experiments using human samples, a group of 12 repeats is typically recommended. After the 
removal of one low quality sample, and the subsequent identification of two endotypes within 
my OA cohort, the number of repeats for each group was greatly reduced. Although statistically 
significant and acceptable results were still generated, a larger sample size would have allowed 
for greater statistical certainty in exploratory analyses. Additionally, the cells used for RNA-
sequencing were tissue-derived, and had therefore undergone isolation, and subsequent FACS. 
Despite optimising a digestion protocol that results in high viability and retained functionality, 
the gene expression signature of these cells will inevitably have been influenced. However, the 
design of this experiment was to compare synovial macrophages between disease type, thereby 
eliminating technical differences in isolation. This therefore gives me confidence that the data 
generated are biologically relevant.  
These results show that using the techniques optimised in Chapter 3, it is possible to carry out 
advanced technical analyses of cell subsets from synovial tissue. RNA-sequencing identified 
the possibility of two distinct macrophage endotypes in OA. These have functionally different 
gene signatures consisting of either cell cycle mechanisms or cartilage and tissue engineering, 
summarised in Figure 5.35. It can be postulated that the differing disease environments between 
the arthritic joints of these OA patients is driving two different polarisation states of these 
macrophages. Although it is likely that these macrophages also contribute to disease 
pathogenesis, the specifics of this are less clear. 
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Chapter 6. Thesis summary and general discussion 
6.1 Thesis Summary 
OA represents a huge burden on patients and society. As there are no disease-modifying 
treatments, there is a major unmet clinical need for OA patients. Inflammation has become 
recognised as a key mediator of OA pathogenesis (Haywood, McWilliams et al. 2003, Baker, 
Grainger et al. 2010, Sellam and Berenbaum 2010, Roemer, Crema et al. 2011, Scanzello and 
Goldring 2012). In particular, there is an emerging body of evidence supporting the role of 
synovial macrophages in OA pathogenesis (Haywood, McWilliams et al. 2003, Blom, van Lent 
et al. 2004, Benito, Veale et al. 2005, Bondeson, Blom et al. 2010, Kraus, McDaniel et al. 2016, 
Manferdini, Paolella et al. 2016, Wu, McNeill et al. 2017). However, technical barriers have 
thus far limited high resolution and in-depth analyses of these cells.  
Three overarching aims were designed to assess the hypothesis that there is heterogeneity at the 
cellular and molecular level in the synovial tissue of osteoarthritis patients, particularly within 
synovial macrophages. Further understanding the specific tissue environments modulating this 
heterogeneity could lead to improved patient stratification and the modification of treatment 
strategies for OA patients. The first aim was to develop technical protocols to allow the 
successful isolation, identification and purification of immune cell populations from synovial 
tissue. The second aim involved the enumeration of immune cell subsets using both manual and 
computational analyses. The final aim was to conduct in-depth analyses on synovial 
macrophages, encompassing surface marker phenotyping, functional analyses and gene 
expression by RNA-sequencing. Supporting data for the contribution of synovial macrophages 
to OA disease were found, in addition to the stratification of OA macrophages into two 
endotypes. 
Through the assessment of published and established protocols, I developed a digestion 
protocol suitable for synovial tissue (Chapter 3). After mechanical digestion, synovial tissue 
was exposed to a suboptimal concentration of the enzyme cocktail liberase for three, 45min- 
digestion rounds in a shaking incubator, with filtration after each digestion round. This protocol 
ensured that cells were only exposed to a low concentration of liberase at any time during the 
digestion process, resulting in minimal cleavage of the extracellular antigens tested and high 
viability of cells. The multiple digestion rounds were necessary to obtain sufficient cell yields. 
The combination of a carefully constructed 12-colour flow cytometry panel and optimised 
FACs allowed the purification of synovial tissue immune cell subsets of interest, namely HLA-
DR+CD14+ macrophages, cDC2s, CD14+ monocytes and CD4+ T cells. 
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For enumeration of the immune cell subsets present in the peripheral blood and synovial tissue 
of OA and IA patients, both manual methods and computational analyses were employed 
(Chapter 4). viSNE produced an informative visual representation of these high parameter data, 
whereas CITRUS provided useful quantitative analyses of cell clusters. Although these types 
of analyses are becoming typically used in the analysis of mass cytometry data, they have also 
been previously applied to flow cytometry data. Examples of this include the identification of 
cell subsets as well as the contrast of healthy and cancerous tissues (Amir el, Davis et al. 2013, 
Bruggner, Bodenmiller et al. 2014, Guilliams, Dutertre et al. 2016, Acuff and Linden 2017). 
Increased immune cell infiltration was observed in the IA synovial samples compared to OA. 
However, an increase in the proportion of macrophages was observed in OA synovial tissue 
compared to IA. This was mirrored by an increased proportion of T cells in the synovial tissue 
of IA. There has been little previous research directly comparing synovial tissue cell subsets 
between OA and IA, particularly using the techniques described here. This observation may 
support the premise that synovial macrophages play a role in the OA pathogenesis. Although 
potentially interesting findings were uncovered in the correlation of clinical and immunological 
information, these did not meet statistical acceptability, and were ultimately limited by the 
sample size. 
An in-depth analysis was conducted on synovial tissue macrophages (Chapter 5). This involved 
the phenotyping of their surface markers by flow cytometry, assessment of functionality, and 
measurement of gene expression by RNA-sequencing. Synovial macrophages were pure and 
expressed expected surface markers, such as HLA-DR, CD14 and CD45. Increased expression 
of a number of surface markers, including CD206, FOLR2 and CD86 was noted in OA samples 
compared to IA samples. Together with their increased proportion in OA synovial tissue, these 
observations may suggest OA synovial tissue macrophages have an alternative activation state 
compared to IA synovial tissue macrophages. This could reflect the modulating effect of these 
differing tissue environments in arthritic joints between disease types. A flow cytometry gating 
strategy for the identification of ‘resident’ and ‘inflammatory’ macrophages in healthy and 
GvHD dermis was applied to OA and IA synovial tissue samples. This demonstrated increased 
proportions of ‘resident’ macrophages in the synovial tissue of OA patients compared to IA. 
However, in OA, the ratio of ‘resident’ and ‘inflammatory’ macrophages was variable, with 
some OA patients showing a similar proportion to IA patients. Observations in the IA synovium 
samples are consistent with the inflammatory dermis, where increased proportions of 
‘inflammatory’ macrophages are also observed in patients with graft versus host disease (Collin 
group, manuscript in preparation). It is possible that the well described inflammatory 
environment in IA synovial tissue is driving the recruitment of monocytes and their 
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differentiation into inflammatory monocyte-derived cells. Although a high ratio of 
‘inflammatory’ to ‘resident’ macrophages was not seen in the OA cohort as a whole, a subset 
of these patients had proportions of ‘inflammatory’ macrophages similar to those seen in IA. In 
addition to identifying heterogeneity in OA patients, this could suggest that the OA patients 
with a similar proportion of ‘inflammatory’ macrophages as IA patients, have a more 
inflammatory OA disease phenotype. This strategy presented a potentially novel method for the 
identification of resident and inflammatory, infiltrating macrophages in synovial tissue. Due to 
the recent development of this strategy, further assessment needs to be conducted. However, 
when applied to the flow cytometry data-set of sequenced macrophage samples, there was no 
clear difference in monocyte or macrophage subsets between the three disease groups tested 
(IA, OA_0 and OA_1) (Appendix 6.1). A number of experiments will therefore be carried out 
to further characterise these resident and infiltrating macrophages in synovial tissue. As this 
identification was based solely on the low and high expression of CD11c, it would be important 
to validate these cells’ ontogeny. Although there is no definitive marker of human monocyte-
derived macrophages, CCR2 has been previously identified as a marker for the recruitment of 
monocytes and DCs into tissues (Daigneault, Preston et al. 2010, Italiani and Boraschi 2014, 
Yang, Zhang et al. 2014, Bernardo, Durant et al. 2016, Gordon and Pluddemann 2017). The 
measurement of CCR2 and other candidate markers such as CD11b and CX3CR1, in addition 
to functional assessment such as migratory capability and differential response to stimulus may 
aid in the identification of monocyte-derived macrophages in synovial tissue. 
Functionality of purified macrophages was assessed by phagocytosis of latex beads using 
confocal microscopy. This demonstrated that synovial macrophages can still phagocytose after 
tissue digestion and FACs. This was a crucial step in ensuring functionality before conducting 
gene-expression and future functional assays. RNA-sequencing was conducted on OA synovial 
macrophages with IA macrophages used as a control group. This confirmed heterogeneity of 
synovial macrophages in OA patients. Macrophages from OA had varied gene expression, and 
could be split into two endotypes (Figure 5.35). These groupings were also segregated by 
hierarchical clustering of immune cell subset percentages determined by flow cytometry, 
demonstrating an increased proportion of macrophages in OA_1 and increased cDC2s in OA_0. 
OA_1 samples were similar to IA samples, where macrophages presented a cell cycle gene 
signature. OA_0 macrophages were distinct from both IA and OA_1 macrophages, 
demonstrating a gene signature rich in tissue engineering pathways. These different 
macrophage endotypes did not correlate with any of the clinical data collected. As none of the 
clinical data were found to be a confounding factors, this suggests these endotypes are not 
caused by factors measured such as age, obesity and gender. 
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A number of limitations were identified in this project. These included the use of tissue 
digestion, use of tissue samples from both knees and wrists, small sample sizes and use of only 
end-stage OA disease samples. However, all of these were deemed either unavoidable and 
effects minimised (digestion of tissue), acceptable (different tissue sites), or an area to be 
developed in future work (small sample sizes). For this project, the use of end-stage OA samples 
was unavoidable, but it has been recognised that to further understand the pathogenesis of OA, 
samples from earlier stages of disease will be essential. 
When designing future experiments to further characterise the OA subgroups identified here, a 
number of factors need to be considered. As only synovial tissue from end-stage OA has been 
used in this thesis, the data presented may only represent end-stage disease. When further 
investigating disease mechanisms and pathogenesis, it will be essential to sample synovial 
tissue from multiple stages of disease to provide a better representation of pathogenesis. In 
addition, larger sample sizes would be beneficial. Although clinical analyses have been 
conducted, access to this data has been limited. It will also be crucial to collect a specific set of 
clinical data from these patients. This additional information could include patient pain and 
joint mobility, general quality of life scores and a standardised, surgeon reported synovial tissue 
colouring score. Ideally, these data will be collected pre-, at time of, and post- sample collection 
and include patient reported outcome measures in the occurrence of medical intervention. 
Determining the relationship between the clinical data of OA patients with immunological data 
will aid in measuring patients’ response to clinical interventions as well as defining new 
diagnostic markers and the modification of treatments strategies for OA patients. 
As discussed in Chapter 4, it would be useful to fully validate the enumeration of synovial tissue 
cell subsets. Immunofluorescence imaging of tissue sections would be a valuable technique to 
approach this. Additionally, it would be interesting to explore the use of imaging by mass 
cytometry. Cytof Imaging Mass Cytometry technology currently allows the staining of up to 32 
proteins in a single tissue section, and it is envisaged that this could reach up to 100 proteins 
once isotypes and antibodies are developed. In addition to the enumeration of cells, this 
approach would allow the staining of potential biomarkers for OA subgroups identified by my 
gene expression experiment. Furthermore, the visualisation of cell location to both tissue 
structure in these arthritic joints, and to multiple other cell subsets, would aid in the 
understanding of cell-cell mechanisms in these differing pathologies. When designing an 
experiment encompassing this technique, it would be important to include the analyses of both 
tissue sections and matched peripheral blood samples. Although being able to identify patients 
by synovial tissue is useful and could be translated to minimally invasive biopsies, it would be 
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advantageous to be able to stratify these patients using peripheral blood samples only. However, 
since OA is not a systemic disease, it is likely that using peripheral blood would not be useful. 
Despite this, the use of minimally invasive biopsies for the stratification of patients for disease 
modifying treatment, preventing unnecessary total joint replacement, is acceptable. This would 
first require the identification of select markers in tissue for the consistent identification of these 
OA subgroups, and then the correlation with blood samples to identify similar markers. Finally, 
a large cohort size, in addition to samples obtained from multi-stages of OA, will be crucial to 
any future work. Being able to identify these patients consistently and easily would aid in the 
modification of their treatment strategies due to the better understanding of the disease 
processes that take place in the affected joint(s). 
It would be useful to determine the cytokine production of synovial macrophages. Although 
cytokine genes were expressed by the synovial macrophages assessed in my gene expression 
experiment (data not shown), these were not observed through differential gene expression 
analysis. This is likely owing to the small sample size. Alongside synovial macrophages, the 
cytokine profiles of whole synovial tissue, in addition to the adipokine contribution from the 
fat pad, will aid in fully understanding the tissue specific environments in these patients, and 
how this may modulate cellular pathogenesis. Since the functionality of macrophages appears 
to be retained after digestion and FACs, it will be useful to carry out further functional 
experiments on these cells. In addition to assessing macrophage cytokine production in 
response to stimuli, this may encompass mixed lymphocyte reactions and proliferation assays. 
Overall, the techniques developed here have allowed the advanced technical analyses of 
synovial tissue cell subsets, in particular synovial tissue macrophages in OA patients. This level 
of analyses in the context of OA and macrophages is novel, can be applied to a range of synovial 
samples, and provides many directions for new hypotheses and future work. 
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6.2 General Discussion 
With the identification of synovial macrophage subgroups in OA, it would be interesting to 
assess the functional differences and cellular mechanisms of pathogenesis between them. This 
would aid in the understanding of macrophage contribution to OA pathogenesis. From the study 
of gene expression and subsequent pathway analyses, the unique gene signatures suggest how 
these macrophages from OA patients, and their specific tissue environments may differ, 
summarised in Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: OA_0 and OA_1 synovial macrophages 
Depiction of potential mechanism of disease pathogenesis in OA_0 and OA_1. OA_0 tissue environment is 
likely centred around cartilage damage and degradation, one of the key characteristics of OA. Synovial 
macrophages present have aberrant tissue repair mechanisms, which results in further cartilage damage. 
Additionally, these macrophages may also contribute directly to cartilage damage through the mediation of 
MMP release by synovial macrophages, and reduced autophagy. SIS3 inhibition of SMAD3 and Rapamycin 
inhibition of mTOR signalling may prove useful methods of reinstating chondrogenesis and autophagy in 
these patients, promoting cartilage repair. Biomarkers in synovial tissue for these patients could include a lack 
of ULK1 expression. OA_1 tissue environment is likely to be inflammatory, similar to that seen in IA patients. 
This inflammatory environment likely polarises synovial macrophages into a proliferative capacity. These 
highly proliferative macrophages may then further contribute to inflammation through the release of TNFα 
and NO. Methotrexate and Rituximab may be useful therapeutic approaches for these patients, halting cell 
cycle at G1/S phase. ULK1 may be a useful predictor for treatment response in these patients. Biomarkers for 
stratification of these patients could include the expression of CTRL, CDT1, E2F8 and ULK1. 
OA_1 OA_0 
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IGFBP5 was significantly overexpressed in OA macrophages compared to IA macrophages, 
particularly in OA_0 macrophages. Since IGFBP5 is associated with the negative regulation of 
inflammatory mediators, this over expression in OA macrophages, particularly OA_0 
macrophages, could reflect a less inflammatory tissue environment compared to IA. OA_1 may 
demonstrate an inflammatory environment similar to that of IA. Likewise, over expression of 
HTRA1 is observed in OA_0 macrophages compared to IA. HTRA1 can modulate synovial 
fibroblasts to produce cartilage catabolic MMPs. Alongside the observed over-expression of 
EFEMP1, potentially acting as a negative regulator of chondrogenesis, this could demonstrate 
a potential mechanism of cartilage destruction, and subsequent failure of cartilage repair in 
these OA_0 patients. SMAD3 was also observed to be over-expressed, and RUNX2 to be 
possibly under expressed in OA_0 macrophages compared to IA and OA_1 macrophages. This 
may be an additional failing, tissue repair mechanism. 
The over-expression of ULK1 in IA and OA_1 macrophages compared to OA_0 macrophages 
was initially of interest. However, it became clear that this was actually a complete lack of 
expression of ULK1 in OA_0 macrophages. ULK1 is protective of cartilage, and could present 
another mechanism of cartilage destruction through reduced autophagy and increased 
chondrocyte death. As ULK1 can be negatively regulated by mTOR activity, it could be 
postulated that inhibition of mTOR activity may promote ULK1 expression in OA_0. This could 
ultimately lead to the restoration of autophagy, and resolution of cartilage damage. Rapamycin 
targets mTOR and treatment has been shown to significantly decrease cartilage degradation and 
furthermore decrease ADAMTS5 and IL-1β expression in cartilage murine OA (Carames, 
Hasegawa et al. 2012). Similar results have been observed in murine OA studies (Cejka, Hayer 
et al. 2010, Takayama, Kawakami et al. 2014). However, there is no evidence for its 
involvement in human OA. Another direction for therapeutic options is the TGFβ/SMAD3 
signalling pathways. There are many therapies for the blocking of TGFβ, however these may 
not be specific. SIS3 is a specific inhibitor of SMAD3 phosphorylation and gene expression, 
without affecting SMAD2. Upregulation of type 1 collagen by scleroderma fibroblasts with 
SIS3 treatment has been previously observed (Jinnin, Ihn et al. 2006). However, there is no 
evidence of the application of SIS3 in the context of OA. This could prove an additional 
mechanism for the restoration of autophagy in these OA_0 patients. To functionally assess the 
contribution to, or inhibition of, cartilage degradation by macrophages in the OA_0 group, a 
modified version of a previously described in vitro cartilage degradation assay could be 
performed (Jetten, Roumans et al. 2014, Radwan, Wilkinson et al. 2015). The culture of 
synovial tissue cells and bovine cartilage discs, with the presence or depletion of these 
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macrophages could reveal the true extent of their contribution to cartilage damage, or 
restoration. 
OA_1 macrophages were similar to IA macrophages, and genes expressed had a strong 
association with cell cycle processes. The over expression of MKi67 in OA_1 macrophages 
compared to OA_0 macrophages was of particular interest since it encodes a well associated 
protein of cell proliferation, Ki67. The over expression of E2F8 and CDT1, which have been 
shown to promote cell proliferation through the modulation of G1/S phase, were also of interest.  
These samples additionally had a higher proportion of macrophages compared with OA_0 
samples, assessed by flow cytometry. The observation of a higher proportion of macrophages 
in OA_1 is likely owing to increased rates of macrophage proliferation within these samples, 
suggested by their gene expression. As OA_1 macrophage samples were similar in gene 
expression to IA macrophages, this macrophage proliferation could be in response to immune 
cell driven inflammation within the joint. Over-expression of CTRL in OA_1 macrophages 
compared to OA_0 macrophages may reflect a more inflammatory environment, and result in 
the further contribution to this inflammatory environment, creating a positive feedback loop.  
It would be interesting to test the differential effects of therapeutic drugs on these cells, which 
may translate to better stratification of OA patients for clinical trials. For example, 
methotrexate, a repurposed cancer drug used first line in RA patients, is a competitive inhibitor 
of dihydrofolate reductase (DHFR), halting cell cycle at S phase. Since OA_1 macrophages 
may be actively proliferating with specific modulation at the G1/S phase, methotrexate 
treatment could be used to inhibit this cell proliferation, and subsequently reduce inflammation. 
Previous trials of methotrexate treatment in OA patients have demonstrated mixed success, 
which could be explained by heterogeneity in OA macrophages observed here (Wenham, 
Grainger et al. 2013, Abou-Raya, Abou-Raya et al. 2014). As methotrexate has associated side 
effects, it would be desirable to identify patients that would respond well to this drug, before 
commencement of treatment. It will be interesting to see results from the ARUK multi-centre 
‘PROMOTE’ study assessing pain reduction and synovitis in OA patients with methotrexate 
treatment. To initially assess the efficacy of methotrexate treatment on these macrophages, the 
in vitro culture of macrophages from OA subgroups +/- soluble methotrexate and assessment 
of resultant proliferation would be intriguing. Similar cultures have previously been conducted 
in macrophages and stromal cell cultures but not in the context of OA heterogeneity (Neurath, 
Hildner et al. 1999, Minaur, Jefferiss et al. 2002, Lo, Steer et al. 2011). Although ULK1 
expression was absent in OA_0 macrophages, as no healthy controls were used it is unknown 
whether the levels measured in OA_1 and IA macrophages are elevated. If these levels are 
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indeed elevated, ULK1 expression could provide a useful identifier for OA patients which may 
respond to methotrexate treatment, as well as rituximab. 
Taken together, these data suggest that there are divergent synovial tissue environments 
between OA_0 and OA_1 patients. It is likely that these environments specifically modulate 
synovial macrophages to differing polarisation states. OA_1 appears to be particularly 
inflammatory, whereas OA_0 is likely to be centred around cartilage degradation, possibly a 
result of chronic mechanical damage. Within OA_0 macrophages there are aberrant tissue 
repair mechanisms, in addition to factors which may directly contribute to cartilage degradation. 
OA_1 macrophages are highly proliferative, reflected by their gene signature, in addition to 
increased proportions in the synovium measured by flow cytometry. It is likely that the 
inflammatory synovial environment directly contributes to these macrophages’ proliferative 
capacity, but there is scope for a positive feedback loop whereby these macrophages further 
exacerbate synovial inflammation.  
With the identification of these OA endotypes, it is now possible to further investigate the 
specific cellular mechanisms of disease pathogenesis. After validation of these endotypes, it 
will be important to identify biomarkers to aid in the accurate identification of these patients. 
Once identified, these biomarkers should be detectable in the peripheral blood or synovial tissue 
in clinical application. Once this identification has been established, recommendations for 
treatment modification can be made based on the functional cellular pathogenesis of each 
endotype. This could ultimately result in disease modification in patients with OA, which has 
previously been unachievable, likely owing to the heterogeneity within this disease. 
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Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.1: FMOs for gating strategy 
Synovial tissue from OA total knee replacement was digested using the optimised protocol shown in Figure 
3.6. Single cell suspension was divided into two before flow cytometry antibody staining. Flow cytometry 
panel shown in Figure 3.16 was used. Left hand panels depict FMO. Right hand panels depict antibody staining. 
A: Sample with and without HLA-DR and CD14 antibodies. B: Sample with and without HLA-DR antibody. 
C: Sample with and without CD4 antibody. Data are representative of two independent experiments. 
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Appendix 3.1: pDC and cDC1 identification 
Synovial tissue from OA total knee replacement was digested using the optimised protocol 
shown in Figure 3.6. A: Expression of CD123 on cDC2 and pDC. B: Expression of CD141 
(left panel) and CD11c (right panel) on cDC2 and cDC1.  
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Appendix 3.2: CD1c FMO 
Synovial tissue from OA total knee replacement was digested using the optimised protocol 
shown in Figure 3.6. Single cell suspension was divided into two before flow cytometry 
antibody staining. Flow cytometry panel shown in Figure 3.17 was used. Left hand panel 
depicts FMO. Right hand panel depicts antibody staining. Data are representative of one 
experiment. 
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Appendix 4.1: Quantification of immune cell subsets in peripheral blood 
PBMCs were isolated from peripheral blood of OA total knee replacement and IA ultrasound guided 
biopsy patients. PBMCs were analysed by flow cytometry using techniques described in Chapter 3. A: 
Proportion of CD4+ and CD4- T-cells in IA and OA peripheral blood. B: Proportion of total monocytes 
in IA and OA peripheral blood. n=23.  
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Appendix 4.2: Quantification of cDC2 in disease and healthy blood 
PBMCs were isolated from peripheral blood of OA total knee replacement and IA ultrasound 
guided biopsy patients in addition to healthy volunteers. Proportion of cDC2 cells in IA, OA 
and healthy blood. Data presented as % of CD45+ cells. n=24. *P≤0.05, ****P≤0.0001. 
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Appendix 4.3: Correlation of cDC2 and BMI 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and 
analysed by flow cytometry using techniques described in Chapter 3. Correlation of BMI and cDC2 
as % of CD45+ cells. Linear regression: R2 = 0.03. P = 0.2. 
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Appendix 4.4: Quantification of HLA-DR+CD14+ Macrophage in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. Quantity of HLA-DR+CD14+ Macrophage in IA 
and OA synovial tissue. Data presented as cells per gram of tissue. 
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Appendix 4.5: Correlation of HLA-DR+CD14+ MØ and CD14+ monocytes with BMI 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. A: Correlation of BMI and CD14+ monocytes 
as % of CD45+ cells. Linear regression: R2 = 0.002. P = 0.76. B: Correlation of BMI and HLA-DR+CD14+ 
MØ as % of CD45+ cells. Linear regression: R2 = 0.002. P = 0.78. 
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Appendix 5.1: Normalisation of counts 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods described 
in Chapter 2. Normalisation of counts was conducted using Limma’s Voom function. Left panel depicts 
counts pre- normalisation. Right panel depicts counts post- normalisation 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.2: CD16+ Macrophages in synovial tissue 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed by flow 
cytometry using techniques described in Chapter 3. A: Identification of a CD16+ MØ population present in synovial tissue 
samples. B: Percentage of CD16+ MØs present in samples of different disease groups. C: Morphological analysis of CD16+ 
and CD16- MØ by cytospin and giemsa staining. D: Verification of CD16 staining in MØ population using unstained 
control. E: Volcano plot of DEGs between CD16+ and CD16- OA patients. F: Distribution of p-values. G: KEGG pathway 
analyses on un-adjusted p-values. *** P = 0.0001. 
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Appendix 5.3: Distribution GO term p-values from Question 3 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods 
described in Chapter 2. Perturbed GO terms passing adjusted p<0.05 and q-value FDR <0.25, based upon 
DEGs from Question 3 (>1.5-fold change; p<0.05, multiple test corrected).  
Appendix 5.4: Distribution GO term p-values from Question 4 
RNA-sequencing of synovial macrophages and data analyses were conducted following methods 
described in Chapter 2. Perturbed GO terms passing adjusted p<0.05 and q-value FDR <0.25, based upon 
DEGs from Question 4 (>1.5-fold change; p<0.05, multiple test corrected).  
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Appendix 5.6: Expression of Ki-67 on synovial macrophages 
Synovial tissue from OA total knee replacement was digested and analysed by flow cytometry using 
techniques described in Chapter 3. Expression of Ki-67 on OA synovial macrophages. Left panel depicts 
overlay dotplot of sample stained with and without Ki-67. Right panel depicts histograms of Ki-67 
expression on synovial macrophages. Data are representative of 1 experiment. 
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Appendix 5.7: Cytokine-Cytokine Receptor Interaction KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.9: Transcriptional Misregulation in Cancer KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
Appendix 5.8: TNF Signalling KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
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Appendix 5.10: NF-Kappa B KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
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Appendix 5.11: Malaria KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
Appendix 5.12: IL-17 Signalling KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
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Appendix 5.13: AGE-RAGE Signalling Pathway in Diabetic Complications KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
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Appendix 5.14: Legionellosis KEGG pathway 
Greater perturbed KEGG pathway from Question 1 (IA v OA) 
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Appendix 5.27: Pertussis KEGG pathway 
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Appendix 5.28: Leishmaniasis KEGG pathway 
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Appendix 5.58: Human Papillomavirus Infection KEGG pathway 
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Appendix 6.1: Quantification of inflammatory monocyte and macrophage subsets in RNA-sequenced 
macrophage samples 
Synovial tissue from OA total knee replacement and IA ultrasound guided biopsy was digested and analysed 
by flow cytometry using techniques described in Chapter 3. Quantification of monocytes ‘1’ (left panel), ‘2’ 
(middle panel) and resident and inflammatory macrophages (right panel)  
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